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ABSTRACT 
Mitochondria are crucial intracellular organelles which play a pivotal role in 
providing energy to living organisms in the form of adenosine triphosphate (ATP). The 
mitochondrial electron transport chain (ETC) coupled with oxidative phosphorylation 
(OX-PHOS) transforms the chemical energy of amino acids, fatty acids and sugars to 
ATP. The mitochondrial electron transport system consumes nearly 90% of the oxygen 
used by the cell. Reactive oxygen species (ROS) in the form of superoxide anions (O2
–
)
 
are generated as byproduct of cellular metabolism due to leakage of electrons from 
complex I and complex III to oxygen. Under normal conditions, the effects of ROS are 
offset by a variety of antioxidants (enzymatic and non-enzymatic).  
Mitochondrial dysfunction has been proposed in the etiology of various 
pathologies, including cardiovascular and neurodegenerative diseases, such as 
Alzheimer’s disease and Parkinson’s disease, ischemia-reperfusion (IR) injury, diabetes 
and aging. To treat these disorders, it is imperative to target mitochondria, especially the 
electron transport chain. One of the methodologies currently used for the treatment of 
mitochondrial and neurodegenerative diseases where endogenous antioxidant defenses 
are inadequate for protecting against ROS involves the administration of exogenous 
antioxidants. 
 As part of our pursuit of effective neuroprotective drugs, a series of pyridinol and 
pyrimidinol analogues have been rationally designed and synthesized. All the analogues 
were evaluated for their ability to quench lipid peroxidation and reactive oxygen species 
 ii   
  
(ROS), and preserve mitochondrial membrane potential (Δm) and support ATP 
synthesis. These studies are summarized in Chapter 2. 
 
  Drug discovery and lead identification can be reinforced by assessing the 
metabolic fate of orally administered drugs using simple microsomal incubation 
experiments. Accordingly, in vitro microsomal studies were designed and carried out 
using bovine liver microsomes to screen available pyridinol and pyrimidinol analogues 
for their metabolic lability. The data obtained was utilized for an initial assessment of 
potential bioavailability of the compounds screened and is summarized fully in Chapter 
3. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
Mitochondria are crucial intracellular organelles and play a pivotal role in 
providing energy to living organisms for their survival in the form of adenosine 
triphosphate (ATP). The mitochondrial electron transport chain (ETC) coupled with 
oxidative phosphorylation (OX-PHOS) transforms the chemical energy of amino acids, 
fatty acids and sugars to ATP (Figure 1.1).
1-4
 
 
 
Figure 1.1. Mitochondrial Membranes and Different Compartments Involved in Electron 
Transport Chain (ETC) and Oxidative Phosphorylation (OX-PHOS). 
 
The mitochondrion has five lipid enzyme complexes, I-V, that are embedded in 
the inner mitochondrial membrane (IMM) and complexes I-IV are part of the electron 
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transport chain (ETC). Complex I and complex II catalyze the transfer of electrons from 
NADH and succinate (through FADH2), respectively, to coenzyme Q10 (CoQ10) and 
simultaneously translocate four protons to the intermembrane space from the 
mitochondrial matrix. CoQ10 carries the electrons to complex III, from where they are 
transferred to cytochrome c. Complex IV receives the electrons from cytochrome c and 
utilizes them to reduce molecular oxygen to water, simultaneously translocating two 
protons to the intermembrane space. In summary, electrons are transported from the TCA 
(tricarboxylic acid) cycle to oxygen, ultimately producing water along with the 
translocation of ten protons at complex I (4H
+
), complex III (4H
+
) and complex IV (2H
+
). 
The proton motive force (PMF) generated by the translocation of ten protons from the 
matrix to intermembrane space is the driving force for ATP synthase to synthesize ATP 
from ADP and inorganic phosphate.
5-10
 
The mitochondrial electron transport system consumes nearly 90% of the oxygen 
used by the cell. Reactive oxygen species (ROS) in the form of superoxide anions (O2
–
)
 
are generated as a byproduct of cellular metabolism due to the leakage of electrons from 
complex I and complex III to oxygen.
11-12
 ROS generation by mitochondria was first 
demonstrated by Jensen along with other investigators in 1961.
13
 It is used by cells as 
natural defense system against pathogens and for signal transduction.
14-16
 ROS 
production is increased when electron carriers possess excess electrons, e.g. due to 
inhibition of OX-PHOS (e.g., dysfunctional mitochondria or several other bioenergetic 
related pathologies) or excessive calorie consumption. Nature has designed a multilayer 
network of mitochondrial antioxidants to detoxify O2
–
 and its disproportion product 
H2O2 in order to balance the appropriate concentration of ROS and avert the generation 
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of even more reactive species such as hydroxyl radical (HO

) and peroxynitrite (ONOO
–
) 
(Figure 1.2).
17-21
  
 
 
Figure 1.2. Schematic for Cooperative Network Between Exogenous and Endogenous 
Antioxidants to Mitigate Oxidative Stress. Adapted From Ref. 19, 20 and 21. 
 
Antioxidants are classified into two classes, namely enzymatic antioxidants
22,23
 
(glutathione peroxidase, catalase and superoxide dismutase) and non-enzymatic 
antioxidants, including -tocopherol (vitamin E, phenolic type), L-ascorbic acid (vitamin 
C, enolic type), -carotene, resveratrol and curcumin (non-flavonoids), and quercetin 
(flavonoid) (Figures 1.3, 1.4 and 1.5).
24-34
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Figure 1.3. Chemical Structures of Vitamins and a Provitamin (-carotene) Serving as 
Antioxidants. 
 
Glutathione peroxidase converts H2O2 to H2O and simultaneously oxidizes 
glutathione (GSH, reduced form) to glutathione (GSSG, oxidized form).
35
 Vitamin E, a 
lipophilic vitamin, is the best known natural antioxidant and has been studied extensively 
since its discovery decades ago. There are eight members of the vitamin E family 
including , , ,  -tocopherols and , , ,  -tocotrienols that have methylated 
hydroquinone moieties and an isoprenoid chain (Figure 1.4).
36,37
  
 
 
  
 
 
Figure 1.4. Chemical Structures of Member of the Vitamin E Family, Which Serve as 
Antioxidants. 
 
 
Form R1 R2 R3 
-tocopherol CH3 CH3 CH3 
-tocopherol CH3 H CH3 
-tocopherol H CH3 CH3 
-tocopherol H H CH3 
Form R1 R2 R3 
-tocotrienol CH3 CH3 CH3 
-tocotrienol CH3 H CH3 
-tocotrienol H CH3 CH3 
-tocotrienol H H CH3 
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Resveratrol, a biologically active non-flavonoid found predominantly in red fruit, 
grapes and red wine, is a potent antioxidant which mediates its effects by sequestering 
free radicals and inducing the synthesis of endogenous antioxidants.
31
 Quercetin is among 
the most common dietary flavonoids and is found ubiquitously, including in berries, 
onions, apples and broccoli (Figure 1.5). It imparts its antioxidant property by means of 
chelation with a transition metal ion (e.g. Fe
2+
) and by free radical scavenging of highly 
reactive species, such as hydroxyl radical (HO

) and the peroxynitrite (ONOO
–
).
34,38-40
   
 
 
 
Figure 1.5. Chemical Structures of Flavonoid (Quercetin) and Non-flavonoid 
(Resveratrol and Curcumin) Phenolic Antioxidants Found in the Human Diet. 
 
Diffusion of O2
– 
across the membrane is not feasible because of its polarity; 
hence the location of O2
– 
and the presence of enzymes regulate its release. Studies 
suggest plausible release of O2
– 
in the matrix by complex I, whereas complex III can 
release them into the IMM space as well as in the matrix (Figure 1.6).
18
 The 
mitochondrial matrix enzyme manganese superoxide dismutase (MnSOD) can convert 
superoxide at the stage of complexes I and III into the more stable H2O2; the latter can 
readily diffuse into the cytosol.
41
 Similarly, copper zinc superoxide dismutase 
(CuZnSOD) transforms O2
–  
to H2O2 in the intermembrane space.
42,43
 Glycerol-3-
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phopshate dehydrogenase (GPDH) can also generate superoxide in the intermembrane 
space during the transformation of glycerol-3-phosphate (G3P) to dihydroxyacetone 
phosphate (DHAP). ROS can also be generated during the -oxidation of fatty acids, 
where electron transferring flavoprotein ubiquinone oxidoreductase (ETF–QOR) oxidizes 
electron transferring flavoprotein (ETF) (Figure 1.6).
44-46
 
 
 
Figure 1.6. Scheme for Mitochondrial O2
–
 Production in FRDA Cells. Adapted From 
Ref. 44-46. 
 
Oxidative stress resulting from the generation of ROS, primarily H2O2, has been 
proposed in the etiology of various pathologies including cardiovascular and 
neurodegenerative diseases, diabetes and aging. ROS generation is enhanced by a 
decrease in the cellular antioxidants network and accumulation of transition metals like 
 7   
  
iron and copper with age or in these pathological environments.
47-53
 Dysfunctional 
mitochondria generate ROS and initiate a feed-forward loop, in which the cycle of ROS 
generation is sustained by ROS-mediated oxidative damage.
20,48,49
 
Treatment of mitochondrial and neurodegenerative diseases in which the 
endogenous antioxidant defenses are inadequate for protecting against ROS involves the 
administration of exogenous antioxidants. This is suggested not only to counterbalance 
the incompetence of the endogenous defense systems but also to augment the overall 
antioxidant response (Figure 1.7).
54-57
  
 
 
Figure 1.7. Chemical Structures of the Synthetic Antioxidants Used as Exogenous 
Antioxidants to Supplement the Self-defense Mechanisms of Cells.
58,59
 
 
The protein complexes of the ETC reside on the IMM, which is composed 
predominantly of phosphatidylcholine, phosphatidylethanolamine and cardiolipin.
60
 
Cardiolipin is an important phospholipid which helps in providing curvature to the IMM, 
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and the organization of cristae structures and respiratory complexes into a supercomplex 
with a larger surface area on the IMM. It anchors complex III and complex IV with the 
cationic cyt c by means of electrostatic interaction to facilitate efficient electron transfer 
among the proximal redox partners.
61-69
 Proximity to ROS generation sites along with a 
high unsaturated fatty acid content makes cardiolipin highly vulnerable to oxidative 
damage.
70
 Lipid peroxidation of cardiolipin disrupts the supercomplex organization and 
results in detachment of cyt c from the IMM. This event leads to ETC inhibition and 
ultimately facilitates apoptosis (Figure 1.8).
71,72 
 
 
 
Figure 1.8. Scheme Illustrating the Significance of Cardiolipin in the Organization of 
Respiratory Complexes into a Supercomplex and the Deleterious Effects of Cardiolipin 
Peroxidation During Oxidative Stress. Adapted From Ref. 73. 
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Several pathological conditions, including cardiac failure, diabetes, ischemia-
reperfusion (IR) injury and neurodegenerative diseases have reported intimate 
involvement of cardiolipin depletion and its peroxidation as one of the major causes 
leading to these pathologies.
73
 Compounds that can preserve cardiolipin against lipid 
peroxidation may be beneficial for patients suffering from these diseases. The electron 
scavenger XJB-5-131 peptide (4-amino-TEMPO conjugated to hemigramicidin S), has 
been designed to target mitochondria and it has been shown to inhibit cardiolipin 
peroxidation by scavenging ROS in rat traumatic brain injury model.
74
 Szeto-Schiller 
(SS) peptides, including SS-31and SS-02 (< 10 amino acids) have been reported to target 
cardiolipin on the IMM and help to restore mitochondrial bioenergetics by modifying the 
activity of ETC protein complexes.
75-77
 The dimethyltyrosine (Dmt) residue present in 
these tetrapeptides scavenges ROS and inhibits lipid peroxidation in vitro (Figure 
1.9).
77,78
  
  
 
Figure 1.9. Structures of Mitochondria-targeted Small Peptide Antioxidants. 
 
The radical chain reactions involved in lipid peroxidation have been studied 
extensively since the 1960s and are summarized in Scheme 1.1. Several possibilities, 
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other than the more common L• dimerization leading to L–L at the chain termination 
step, are feasible to generate stable species, such as L–O–L and L–O–O–L.  In principle, 
inhibition of lipid peroxidation can be achieved in a number of ways (Scheme 1.2), which 
includes suppression of initiator L• responsible for the propagation of the radical chain 
reaction. In a second approach, antioxidants serving as a hydrogen atom donor can 
interrupt the chain reactions by trapping the peroxyl radical (LOO•).79-81  
 
 
Scheme 1.1. Lipid Peroxidation Chain Reactions in Dysfunctional Mitochondria. 
 
 
Scheme 1.2. Inhibition of Lipid Peroxidation Using -TOH as an Antioxidant. 
 
It has been well established that during lipid peroxidation, -TOH reacts 
spontaneously with peroxyl radicals by transferring its phenolic hydrogen atom to the 
peroxyl radical in the chain propagation step. Resonance stabilization of -TOH radicals 
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(-TO•) generated after the phenolic hydrogen transfer facilitates the above 
transformation. Delocalization of unpaired electrons of oxygen into the aromatic ring 
structure makes -TOH derived radicals less reactive for abstracting another H• from the 
unsaturated fatty acid moiety of the phospholipid membrane. -TOH can be regenerated 
from the stabilized -TOH radicals by cooperating with the other redox molecules, such 
as vitamin C and NADH (Scheme 1.3).
82-84
  
 
Scheme 1.3. -TOH Mediated Lipid Peroxidation Quenching, and Ascorbic Acid and 
NADH Mediated Recycling of -TOH. 
 
Appropriate functioning of mitochondria is really critical for sustaining life, and 
especially requires the ETC to continuously supply cells with ATP. Restoration of 
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mitochondrial function is essential for blunting the progression of mitochondrial diseases. 
Many compounds having desirable efficacy in vitro do not impart the anticipated efficacy 
in vivo due to their rapid metabolic clearance, which results in compromised 
pharmacological potency. Xenobiotics (foreign compounds) in the liver after oral 
absorption are metabolized by the oxidative enzymes which eventually affect their half-
life and oral bioavailability.
85,86
 Drug discovery and lead identification/optimization can 
be reinforced by assessing the metabolic fate of orally administered drugs early during 
lead optimization using simple microsomal incubation experiments. Thus the 
identification of small molecule antioxidants having good biological activity and reduced 
lability to oxidative metabolism has become a critical goal. 
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CHAPTER 2 
 
 
SYNTHESIS AND CHARACTERIZATION OF PYRIDINOL AND PYRIMIDINOL 
AS MULTIFUNCTIONAL RADICAL QUENCHERS 
 
2.1. Introduction 
 
 
Mitochondrial dysfunction has been proposed in the etiology of various 
pathologies, including cardiovascular and neurodegenerative diseases, such as 
Alzheimer’s disease and Parkinson’s disease, ischemia-reperfusion (IR) injury, diabetes 
and aging.
47-50
 To treat these disorders, it is imperative to target mitochondria, especially 
the electron transport chain. One of the methodologies currently used for the treatment of 
mitochondrial and neurodegenerative diseases where endogenous antioxidant defenses 
are inadequate for protecting against ROS involves the administration of exogenous 
antioxidants.
54-57,87
 Coenzyme Q10 (CoQ10), present endogenously within the inner 
mitochondrial membrane (IMM), plays a central role in serving as an electron shuttle, 
connecting complex I and complex II to complex III. The reduced form of endogenous 
CoQ10, CoQ10H2, found predominantly in the IMM is the most potent natural lipophilic 
antioxidant. It can be converted back to CoQ10 proficiently by the respiratory chain via 
redox cycling (Figure 2.1).
88-90
 
 
Figure 2.1. Scheme Displaying the Redox Cycling of CoQn in the IMM. 
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 It is widely accepted and well supported by various in vitro studies that CoQ10H2 
is able to inhibit lipid peroxidation by sequestering the radicals generated in the chain 
initiation process, and by quenching superoxide which generates ubisemiquinone and 
hydrogen peroxide. Hence, CoQ10 has been used therapeutically in CoQ10 deficient cells 
to restore the proper electron flow between the complexes and avert accumulation of 
electrons at complex I. This ultimately helps in reducing oxidative stress due to ROS 
generation.  But its utility in restoring mitochondrial function by augmenting the level of 
antioxidants is limited due to its extreme hydrophobicity and consequent poor 
bioavailability. CoQ10 is accumulated in the outer mitochondrial membrane (OMM) and 
cannot impart any efficacy without access to the inner mitochondrial membrane 
(IMM).
88,91-96
 
Idebenone is a synthetic analogue of CoQ10 initially developed by Takeda 
Pharmaceuticals for treating cognitive disorders and Alzheimer’s disease.97 Idebenone 
has conditional approval in Canada where it is sold under the trade name Catena® for the 
treatment of Friedreich’s Ataxia.98-100 A Phase IIIb clinical trial on Friedreich’s ataxia 
patients has recently been completed in North America but the results are still pending. 
Accordingly, idebenone is not yet approved as a prescribed drug in North America or 
Europe.
101-104
 Conversely, studies have established the inhibitory effects of idebenone on 
complex I in the ETC and documented its poor bioavailability after passage through the 
liver (Figure 2.2).
105-107 
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Figure 2.2. Natural and Synthetic Quinone Antioxidants. 
 
There is considerable interest in identifying the structural elements in CoQ10 
responsible for imparting therapeutic efficacy of utility in treating neurodegenerative and 
mitochondrial disorders. Porter and coworkers first reported the nitrogen heterocyclic -
TOH type analogues having one nitrogen atom (3-position) and two nitrogen atoms (3- 
and 5- positions) in the phenolic ring,
108-110
 as well as bicyclic pyridinol type analogues 
formed by fusion of C5 in the ring with the alkyl group of the amine (Figure 2.3).
111
 It 
has been demonstrated both by in silico and in vitro experiments that nitrogen 
incorporation in the phenolic ring contributes to improved air stability due to increased 
ionization potential (IP) and lowering of O–H bond dissociation energy (BDE).108-110 
 
 
Figure 2.3. Chemical Structures of -TOH Type Analogues Having Pyrimidine and 
Pyridine core (a and b) and Bicyclic Pyridinol Analogues (c and d). 
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These series of compounds behave similarly to α-TOH and could be regenerated 
in the cell by cooperating with the other redox molecules, such as vitamin C and 
NADH.
82-84
 The pyridinol and pyrimidinol analogues could be recycled by superoxide 
also, as they can be reduced at the oxidizing potentials (Figure 2.4).
112
  
 
Figure 2.4. (a) Resonance Stabilized 5-Pyridinoxyl/Pyrimidinoxyl Radical Generated by 
the Reaction of Analogues with Lipid Radicals and its Relationship to the Reduced and 
Oxidized Forms of the Corresponding Analogues. (b) Proposed Catalytic Cycle for the 
Compounds Acting as Lipid Radicals and Superoxide Quencher. Adapted From Ref. 112. 
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Encouraging results have been obtained in vitro using the pyrimidinol and 
pyridinol analogues, as assessed by their ability to scavenge free radicals, and preserve 
mitochondrial function from oxidative stress in a number of cell lines originated from 
patients having mitochondrial and neurodegenerative diseases.
112-118
 Some of the 
pyrimidinol analogues have supported ATP production in cultured CoQ10 deficient 
lymphocytes and FRDA fibroblasts and lymphocytes. These compounds are referred to as 
multifunctional radical quenchers (MRQs) as they suppress one-electron trafficking in 
dysfunctional mitochondria, with multiple beneficial effects.
117,118
 
These encouraging results prompted further structural optimization studies that 
might lead to more potent and efficacious compounds. The optimized compounds will 
ultimately be studied for in vivo efficacy in animal models of mitochondrial and 
neurodegenerative diseases. The structures of the compound 2.1 and the lead compounds 
2.2 (pyrimidinol) and 2.9 (pyridinol) are shown in Figures 2.5 and 2.6. The structures of 
the rationally designed and synthesized compounds are shown in Figures 2.6 to 2.10. 
 
 
  
Figure 2.5. Compounds Chosen for Further Structural Optimization. 
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Figure 2.6. Series of Pyridinol Analogues With Linear Alkyl Side Chains Synthesized 
and Evaluated. 
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Figure 2.7. Series of Pyridinol Analogues With Modified Alkyl Side Chains Synthesized 
and Evaluated. 
 
 
 
 
Figure 2.8. Series of Pyridinol Analogues With Cyclic Amino Groups Synthesized and 
Evaluated. 
 
 
 
Figure 2.9. Bicyclic Pyridinol Analogues Synthesized and Evaluated. 
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Figure 2.10. Series of Pyrimidinol Analogues Synthesized and Evaluated. 
 
 
2.2. Results 
 
In order to synthesize pyridinol analogues with different alkyl side chain lengths, 
the fully protected heterocyclic core was first prepared starting from pyridoxine 
hydrochloride. Aliphatic side chains were attached to the core followed by deprotection 
to obtain the proposed analogues (Figure 2.11). The synthetic routes employed in this 
thesis were considerably more efficient than in previously reported studies.
116
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Figure 2.11. Retrosynthetic Analysis for the Pyridinol Analogues With a Dimethylamino 
Substituent at the Position Ortho to the Ring Nitrogen. 
 
The synthetic approach for pyridinol analogues having a cyclic amino group 
involved the synthesis of 6-iodo substituted heterocyclic core from pyridoxine 
hydrochloride (Figure 2.12). The fully substituted core was obtained by C-N coupling of 
a cyclic amine with benzyl protected 6-iodo pyridinol. Aliphatic side chains were 
attached to the core followed by deprotection to obtain the proposed analogues. 
 
Figure 2.12. Retrosynthetic Analysis for the Pyridinol Analogues With a Cyclic Amino 
Substituent at the Position Ortho to the Ring Nitrogen. 
 
 
In order to synthesize bicyclic pyridinol analogues with different length alkyl side 
chains, the fully protected heterocyclic core was first prepared starting from potassium 
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phthalamide and 2-bromopropionate (Figure 2.13). Aliphatic side chains were attached to 
the core followed by deprotection to obtain the proposed analogues. 
 
 
 
Figure 2.13. Retrosynthetic Analysis for the Bicyclic Pyridinol Analogues. 
 
 
The synthetic approach for pyrimidinol analogues having a cyclic amino group 
involved the synthesis of the substituted heterocyclic core by C-N coupling of a cyclic 
amine with a 2-chloro- or 2-iodo-pyrimidinol (Figure 2.14). Aliphatic side chains were 
incorporated onto the core followed by introduction of a hydroxyl group to obtain the 
desired analogues. 
 
 
Figure 2.14. Retrosynthetic Analysis for the Pyrimidinol Analogues. 
 
 
In order to synthesize pyrimidinol analogues with a hexadeuterated 
dimethylamino group, a concise strategy was followed (Figure 2.15). 2-Amino-4-chloro-
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6-methyl pyrimidine was converted to the fully deuterated dimethylamino substituted 
pyrimidine, which was followed by the replacement of the chloro substituent with an 
alkoxy group. An aliphatic side chain was introduced onto the core followed by 
introduction of a hydroxyl group to obtain the desired analogues. 
 
 
 
Figure 2.15. Retrosynthetic Analysis for the Pyrimidinol Analogues With a Fully 
Deuterated Dimethylamine. 
 
2.2.1. Synthesis of Pyridinol and Pyrimidinol Analogues 
2.2.1.1. Synthesis of Pyridinol Analogues With Linear Alkyl Side Chains 
The route employed for synthesis of the desired pyridinol antioxidants with linear 
alkyl side chains is illustrated in Scheme 2.1. Accordingly, 6-amino-2,4,5-
trimethylpyridin-3-ol (2.33) was synthesized in 23% yield by a method reported 
previously.
117,119
 Reductive alkylation of 2.33 using formalin and sodium 
cyanoborohydride afforded 2.34 in 94% yield. The intermediate 3-pyridinol (2.34) was 
O-benzylated using benzyl bromide and NaH to afford the O-benzylated core 2.35 in 
72% yield. Aliphatic side chains were introduced by alkylation of 2.35 using Schlosser’s 
super base (a mixture of KOtBu and n-BuLi) and the appropriate alkyl bromide.
120
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Alkylation resulted in a pair of regioisomers which were readily separated by silica gel 
chromatography to afford 2.36–2.45. The alkylated products were treated with 
Pearlman’s catalyst and H2 in MeOH to afford the desired pyridinol analogues 2.3–2.12.  
 
 
 
Scheme 2.1. Route Employed for the Synthesis of Pyridinol Analogues With Linear 
Alkyl Side Chains (2.3  2.12). 
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2.2.1.2. Synthesis of Pyridinol Analogues With Modified Linear Alkyl Side Chains 
 
Compound 2.46 was synthesized by a cross metathesis reaction between vinyl 
cyclohexane and 11-bromo-1-undecene using 2nd generation Grubb’s catalyst121 
followed by hydrogenation in presence of palladium-on-carbon (Scheme 2.2). The 
modified side chain was introduced by alkylation of 2.35 using Schlosser’s super base (a 
mixture of KOtBu and n-BuLi).
120
 Alkylation resulted in a pair of regioisomers which 
were readily separated by silica gel chromatography to afford 2.47 and 2.48 in 14% and 
42% yields, respectively. The alkylated products were treated with Pearlman’s catalyst 
and H2 in MeOH to afford the desired pyridinol analogues 2.13 and 2.14 in 82% and 78% 
yields, respectively. 
 
 
 
Scheme 2.2. Route Employed for the Synthesis of Pyridinol Analogues Having Terminal 
Cyclohexyl Groups (2.13 and 2.14). 
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10-Phenyldecyl-4-methylbenzenesulfonate (2.49) was synthesized in 85% yield 
by tosylation of 10-phenyldecan-1-ol using p-toluenesulfonyl chloride, TEA and DMAP 
(Scheme 2.3). The modified side chain was introduced by alkylation of 2.35 using 
TMEDA and n-BuLi to afford 2.50 in 24% yield. The alkylated product was treated with 
Pearlman’s catalyst and H2 in MeOH to obtain the desired pyridinol analogue 2.15 in 
76% yield. 
 
 
 
Scheme 2.3. Route Employed for the Synthesis of a Pyridinol Analogue Having a 
Terminal Phenyl Group (2.15). 
 
 
1-Bromo-11-phenylundecane (2.51) was synthesized in 85% yield by a cross 
metathesis reaction between styrene and 11-bromo-1-undecene using 2nd generation 
Grubb’s catalyst121 followed by hydrogenation in presence of palladium-on-carbon 
(Scheme 2.4). The modified side chain was introduced by alkylation of 2.35 using 
Schlosser’s super base (a mixture of KOtBu and n-BuLi).120 Alkylation resulted in a pair 
of regioisomers which were readily separated by silica gel chromatography to afford 2.52 
and 2.53 in 16% and 43% yields, respectively. The alkylated products were treated with 
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Pearlman’s catalyst and H2 in MeOH to afford the desired pyridinol analogues 2.16 and 
2.17 in 70% and 79% yields, respectively. 
 
 
 
Scheme 2.4. Route Employed for the Synthesis of Pyridinol Analogues Having Terminal 
Phenyl Groups (2.16 and 2.17). 
 
(7R,11R,E)-1-Bromo-3,7,11,15-tetramethylhexadec-2-ene (2.54) was synthesized 
in 64% yield by bromination of phytol using PBr3 in pentane (Scheme 2.5).
122
 The 
modified side chain was introduced by alkylation of 2.35 using TMEDA and n-BuLi to 
afford 2.55 in 20% yield.
116
 The alkylated product was treated with Pearlman’s catalyst 
and H2 in MeOH to obtain the desired pyridinol analogue 2.18 in 85% yield. 
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Scheme 2.5. Route Employed for the Synthesis of Pyridinol Analogue Having Phytyl 
Side Chain (2.18). 
 
2.2.1.3. Synthesis of Pyridinol Analogues With Cyclic Amino Groups 
A different synthetic route was employed to synthesize the pyridinol analogues 
containing an exocyclic amine (Scheme 2.6). First, commercially available pyridoxine 
hydrochloride (vitamin B6) was treated with SOCl2 then with zinc dust in AcOH, 
followed by treatment with morpholine–iodine charge transfer complex (2.56) to afford 
iodopyridinol (2.57) in 58% yield.
119,123
 Morpholine–iodine complex was synthesized by 
a reported method.
124,125
 Briefly, morpholine and iodine were stirred in benzene in the 
dark to afford the charge transfer complex (2.56) in 88% yield. O-Benzylation of 2.57 
was achieved in 62% yield using K2CO3 and BnBr. Catalytic cross-coupling of halide 
2.58 with azetidine was achieved using tris(dibenzylideneacetone)dipalladium (0) 
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(Pd2(dba)3), 1,3-bis(2,6-diisopropylphenyl)-imidazolium chloride (ImPrPh2•HCl) and 
KOtBu to afford 2.59 in 71% yield.
126
 The hexadecyl side chain was introduced using 
Schlosser’s super base and 1-bromopentadecane to afford 2.60 and 2.61 in 23% and 40% 
yields, respectively.
120
 Finally, treatment of 2.60 and 2.61 with Pearlman’s catalyst and 
H2 in MeOH afforded analogues 2.19 and 2.20 in 85% and 94% yields, respectively. 
 
 
 
Scheme 2.6. Route Employed for the Synthesis of Pyridinol Analogues With an 
Azetidine Substituent (2.19 and 2.20). 
 
In order to synthesize a pyrimidinol analogue with a 6-member exocyclic amine 
(piperidine) core 2.58 was used (Scheme 2.7). Catalytic cross-coupling of halide 2.58 
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with piperidine was achieved using tris(dibenzylideneacetone)dipalladium (0) 
(Pd2(dba)3), 1,3-bis(2,6-diisopropylphenyl)-imidazolium chloride (ImPrPh2•HCl) and 
KOtBu to afford 2.62 in 79% yield.
126
 The hexadecyl side chain was introduced using 
Schlosser’s super base and 1-bromopentadecane to afford 2.63 in 43% yield.120 Finally, 
treatment of 2.63 with Pearlman’s catalyst and H2 in MeOH afforded 2.21 in 66% yield. 
 
 
 
 
Scheme 2.7. Route Employed for the Synthesis of Pyridinol Analogue With a Piperidine 
Substituent (2.21). 
 
The synthesis of morpholine substituted pyridinol analogues involved the 
catalytic cross-coupling of halide 2.58 with morpholine using 
tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3), 1,3-bis(2,6-diisopropylphenyl)-
imidazolium chloride (ImPrPh2•HCl) and KOtBu to afford 2.64 in 81% yield (Scheme 
2.8).
126
 The hexadecyl side chain was introduced using Schlosser’s super base and 1-
bromopentadecane to afford 2.65 and 2.66 in 14% and 42% yields, respectively.
120
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Finally, treatment of 2.65 and 2.66 with Pearlman’s catalyst and H2 in MeOH afforded 
analogues 2.22 and 2.23 in 67% and 97% yields, respectively. 
 
 
Scheme 2.8. Route Employed for the Synthesis of Pyridinol Analogues With a 
Morpholine Substituent (2.22 and 2.23). 
 
2.2.1.4. Synthesis of Bicyclic Pyridinol Analogues 
In order to synthesize the bicyclic pyridinol analogues, commercially available 
potassium phthalimide was treated with 2-bromopropionate in dry DMF to afford 2.67 in 
98% yield. Rearrangement of compound 2.67 by treatment with freshly prepared sodium 
methoxide in MeOH afforded 2.68 in 86% yield.
127,128
 Compound 2.68 was O-benzylated 
using benzyl bromide to afford 2.69 in 72% yield.  Treatment of 2.69 with neat POCl3 
afforded 2.70 in 57% yield.
129
 The catalytic cross-coupling of halide 2.70 with 
dimethylamine hydrochloride using tris(dibenzylideneacetone)dipalladium (0) 
(Pd2(dba)3), 1,3-bis(2,6-diisopropylphenyl)-imidazolium chloride (ImPrPh2•HCl) and 
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KOtBu afforded 2.71 in 79% yield (Scheme 2.9).
126
 The protected bicyclic pyridinol core 
was alkylated by generating carbanion using Schlosser’s super base and adding 1-
bromoalkane to afford 2.72 and 2.73 in 32% and 35% yields, respectively.
120
 Finally, 
treatment of 2.72 and 2.73 with Pearlman’s catalyst and H2 in MeOH–CHCl3 afforded 
analogues 2.24 and 2.25 in 12% and 23% yields, respectively. 
 
 
 
Scheme 2.9. Route Employed for the Synthesis of Bicyclic Pyridinol Analogues (2.24 
and 2.25). 
 
2.2.1.5. Synthesis of Pyrimidinol Analogues With Cyclic Amino Groups 
 
 The route employed for the synthesis of pyrimidinol analogue 2.26 is illustrated in 
Scheme 2.10. Accordingly, 2-amino-4-methoxy-6-methylpyrimidine was treated with 
isoamylnitrite, diiodomethane, iodine and CuI to afford 2-iodo-4-methoxy-6-methyl 
pyrimidine (2.74) in 37% yield.
130
 The catalytic cross coupling of halide 2.74 using 
azetidine hydrochloride, CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4Phen) and 
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Cs2CO3 afforded 2.75 in 72% yield.
131
 The hexadecyl side chain was introduced using n-
BuLi and 1-bromopentadecane to afford 2.76 in 25% yield. Treatment of 2.76 with N-
bromosuccinimide in the dark afforded 2.77 in 96% yield. The final product, 2.26, was 
obtained in 34% yield by treatment of 2.77 with n-BuLi in presence of TMEDA, then 
with trimethyl borate, and lastly with hydrogen peroxide in the subsequent steps.
118 
 
 
 
Scheme 2.10. Route Employed for the Synthesis of Methoxy Pyrimidinol Analogue With 
a Cyclic Amino Group (2.26). 
 
 
The synthetic scheme employed for pyrimidinol analogue 2.27 is illustrated in 
Scheme 2.11. The catalytic cross coupling of 2-chloro-4,6-dimethylpyrimidine using 
azetidine hydrochloride, CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4Phen) and 
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Cs2CO3 afforded 2.78 in 65% yield.
131
 The hexadecyl side chain was introduced using n-
BuLi and 1-bromopentadecane to afford 2.79 in 42% yield. Treatment of 2.79 with N-
bromosuccinimide in the dark afforded 2.80 in 96% yield. The final product, 2.27, was 
obtained in 55% yield by the treatment of 2.80 with trimethyl borate followed by n-BuLi, 
and lastly with hydrogen peroxide.
118
 
 
 
 
 
Scheme 2.11. Route Employed for the Synthesis of Pyrimidinol Analogue With a Cyclic 
Amino Group (2.27). 
 
The synthesis of 2.28 started with the treatment of 2,4-dichloro-6-
methylpyrimidine with EtOH and NaH in anh THF to afford 2.81 in 51% yield (Scheme 
2.12). The catalytic cross coupling of 2-chloro-4-ethoxy-6-methylpyrimidine using 
azetidine hydrochloride, CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4Phen) and 
Cs2CO3 afforded 2.82 in 84% yield.
131
 The hexadecyl side chain was introduced using n-
BuLi and 1-bromopentadecane to afford 2.83 in 45% yield. Treatment of 2.83 with N-
bromosuccinimide in the dark afforded 2.84 in 94% yield. The final product 2.28 was 
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obtained in 72% yield by the treatment of 2.84 with n-BuLi followed by trimethyl borate, 
and lastly with hydrogen peroxide.
118
 
 
 
 
Scheme 2.12. Route Employed for the Synthesis of Ethoxy Pyrimidinol Analogue 2.28. 
 
 
The synthetic scheme employed for the preparation of 2.29 is illustrated in 
Scheme 2.13. 2,4-Dichloro-6-methylpyrimidine was first treated with 1-pentadecanol and 
NaH in anh THF to afford crude 2-chloro-4-pentadecoxy-6-methylpyrimidine, which was 
coupled with azetidine hydrochloride using CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline 
(Me4Phen) and Cs2CO3 to afford 2.85 in 76% yield over two steps.
131
 Treatment of 2.85 
with N-bromosuccinimide in the dark afforded 2.86 in 90% yield. The final product 2.29 
was obtained in 60% yield by the treatment of 2.86 with n-BuLi followed by trimethyl 
borate, and lastly with hydrogen peroxide.
118
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Scheme 2.13. Route Employed for the Synthesis of Pyrimidinol Analogue 2.29. 
 
 
The route employed for the synthesis of 2.30 is illustrated in Scheme 2.14. 2,4-
Dichloro-6-methylpyrimidine was first treated with 1-cyclobutanol and NaH in anh THF 
to afford crude 2-chloro-4-cyclobutoxy-6-methylpyrimidine, which was coupled with 
azetidine hydrochloride using CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4Phen) 
and Cs2CO3 to afford 2.87 in 74% yield over two steps.
131
 The hexadecyl side chain was 
introduced using n-BuLi and 1-bromopentadecane to afford 2.88 in 37% yield. Treatment 
of 2.88 with N-bromosuccinimide in the dark afforded 2.89 in 92% yield. The final 
product 2.30 was obtained in 60% yield by the treatment of 2.89 with n-BuLi followed by 
trimethyl borate, and lastly with hydrogen peroxide.
118
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Scheme 2.14. Route Employed for the Synthesis of Pyrimidinol Analogue 2.30. 
 
 
2.2.1.6. Synthesis of Deuterated Pyrimidinol Analogues 
 
 
Synthesis of 2.31 started with the treatment of 2-amino-4-chloro-6-
methylpyrimidine with CD3I and NaH in anh THF to afford 2.90 in 86% yield (Scheme 
2.15). Treatment of compound 2.90 with CD3OD and NaH in anh THF afforded 2.91 in 
66% yield in the next step. The hexadecyl side chain was introduced using n-BuLi and 1-
bromopentadecane to afford 2.92 in 47% yield. Treatment of 2.92 with N-
bromosuccinimide in the dark afforded 2.93 in 90% yield. The final product 2.31 was 
obtained in 63% yield by the treatment of 2.93 with n-BuLi followed by trimethyl borate, 
and lastly with hydrogen peroxide.
118
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Scheme 2.15. Route Employed for the Synthesis of Pyrimidinol Analogue 2.31. 
 
 
The synthetic route employed for the preparation of 2.32 is illustrated in Scheme 
2.16. Treatment of compound 2.90 with 1-cyclobutanol and NaH in anh THF afforded 
2.94 in 65% yield. The hexadecyl side chain was introduced using n-BuLi and 1-
bromopentadecane to afford 2.95 in 56% yield. Treatment of 2.95 with N-
bromosuccinimide in the dark afforded 2.96 in 91% yield. The final product 2.32 was 
obtained in 67% yield by the treatment of 2.96 with n-BuLi followed by trimethyl borate, 
and lastly with hydrogen peroxide.
118
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Scheme 2.16. Route Employed for the Synthesis of Pyrimidinol Analogue 2.32. 
 
 
2.2.2. Biochemical and Biological Evaluation of Pyridinol and Pyrimidinol 
Analogues 
2.2.2.1. Mitochondrial Electron Transport Chain Function 
 
Inhibition of any of the mitochondrial respiratory chain complexes can limit the 
potential therapeutic utility of CoQ10 analogues. Accordingly, it is desirable to prepare 
analogues that are minimally inhibitory to the respiratory chain. As an initial screen, the 
effects of the compounds on NADH oxidase activity have been studied, which 
encompasses the functions of mitochondrial complexes I, III and IV. The importance of 
side chain length on the interaction of coenzyme Q10 analogues with the mitochondrial 
respiratory chain to achieve improved bioenergetic and antioxidant activity have been 
well documented.
115-118,132
 In the light of those findings, analogues having different side 
chain lengths attached to the modified redox core have been designed and synthesized 
(Figures 2.6–2.10). The inhibitory effects of the test compounds on NADH oxidase 
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(complexes I, III and IV) function were evaluated using submitochondrial particles 
(SMP). The results are presented in Table 2.1, and show that the inhibitory behavior of 
these compounds was dose dependent. Compound 2.1, having a 10 carbon atom side 
chain and a polar terminal hydroxyl group, strongly inhibited NADH oxidase, as had 
been shown before.
116,117
 Removing the polar hydroxyl group (compounds 2.3 and 2.4) 
resulted in a slightly less inhibitory effect than was observed for compound 2.1. 
Increasing the side chain length to 13, 15, 16 and 19 carbon atoms largely abolished the 
inhibitory effect of these derivatives (2.5–2.12).  Modifying the linear alkyl side chain as 
in compounds 2.13–2.18 afforded no significant improvement over compounds 2.5–2.12. 
Replacement of the dimethylamino moiety at position 6 of the pyridinol redox core with a 
cyclic amino group (2.19–2.23) produced no significant incremental inhibitory effect on 
the respiratory chain. The bicyclic pyridinols (2.24 and 2.25) were also found not to show 
much improvement over other pyridinols. 
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Table 2.1. The Inhibitory Effect of Compounds on Bovine Heart Mitochondrial NADH 
Oxidase Activity (Complexes I, III and IV). The Experiment was Performed by Sriloy 
Dey. 
 NADH oxidase activity (%)
a
 
Compound 1 µM 5 µM 10 µM 
Untreated control 100 100 100 
2.1 27 ± 1 9 ± 1 6 ± 1 
2.3 35 ± 1 28 ± 1 13 ± 1 
2.4 49 ± 1 35 ± 1 8 ± 1 
2.5 81 ± 1 73 ± 1 43 ± 1 
2.6 99 ± 1 96 ± 2 75 ± 2 
2.7 81 ± 1 73 ± 1 43 ± 1 
2.8 88 ± 1 85 ± 1 80 ± 1 
2.9 98 ± 2 95 ± 2 92 ± 1 
2.10 95 ± 1 93 ± 1 86 ± 1 
2.11 93 ± 1 88 ± 1 85 ± 1 
2.12 98 ± 1 83 ± 1 81 ± 1 
2.13 62 ± 2 57 ± 1 40 ± 1 
2.14 91 ± 1 90 ± 3 91 ± 1 
2.15 85 ± 2 72 ± 3 62 ± 2 
2.16 57 ± 3 37 ± 1 20 ± 1 
2.17 85 ± 2 72 ± 3 62 ± 2 
2.18 85 ± 1 85 ± 2 79 ± 1 
2.19 93 ± 4 94 ± 2 95 ± 3 
2.20 95 ± 2 89 ± 2 79 ± 5 
2.21 81 ± 3 78 ± 4 67 ± 5 
2.22 96 ± 2 74 ± 9 69 ± 7 
2.23 79 ± 4 73 ± 8 52 ± 6 
2.24 98 ± 1 89 ± 2 83 ± 2 
2.25 79 ± 2 77 ± 2 74 ± 2 
a
 Relative to untreated control. 
 
2.2.2.2. Inhibition of Lipid Peroxidation 
 
The ability of the pyridinol analogues to quench lipid peroxidation was studied in 
FRDA lymphocytes that had been depleted of glutathione by treatment with diethyl 
maleate (DEM). C11-BODIPY
581/591
, a hydrophobic fatty acid fluorophore which inserts 
preferentially in membranes, has been shown previously to enable quantification of fatty 
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acid oxidation and antioxidant activity in live cells.
133
 The oxidation of the 
polyunsaturated butadienyl portion of the dye results in a shift of the fluorescence 
emission peak from red to green. The degree of probe oxidation was followed using flow 
cytometry as reported before.
115-117,133
 Cells were analyzed for a shift of the fluorescence 
emission peak from red to green with excitation/emission wavelengths of 490/510 nm. 
The median mean fluorescence values were used for further analysis. Increasing green 
fluorescence intensity indicated lipid peroxidation. The results, presented in Table 2.2, 
show the most potent lipid peroxidation quenching activity for compounds 2.6–2.10, 
2.19, 2.20 and 2.23. Compound 2.1 had lower activity for suppressing lipid peroxidation 
in comparison with analogues with the same side chain length lacking a hydroxyl group 
(2.3 and 2.4). These results were in agreement with the previous reports for pyrimidinol 
derivatives.
116,118
 No difference in the lipid peroxidation scavenging activity was noted 
for the regioisomeric pairs of pyridinol analogues. Compounds 2.19 and 2.20, having an 
azetidine group, and 2.22 and 2.23, having a morpholine group at the 6-position of the 
pyridinol core, were slightly less effective than their counterparts with the dimethylamino 
moiety (2.9 and 2.10). The analogues having nonadecyl side chains (2.11 and 2.12) had 
significantly reduced ability to quench lipid peroxidation in comparison to the analogues 
having 16 carbon atom side chain (2.9, 2.10, 2.19 and 2.20). Compounds (2.13–2.17) 
having a modified side chain exhibited a moderate ability to quench lipid peroxidation in 
comparison to 2.9 and 2.10. Compound 2.18, having a phytyl-type side chain and bicyclic 
pyridinols 2.24 and 2.25 did not exhibit good suppression of lipid peroxidation. 
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Table 2.2. Suppression of Lipid Peroxidation by Pyridinol Antioxidants in Cultured 
FRDA Lymphocytes Treated with DEM. The Experiment was Performed by Dr. Omar 
M. Khdour. 
 
 Lipid peroxidation scavenging activity (%) 
 100 nM 250 nM 
Untreated control 100 100 
2.1 25 ± 4 45 ± 3 
2.3 70 ± 3 80 ± 3 
2.4 67 ± 4 79 ± 3 
2.5 76 ± 5 86 ± 4 
2.6 81 ± 3 88 ± 2 
2.7 78 ± 5 89 ± 2 
2.8 76 ± 6 86 ± 3 
2.9 85 ± 1 94 ± 2 
2.10 81 ± 3 92 ± 2 
2.11 35 ± 3 58 ± 5 
2.12 33 ± 6 60 ± 3 
2.13 57 ± 6 77 ± 3 
2.14 60 ± 2 80 ± 3 
2.15 68 ± 4 82 ± 3 
2.16 75 ± 2 83 ± 3 
2.17 71 ± 2 84 ± 2 
2.18 9 ± 1 26 ± 3 
2.19 68 ± 3 85 ± 4 
2.20 70 ± 3 87 ± 2 
2.21 44 ± 5 68 ± 5 
2.22 62 ± 4 78 ± 3 
2.23 70 ± 3 84 ± 4 
2.24 8 ± 3 14 ± 4 
2.25 10 ± 3 12 ± 4 
 
 
2.2.2.3. Suppression of Reactive Oxygen Species 
 
The ability of the pyridinol analogues 2.1–2.25 to suppress ROS induced by 
depletion of glutathione was evaluated in FRDA lymphocyte cells. The intracellular ROS 
level was measured based on the ROS-induced formation of the highly fluorescent 
product 2′,7′-dichlorofluorescein (DCF) from the non-fluorescent dye 2′,7′-
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dichlorodihydrofluorescein diacetate (DCFH-DA).
134
 The results are presented in Table 
2.3, and fairly closely paralleled those found for lipid peroxidation. The regioisomeric 
compounds 2.9 and 2.10 were the most potent in suppressing ROS, and did so in a 
concentration dependent manner. Compounds 2.5–2.8 were also good in suppressing 
ROS but were slightly less effective at 250 nM concentration as compared to 2.9.The 
compounds having a decyl side chain (2.3 and 2.4) afforded slightly less protection 
against ROS. Compound 2.1 was the least effective analogue in suppressing ROS. 
Compounds with side chains longer than 16 carbon atoms (2.11 and 2.12) were poor ROS 
quenchers, in agreement with the present lipid peroxidation results. Compounds with a 
modified chain (2.13–2.17) showed moderate ROS quenching similar to compounds 
having a decyl side chain (2.3 and 2.4). Once again the regioisomeric analogues having 
an azetidine group (2.19 and 2.20) or morpholine group (2.22 and 2.23) were slightly less 
effective than the regioisomers pair (2.9 and 2.10) in suppressing ROS levels. Compound 
2.21 with piperidine group was even less effective than the other analogue having cyclic 
amino group. The bicyclic pyridinols (2.24 and 2.25) and compound 2.18 did not 
effectively suppress ROS.  
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Table 2.3. Suppression of ROS Production by Pyridinol Antioxidants in Cultured FRDA 
Lymphocytes Pretreated with DEM. The Experiment was Performed by Dr. Omar M. 
Khdour. 
 
 ROS Scavenging Activity (%) 
Compound 100 nM 250 nM 500 nM 
Untreated control 100 100 100 
2.1 3 ± 1 17 ± 4 25 ± 5 
2.3 47 ± 7 70 ± 6 80 ± 3 
2.4 49 ± 6 72 ± 6 89 ± 2 
2.5 68 ± 1 87 ± 2 95 ± 1 
2.6 70 ± 4 85 ± 2 97 ± 3 
2.7 79 ± 2 92 ± 2 94 ± 2 
2.8 77 ± 3 90 ± 3 94 ± 1 
2.9 80 ± 4 97 ± 2 100 ± 1 
2.10 82 ± 5 95 ± 5 97 ± 2 
2.11 4 ± 1 24 ± 4 37 ± 4 
2.12 5 ± 2 31 ± 4 43 ± 3 
2.13 46 ± 3 72 ± 2 83 ± 2 
2.14 43 ± 5 66 ± 5 80 ± 4 
2.15 58 ± 5 83 ± 3 88 ± 4 
2.16 64 ± 2 85 ± 4 96 ± 3 
2.17 61 ± 5 85 ± 2 90 ± 3 
2.18 7 ± 2 17 ± 3 30 ± 2 
2.19 57 ± 4 78 ± 3 88 ± 7 
2.20 62 ± 3 80 ± 3 89 ± 4 
2.21 35 ± 3 59 ± 4 74 ± 4 
2.22 56 ± 4 70 ± 3 80 ± 4 
2.23 64 ± 2 83 ± 4 90 ± 3 
2.24 12 ± 2 26 ± 5 33 ± 2 
2.25 10 ± 3 25 ± 3 34 ± 4 
 
 
2.2.2.4. Preserving Mitochondrial Inner Membrane Potential (Δm) 
 
The ability of the test compounds to maintain mitochondrial inner membrane 
potential (Δψm) under conditions of oxidative stress was studied as described 
previously.
115-118
 Δψm was measured using tetramethylrhodamine methyl ester (TMRM), 
a lipophilic cation that accumulates selectively within polarized mitochondria. The extent 
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of its uptake, as measured by intensity of cellular TMRM red fluorescence, is 
proportional to mitochondrial function.
135
 Figure 2.16 illustrates representative two-
dimensional density dot plots of TMRM-stained lymphocyte cells showing the 
percentage of cells with intact Δψm (TMRM fluorescence in top right quadrant) vs the 
percentage of cells with depolarized Δψm (TMRM fluorescence in bottom left and right 
quadrants). Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), a 
commonly used uncoupler of oxidative phosphorylation in mitochondria, was employed 
as a positive control to dissipate the chemiosmotic proton gradient, which results in 
lowering of TMRM fluorescence as a result of the depolarization of mitochondrial inner 
membrane potential. Table 2.4 summarizes the percentage of FRDA lymphocytes with 
intact Δψm in the flow cytometric dot plot profiles. Treatment with 5 mM DEM resulted 
in a decrease in the percentage of cells with TMRM fluorescence in the top right 
quadrant, indicating depolarization of Δψm upon DEM treatment. Compounds that 
suppress ROS and lipid peroxidation may be expected to preserve mitochondrial 
membrane potential under conditions of induced oxidative stress.  Compound 2.1, having 
the idebenone side chain, was the least active of the pyridinols in this assay, consistent 
with the ROS and lipid peroxidation results. Again, the analogues with longer side chains 
(2.11 and 2.12), compound with phytyl type side chain (2.18) and bicyclic pyridinols 
(2.24 and 2.25) were also less effective in preventing mitochondrial depolarization under 
oxidative stress. The regioisomeric pair with 10, 13, 15 and 16 carbon atoms chain length 
(2.3–2.10) again conferred the good protection, and acted in a dose-dependent manner 
(Figure 2.16). The azetidine analogues (2.19 and 2.20) and morpholine analogues (2.22 
and 2.23) were slightly less effective in preserving Δψm at lower concentration than the 
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other hexadecyl side chain analogues (2.9 and 2.10), giving results similar to the ROS 
and lipid peroxidation assays.  
 
Control DEM FCCP 
   
2.1 (100 nM) 2.1 (250 nM) 2.1 (500 nM) 
   
2.3 (100 nM) 2.3 (250 nM) 2.3 (500 nM) 
   
2.4 (100 nM) 2.4 (250 nM) 2.4 (500 nM) 
   
   
2.5 (100 nM) 2.5 (250 nM) 
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2.6 (100 nM) 2.6 (250 nM) 
  
2.7 (100 nM) 2.7 (250 nM) 2.7 (500 nM) 
   
2.8 (100 nM) 2.8 (250 nM) 2.8 (500 nM) 
   
2.9 (100 nM) 2.9 (250 nM) 2.9 (500 nM) 
   
2.10 (100 nM) 2.10 (250 nM) 2.10 (500 nM) 
   
2.11 (100 nM) 2.11 (250 nM) 2.11 (500 nM) 
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2.12 (100 nM) 2.12 (250 nM) 2.12 (500 nM) 
   
2.13 (100 nM) 2.13 (250 nM) 
  
2.14 (100 nM) 2.14 (250 nM) 
  
2.15 (100 nM) 2.15 (250 nM) 2.15 (500 nM) 
   
2.16 (100 nM) 2.16 (250 nM) 
  
2.17 (100 nM) 2.17 (250 nM) 
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2.18 (100 nM) 2.18 (250 nM) 
  
2.19 (100 nM) 2.19 (250 nM) 2.19 (500 nM) 
   
2.20 (100 nM) 2.20 (250 nM) 2.20 (500 nM) 
   
2.22 (100 nM) 2.22 (250 nM) 2.22 (500 nM) 
   
2.23 (100 nM) 2.23 (250 nM) 2.23 (500 nM) 
   
2.24 (100 nM) 2.24 (250 nM) 2.24 (500 nM) 
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2.25 (100 nM) 2.25 (250 nM) 2.25 (500 nM) 
   
 
Figure 2.16.  Representative Flow Cytometric Two-dimensional Color Density Dot Plot 
Analyses of the Ability of Compounds to Maintain Mitochondrial Membrane Potential 
(Δm) in DEM-treated FRDA Lymphocytes Cells Stained With 250 nM TMRM and 
Analyzed Using the FL2-H Channel as Described in the Experimental Section. The 
Percentage of Cells With Intact Δm is Indicated in the Top Right Quadrant of Captions. 
Representative Examples From at Least two/three Independent Experiments are Shown. 
A Total of 10,000 Events Were Recorded for Each Sample and Analyzed With the 
CellQuest Software (BD Biosciences). The Experiment was Performed by Dr. Omar M. 
Khdour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52   
  
Table 2.4. Pyridinol Antioxidants Preserve Mitochondrial Membrane Potential (Δψm) in 
Cultured FRDA Lymphocytes Pretreated with DEM. The Experiment was Performed by 
Dr. Omar M. Khdour. 
 
 % of cells with intact Δψm 
Compound 100 nM 250 nM 500 nM 
Control 94 ± 2 94 ± 2 94 ± 2 
DEM 13 ± 4 13 ± 4 13 ± 4 
FCCP 20 ± 6 20 ± 6 20 ± 6 
2.1 23 ± 2 38 ± 3 49 ± 2 
2.3 63 ± 3 84 ± 2 89 ± 2 
2.4 58 ± 3 77 ± 2 89 ± 2 
2.5 61 ± 4 79 ± 2 – 
2.6 54 ± 2 77 ± 3 – 
2.7 59 ± 4 78 ± 2 86 ± 2 
2.8 63 ± 4 75 ± 1 88 ± 1 
2.9 69 ± 2 83 ± 2 91 ± 1 
2.10 61 ± 2 81 ± 4 90 ± 2 
2.11 24 ± 2 45 ± 4 – 
2.12 22 ± 3 43 ± 2 – 
2.13 46 ± 4 70 ± 2 – 
2.14 48 ± 4 72 ± 3 – 
2.15 44 ± 3 67 ± 3 84 ± 5 
2.16 49 ± 2 77 ± 2 – 
2.17 38 ± 4 66 ± 4 – 
2.18 20 ± 4 33 ± 4 – 
2.19 62 ± 2 74 ± 3 85 ± 3 
2.20 60 ± 3 80 ± 3 87 ± 3 
2.21 38 ± 6 49 ± 3 67 ± 3 
2.22 54 ± 3 69 ± 4 83 ± 4 
2.23 57 ± 1 73 ± 4 86 ± 1 
2.24 15 ± 5 20 ± 3 42 ± 4 
2.25 13 ± 4 18 ± 4 25 ± 5 
 
 
2.2.2.5. Cellular ATP Levels 
            There is currently no curative treatment for patients with mitochondrial diseases. 
Current goals for mitochondrial disease therapy are focused on increasing production of 
ATP and reducing reactive oxygen species levels in an effort to improve, or at least 
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stabilize, disease signs and symptoms. A nutrient-sensitized screening strategy to identify 
CoQ10 analogues that function within the mitochondrial respiratory chain and augment 
ATP was used as described before.
117,118
 The intracellular ATP level was measured in 
glucose-free media. The cells were grown on galactose-containing media to maximize 
ATP production via oxidative phosphorylation, and they become more sensitive to 
mitochondrial respiratory chain inhibitors than cells grown on glucose medium.
136,137 As 
shown in Table 2.5, 5 µM concentration of compounds 2.7–2.12, 2.18, 2.19 and 2.20 had 
minimal effects on the cellular ATP concentrations. As expected, the ATP levels 
diminished at higher concentrations of the test compounds (10 and 25 µM), consistent 
with their inhibition of NADH oxidase activity (Table 2.1). Compound 2.1, having a 
hydroxydecyl side chain, strongly diminished ATP levels in a concentration-dependent 
fashion in the CoQ10 deficient lymphocytes. Compounds 2.3 and 2.4, which differ from 
compound 2.1 only by the absence of the side chain OH group, reduced ATP levels by 
approximately 10-15% at 5 μM concentration compared to the control, and essentially 
completely depleted intracellular ATP level at 25 μM concentration. Compound 2.5, with 
13 carbon atom side chain showed favorable response at 10 μM concentration (~20% 
reduction in ATP levels) over compounds 2.3 and 2.4, whereas its regioisomer 2.6 did not 
show similar efficacy. Increasing the side chain length to 15 and 16 carbon atoms (2.7–
2.10) showed a favorable response in CoQ10-deficient lymphocytes at 5 μM concentration 
(no diminution beyond the basal level) but did diminish ATP levels at higher 
concentrations. Similar patterns were observed with compounds having exocyclic 
azetidine group (2.19 and 2.20) and morpholine group (2.22 and 2.23), but they were 
slightly less effective than 2.9 and 2.10. In the case of compounds with a longer (19 
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carbon atom) side chain (2.11 and 2.12) and compound 2.18, ATP levels did not diminish 
significantly even at higher concentrations. This may be explained by their limited 
interaction with the mitochondrial respiratory chain, as noted from the NADH oxidase 
assay (Table 2.1).  
 
Table 2.5. Total ATP Concentration in CoQ10 Deficient Lymphocytes Following 
Incubation With Pyridinol Antioxidants for 48 h. The Experiment was Performed by Dr. 
Omar M. Khdour. 
 
 Total ATP level (% control) in CoQ10 deficient lymphocytes 
Compound 5 µM 10 µM 25 µM 
2.1 50 ± 4 20 ± 2 3 ± 1 
2.3 89 ± 2 52 ± 4 13 ± 9 
2.4 87 ± 2 40 ± 3 2 ± 1 
2.5 92 ± 4 81 ± 4 31 ± 5 
2.6 75 ± 6 24 ± 1 3 ± 1 
2.7 98 ± 2 78 ± 5 45 ± 3 
2.8 95 ± 3 79 ± 5 48 ± 2 
2.9 100 ± 3 79 ± 6 41 ± 6 
2.10 96 ± 1 80 ± 3 37 ± 1 
2.11 102 ± 3 102 ± 4 99 ± 3 
2.12 106 ± 6 103 ± 6 86 ± 3 
2.13 83 ± 3 74 ± 1 39 ± 1 
2.14 77 ± 1 69 ± 2 17 ± 1 
2.16 63 ± 6 54 ± 3 35 ± 2 
2.17 23 ± 9 8 ± 4 2 ± 1 
2.18 108 ± 6 102 ± 2 89 ± 2 
2.19 92 ± 6 70 ± 5 38 ± 4 
2.20 98 ± 3 76 ± 4 50 ± 3 
2.22 93 ± 4 75 ± 4 40 ± 2 
2.23 95 ± 3 77 ± 5 45 ± 3 
 
 
The compounds in the pyrimidinol series (2.30–2.32) reliably increased the ATP 
levels in cultured FRDA lymphocytes (Table 2.6), similar to previously reported studies 
on other pyrimidinol analogues.
117,118
 These three compounds augmented ATP levels and 
the increase was similar to lead compound 2.2 at 1 µM and 5 µM concentrations. Also, 
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they diminished ATP levels less at a high concentration (20 µM), whereas 2.2 diminished 
the ATP levels by ~20% at the same concentration.   
 
Table 2.6. Total ATP Concentration in FRDA Lymphocytes Following Incubation With 
Pyrimidinol Antioxidants for 48 h. The Experiment was Performed by Dr. Omar M. 
Khdour. 
 
 Total ATP level (% control) in FRDA lymphocytes 
Compound 1 µM 5 µM 20 µM 
2.2 111 ± 3 107 ± 5 82 ± 2 
2.30 101 ± 2 111 ± 3 93 ± 3 
2.31 107 ± 3 108 ± 3 93 ± 5 
2.32 103 ± 3 110 ± 4 99 ± 6 
 
 
2.2.2.6. Cytoprotection 
 
 
The ability of the test compounds (2.1–2.25) to confer cytoprotection was 
evaluated using six different lymphocyte cell lines, from individuals with Leigh’s 
syndrome, FRDA, Leber’s syndrome, Alzheimer’s disease, Parkinson’s disease and 
early-onset morbid obesity.
117
 Lymphocytes were treated with diethyl maleate to induce 
oxidative stress through depletion of glutathione. The cytoprotection results obtained 
with various cultured cells are shown in Tables 2.7–2.12. The cytoprotective effects of all 
of the compounds were dose dependent in the concentration range from 0.1 µM to 2.5 
µM in all six cell lines. None of the compounds provided significant cytoprotection from 
DEM-induced stress when employed at 0.1 µM concentration in Leigh’s lymphocytes 
(Table 2.7). However, all but five of the compounds (2.11, 2.12, 2.18, 2.24 and 2.25) 
provided significant (> 75%) cytoprotection when employed at 2.5 µM concentration in 
Leigh’s lymphocytes. The removal of the side chain OH group from compound 2.1 
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(affording compound 2.3) resulted in a substantial improvement in the ability of the 
compound to confer cytoprotection when employed at 0.5 µM concentration. The same 
improvement in cytoprotection was obtained for isomeric compound 2.4. Compounds 2.5 
and 2.6 (with 13 carbon atoms side chain length), and compounds 2.7 and 2.8 (with 15 
carbon atoms side chain length) did not show any improvement in cytoprotection over 
compound 2.4. Increasing the side chain length (from 10 to 16 carbon atoms) in 
compounds 2.9 and 2.10 gave slightly improved cytoprotection (relative to 2.3) only at 
0.1 µM concentration. A further increase in side chain length (to 19 carbon atoms; 2.11 
and 2.12) significantly lowered cytoprotective activity, consistent with previously 
published results for other pyrimidinol analogues.
118
 Lesser cytoprotective activity was 
observed for compounds 2.13–2.17 having modified side chains. It is interesting that 
compounds 2.19, 2.20, 2.22 and 2.23, having the same 16-carbon side chain as in 
compounds 2.9 and 2.10, but with an exocyclic azetidine or morpholine substituent, 
exhibited comparable cytoprotection. The bicyclic compounds (2.24 and 2.25) failed to 
show any significant cytoprotection even at higher concentration. 
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Table 2.7. Cytoprotective Effects of CoQ10 Analogues on the Viability of Cultured 
Leigh’s Syndrome Lymphocytes Treated With DEM. The Experiment was Performed by 
Walter G. Johnson. 
 
 Viable cells (%) 
Compound 0.1 µM 0.5 µM 2.5 µM 
2.1 20 ± 1 36 ± 6 74 ± 4 
2.3 6 ± 2 77 ± 3 79 ± 3 
2.4 19 ± 4 87 ± 4 86 ± 4 
2.5 20 ± 5 75 ± 2 78 ± 1 
2.6 17 ± 5 74 ± 2 76 ± 2 
2.7 9 ± 2 79 ± 5 84 ± 1 
2.8 8 ± 2 79 ± 3 85 ± 1 
2.9 29 ± 1 78 ± 2 83 ± 4 
2.10 29 ± 1 76 ± 1 84 ± 2 
2.11 9 ± 3 10 ± 2  9 ± 1 
2.12 9 ± 1 15 ± 5 61 ± 7 
2.13 8 ± 1 13 ± 4 81 ± 1 
2.14 15 ± 2 45 ± 19 79 ± 3 
2.15 17 ± 4 88 ± 4 92 ± 2 
2.16 6 ± 3 82 ± 3 78 ± 4 
2.17 15 ± 1 77 ± 1 80 ± 5 
2.18 5 ± 1 11 ± 1 10 ± 1 
2.19 13 ± 2 82 ± 1 81 ± 2 
2.20 18 ± 4 95 ± 3 92 ± 2 
2.22 12 ± 2 86 ± 4 89 ± 4 
2.23 14 ± 4 85 ± 9 94 ± 4 
2.24  8 ± 1  9 ± 1 27 ± 4 
2.25 12 ± 3 8 ± 2 10 ± 2 
 
In FRDA lymphocyte cells, compounds 2.5–2.10, 2.15, 2.19, 2.20, 2.22 and 2.23 
retained very good (>50%) potency even when tested at 0.1 µM concentration (Table 
2.8). All of the test compounds were found to maintain cell viability to the extent of 
>85% when tested at 2.5 µM concentration in FRDA lymphocytes with the exception of 
compound 2.11. All but four of the compounds (2.1, 2.11, 2.12 and 2.19) afforded at least 
>75% cytoprotection when tested at 0.5 µM concentration in FRDA lymphocytes. 
Compounds 2.30–2.32 in the pyrimidinol series exhibited comparable cytoprotection as 
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the previously reported compound 2.2 at 0.5 µM and 2.5 µM concentrations. Compounds 
2.30 and 2.31 conferred >90% cytoprotection at 0.5 µM and 2.5 µM concentrations. 
Interestingly, these three pyrimidinol analogues (2.30–2.32) were less protective when 
employed at 0.1 µM concentration as compared to 2.2.
117,118
  
 
Table 2.8. Cytoprotective Effects of CoQ10 Analogues on the Viability of Cultured 
FRDA Lymphocytes Treated With DEM. The Experiment was Performed by Basab Roy, 
Dr. Yana Chen and Chenhong Tang. 
 
 
 Viable cells (%) 
Compound 0.1 µM 0.5 µM 2.5 µM 
2.1 17 ± 1 28 ± 2 87 ± 5 
2.2 68 ± 1 88 ± 3 95 ± 2 
2.3 36 ± 7 74 ± 1 87 ± 3 
2.4 34 ± 2 84 ± 7 86 ± 1 
2.5 71 ± 5 81 ± 4 94 ± 2 
2.6 67 ± 4 79 ± 4 92 ± 3 
2.7 58 ± 2 75 ± 2 85 ± 2 
2.8 67 ± 4 83 ± 4 89 ± 2 
2.9 80 ± 10 91 ± 5 92 ± 3 
2.10 52 ± 4 75 ± 2 84 ± 2 
2.11 17 ± 15 38 ± 10 76 ± 13 
2.12 20 ± 7 50 ± 4 87 ± 3 
2.15 53 ± 6 80 ± 5 96 ± 2 
2.19 54 ± 2 70 ± 2 87 ± 2 
2.20 58 ± 3 79 ± 2 92 ± 3 
2.22 51 ± 1 76 ± 5 91 ± 2 
2.23 65 ± 5 74 ± 2 93 ± 3 
2.30 21 ± 10 94 ± 5 95 ± 4 
2.31 49 ± 10 90 ± 13 92 ± 6 
2.32 30 ± 3 77 ± 10 86 ± 15 
 
 
 The cytoprotection results obtained with cultured Leber’s lymphocytes are shown 
in Table 2.9. None of the compounds afforded >90% cytoprotection at any tested 
concentration, but three compounds (2.10, 2.19 and 2.20) did give 88, 85 and 84% 
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protection, respectively, when employed at 2.5 µM concentration. Of the three, 
compound 2.20 gave 77% cytoprotection when used at 0.5 µM concentration, while the 
comparable values for compounds 2.10 and 2.19 were only 57% and 23%, respectively. 
Seven compounds (2.5–2.8, 2.15, 2.22 and 2.23) gave >70% protection from induced 
oxidative stress when used at 2.5 µM concentration, and all of these compounds also 
afforded >55% cytoprotection when tested at 0.5 µM concentration. Compound 2.21 was 
less effective, although its difference from 2.23 was less pronounced than in some other 
assays (vide infra). Compounds 2.24 and 2.25 were essentially inactive as 
cytoprotectants. None of the tested compounds afforded reasonable protection when used 
at 0.1 µM concentration. 
 
Table 2.9. Cytoprotective Effects of CoQ10 Analogues on the Viability of Cultured 
Leber’s Lymphocytes Treated With DEM. The Experiment was Performed by Walter G. 
Johnson and Dr. Darshini Patel. 
 
 Viable cells (%) 
Compound 0.1 µM 0.5 µM 2.5 µM 
2.5 22 ± 2 65 ± 6 73 ± 4 
2.6 26 ± 5 67 ± 1 78 ± 4 
2.7 14 ± 1 62 ± 5 76 ± 5 
2.8 17 ± 3 68 ± 4 78 ± 2 
2.10 24 ± 3 57 ± 5 88 ± 2 
2.15 31 ± 3 67 ± 2 77 ± 3 
2.19 16 ± 5 23 ± 6 85 ± 3 
2.20 23 ± 2 77 ± 8 84 ± 4 
2.21 45 ± 1 55 ± 4 68 ± 4 
2.22 20 ± 2 69 ± 5 76 ± 4 
2.23 18 ± 2 64 ± 4 74 ± 4 
2.24 15 ± 2 13 ± 4 8 ± 3 
2.25 7 ± 3 8 ± 2 16 ± 6 
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The cytoprotective effects of pyridinol analogues for Alzheimer’s disease 
lymphocytes are summarized in Table 2.10. Five compounds afforded at least 90% 
cytoprotection when employed at 2.5 µM concentration. These included 2.5, 2.6, 2.15, 
2.20 and 2.23. At this concentration three other compounds (2.10, 2.19 and 2.22), 
exhibited 80-90% cytoprotection, while two compounds (2.7 and 2.8) gave >70% 
protection. All of the compounds exhibited dose dependent cytoprotection, and all 
retained significant activity even at 0.1 µM concentration. 
 
Table 2.10. Cytoprotective Effects of CoQ10 Analogues on the Viability of Cultured 
Alzheimer’s Disease Lymphocytes Treated With DEM. The Experiment was Performed 
by Basab Roy. 
 
 Viable cells (%) 
Compound 0.1 µM 0.5 µM 2.5 µM 
2.5 61 ± 4 73 ± 5 95 ± 2 
2.6 55 ± 2 66 ± 5 92 ± 4 
2.7 34 ± 2 56 ± 4 72 ± 4 
2.8 40 ± 1 51 ± 4 76 ± 2 
2.10 51 ± 2 76 ± 2 87 ± 2 
2.15 50 ± 5 62 ± 3 90 ± 2 
2.19 48 ± 4 71 ± 1 89 ± 3 
2.20 53 ± 5 75 ± 4 93 ± 3 
2.22 35 ± 4 68 ± 5 87 ± 3 
2.23 31 ± 3 64 ± 6 90 ± 1 
 
 
 
Very favorable results were obtained using Parkinson’s disease lymphocytes, as 
summarized in Table 2.11. All but two of the compounds (2.21 and 2.25) gave >90% 
cytoprotection when tested at 2.5 µM concentration. It may be noted that this was the 
only cell protection assay in which 2.24 gave favorable results, and even then only at a 
single concentration. All but four of the compounds (2.19, 2.21, 2.24 and 2.25) also 
afforded >90% cytoprotection when tested at 0.5 µM concentration. Five compounds 
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(2.5, 2.8, 2.10, 2.20 and 2.23) retained very good (>70%) potency even when tested at 0.1 
µM concentration. Finally, it is worth noting the large different in efficacy at all three 
tested concentrations between 2.21 and its close structural analogue 2.23. 
 
Table 2.11. Cytoprotective Effects of CoQ10 Analogues on the Viability of Cultured 
Parkinson’s Disease Lymphocytes Treated With DEM. The Experiment was Performed 
by Chenhong Tang. 
 
 Viable cells (%) 
Compound 0.1 µM 0.5 µM 2.5 µM 
2.5 75 ± 11 93 ± 1 91 ± 4 
2.6 57 ± 14 93 ± 2 95 ± 2 
2.7 49 ± 7 93 ± 4 98 ± 1 
2.8 82 ± 9 90 ± 9 96 ± 4 
2.10 77 ± 12 94 ± 5 97 ± 3 
2.15 54 ± 23 95 ± 3 98 ± 5 
2.19 30 ± 6 83 ± 5 98 ± 5 
2.20 70 ± 10 96 ± 3 101 ± 3 
2.21 18 ± 14 40 ± 27 46 ± 26 
2.22 68 ± 13 97 ± 2 95 ± 2 
2.23 78 ± 9 97 ± 2 98 ± 3 
2.24 26 ± 8 52 ± 8 93 ± 4 
2.25 21 ± 11 28 ± 10 72 ± 18 
 
 
 
The cytoprotection results obtained with cultured early-onset morbid obesity 
lymphocytes are summarized in Table 2.12. Three of the compounds (2.6, 2.22 and 2.23) 
afforded at least 90% cytoprotection from stress induced by diethyl maleate, and the 
remaining compounds provided at least 84% cytoprotection when used at 2.5 µM 
concentration. Further, with the exception of 2.19, their cytoprotective efficacy was 
largely retained at 0.5 µM concentration. All of the compounds exhibited <40% 
cytoprotection when tested at 0.1 µM concentration. 
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Table 2.12. Cytoprotective Effects of CoQ10 Analogues on the Viability of Cultured 
Early-onset Morbid Obesity Lymphocytes Treated With DEM. The Experiment was 
Performed by Dr. Yana Chen. 
 
 Viable cells (%) 
Compound 0.1 µM 0.5 µM 2.5 µM 
2.5 34 ± 13 86 ± 4 86 ± 6 
2.6 21 ± 5 82 ± 1 90 ± 2 
2.7 36 ± 9 84 ± 1 89 ± 1 
2.8 32 ± 7 83 ± 2 85 ± 4 
2.10 22 ± 4 86 ± 1 89 ± 2 
2.15  31 ± 10 83 ± 1 87 ± 3 
2.19 30 ± 4 55 ± 2 84 ± 4 
2.20 38 ± 5 82 ± 5 86 ± 3 
2.22 28 ± 1 88 ± 3 95 ± 1 
2.23 27 ± 12 87 ± 9 90 ± 3 
 
 
 
2.3. Discussion 
 
 
 As part of the ongoing efforts to identify compounds having potential utility in 
treating neurodegenerative and mitochondrial disorders, a number of pyridinol and 
pyrimidinol analogues have been prepared. The synthetic route employed for the 
preparation of the new pyridinol analogues is different, and considerably more efficient, 
than that used in previously reported studies.
116
 The original scheme was devised in the 
belief that selective alkylation of the intermediate 2.35 could be effected to obtain 
analogue 2.3 selectively. But in the event of alkylation using TMEDA and n-BuLi a pair 
of regioisomers was obtained in rather low yield; in some of the cases only one of the 
isomer was obtained, also in poor yield. Several mixtures of bases were tried for 
alkylation along with different reaction conditions, such as increasing the number of 
equivalence of n-BuLi and using a 10 M n-BuLi solution but none gave the desired 
results. Only Schlosser’s super base120 (a mixture of KOtBu and n-BuLi) gave improved 
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yields, although a pair of regioisomers was formed; those were readily separated on a 
silica gel column (Schemes 2.1–2.5). For the synthesis of analogues 2.13, 2.14, 2.16 and 
2.17 modified alkyl side chains were synthesized using Grubb’s metathesis121 of 11-
bromo-1-undecene and the corresponding alkene followed by hydrogenation. Compound 
2.18 was synthesized by the alkylation of 2.35 using TMEDA and n-BuLi. It was 
anticipated that the introduction of a phytyl side chain could facilitate the transport of 
2.18 into the cells by α-tocopherol transfer protein (αTTP); instead, 2.18 turned out to be 
inhibitory to the ETC.
138
 
 In order to synthesize pyridinol analogues with exocyclic amino groups a 
different strategy was employed, involving the synthesis of fully protected heterocyclic 
cores for each of the analogues prior to the alkylation reaction with Schlosser’s super 
base
120
 (Schemes 2.6–2.8). The protected heterocyclic core was synthesized by the C-N 
coupling of a cyclic amine with the benzyl protected 6-iodopyridinol.
126
 The synthesis of 
the 6-iodo pyridinol was troublesome. Several methods and reagents were tried (e.g. NIS 
in AcOH) but only a morpholine–iodine complex124,125 gave the desired product in 
moderately good yield.  
 The synthesis of bicyclic pyridinols started with a coupling reaction between 
potassium phthalamide and 2-bromopropionate (Scheme 2.9). Rearrangement of 2.67 to 
afford 2.68 was very challenging. Several attempts were made to isolate the product via 
re-precipitation but failed. Finally, reaction condition and re-precipitation was optimized 
to afford 2.68 in better yield.
127,128
 Chlorination of 2.69 was tried with PCl5 in CCl4 at 
reflux, neat POCl3 at reflux, POCl3 in CH2Cl2 at reflux, POCl3 in CH2Cl2 and TEA at 
reflux but all of these resulted in degradation of the starting material. The reaction was 
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performed successfully in a sealed tube at 90 °C using one equivalent of POCl3 to afford 
2.70 in moderate yield.
129
 Several attempts were made to introduce the dimethylamine 
functionality by using dimethylamine in aqueous solution. Treatment of 2.70 with DMF 
under microwave conditions at 180 °C resulted in degradation of the starting material. 
The use of NiCl2 as a catalyst also failed to help significantly. Finally, catalytic cross-
coupling of halide 2.70 with dimethylamine hydrochloride using 
tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3), 1,3-bis(2,6-diisopropylphenyl)-
imidazolium chloride (ImPrPh2•HCl) and KOtBu afforded 2.71 in reasonably good yield 
(Scheme 2.9).
126
 Debenzylation to afford the final product proceeded readily but the 
product was unstable toward silica gel and hence purification was difficult. HPLC was 
used to purify the sample after several failed attempts using silica gel chromatography. 
Elution with 0.1% TFA and MeOH afforded pure compounds 2.24 and 2.25, although in 
poor yields.  
 For the synthesis of compound 2.26, first 2-amino-4-methoxy-6-
methylpyrimidine was transformed to 2-iodo-4-methoxy-6-methylpyrimidne by a 
Sandmeyer reaction using isoamylnitrite, diiodomethane, iodine and CuI (Scheme 
2.10).
130
 A cross-coupling reaction of azetidine hydrochloride with the 2-iodopyrimidine 
failed when ImPrPh2•HCl and Pd2(dba)3 was used, although, the same combination 
worked well for the pyridine analogues. So a different ligand, 3,4,7,8-tetramethyl-1,10-
phenanthroline (Me4Phen), was used in the presence of CuI and Cs2CO3 for the cross-
coupling reaction to afford the required heterocyclic core, 2.75, in good yield.
131
 The 
alkylation was performed using n-BuLi and 1-bromopentadecane. The alkylated core was 
brominated using NBS and then transformed to final product using n-BuLi, 
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trimethoxyborane and H2O2.
118
 Compound 2.27 was made by following the same method 
as for compound 2.26 (Scheme 2.11), except that in the last step, for the conversion of 5-
bromopyrimidine to 5-hydroxypyrimidine, trimethoxyborane was added before n-BuLi 
and stirred together with the 5-bromopyrimidine for 30 min. This was done to avoid the 
conversion of 5-bromopyrimidine back to the debrominated pyrimidine heterocyclic core 
(2.79).  
 The synthetic schemes employed for the syntheses of compounds 2.28–2.30 were 
identical (Schemes 2.12–2.14). They started with the treatment of 2,4-dichloro-6-
methylpyrimidine with NaH and the corresponding alcohol to form the ether linkage with 
the pyrimidine core, followed by the catalytic cross coupling of 2-chloro-4-alkoxy-6-
methylpyrimidine using azetidine hydrochloride, CuI, 3,4,7,8-tetramethyl-1,10-
phenanthroline (Me4Phen) and Cs2CO3 to afford the desired heterocyclic core.
131
 
Alkylation was performed on 2.82 and 2.87 using n-BuLi and 1-bromopentadecane but 
not on 2.85, as it already had the long chain in the ether linkage with the heterocyclic 
core. The obtained intermediates were brominated using NBS and then transformed to 
final products using n-BuLi and subsequent quick addition of trimethoxyborane followed 
by treatment with H2O2.
118
 
 For the synthesis of 2.31and 2.32 the hexadeuterated heterocyclic core (2.90) was 
first synthesized by the treatment of 2-amino-4-chloro-6-methylpyrimidine with CD3I 
and NaH in anh THF (Schemes 2.15 and 2.16). Treatment of compound 2.90 with 
CD3OD and NaH afforded 2.91, whereas 1-cyclobutanol and NaH afforded 2.94 in good 
yield. Alkylation was performed using n-BuLi and 1-bromopentadecane. The obtained 
intermediates were brominated using NBS and then transformed to the final products 
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using n-BuLi and subsequent quick addition of trimethoxyborane followed by treatment 
with H2O2.
118
 
 As shown in Table 2.2, all of the new pyridinol derivatives have been tested for 
their ability to quench lipid peroxidation in FRDA lymphocytes following oxidative 
challenge with diethyl maleate (DEM). DEM reacts chemically (and irreversibly) with 
glutathione, inactivating it stoichiometrically such that it no longer provides protection 
against oxidative stress.
115-117,133
 As a consequence, ROS levels increase, and in turn lipid 
peroxidation also increases. The omission of the side chain OH group from 2.1 (affording 
2.3) resulted in a substantial improvement in the ability of the compound to quench lipid 
peroxidation. The side chain of 2.1, of course, is the same as that found in idebenone and 
OH group removal improved the stability of the compound and made them less inhibitory 
to the ETC. The same improvement in suppression of lipid peroxidation was obtained for 
isomeric compound 2.4. Increasing the side chain length (from 10 to 13, 15 and 16 
carbon atoms) afforded compounds 2.5–2.10. Compounds 2.7–2.10 had somewhat 
improved activity as well in suppressing lipid peroxidation. A further increase in side 
chain length as in compound 2.11 and 2.12 significantly lowered activity. The attachment 
of a cyclohexyl ring to the end of a 12-carbon side chain (2.13 and 2.14), affording 
derivatives in which the side chain extended the same overall length from the redox core 
as in 2.9, gave compounds with activities comparable to 2.3 and 2.4. The analogues 
having an aromatic ring in place of the cyclohexyl ring in the modified chain (2.16 and 
2.17) had slightly improved activity, comparable to 2.5 and 2.6. Interestingly, the 
introduction of a tetramethylated 17 carbon side chain in the form of a phytyl group 
(compound 2.18) dramatically lowered activity, even though no polar functionality was 
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present. The bicyclic pyridinol analogues 2.24 and 2.25 also failed to show any protection 
against lipid peroxidation. It may be noted that the concentrations at which the 
compounds were tested (100 and 250 nM) were rather low and most of these compounds 
may properly be regarded as capable of potent suppression of lipid peroxidation. 
 The compounds were also tested for suppression of ROS in FRDA 
lymphocytes,
134
 affording results that fairly closely paralleled those found for lipid 
peroxidation (Table 2.3). The analogues were tested at low (100, 250 and 500 nM) 
concentrations; the results reflect quite potent ROS suppression abilities. With the 
exception of a few analogues (notably 2.1, 2.11, 2.12, 2.18, 2.24 and 2.25), the analogues 
suppressed ROS with potency and efficacy sufficient to consider them as potential 
therapeutic agents (at least based on this single parameter).  
 Table 2.4 and Figure 2.16 summarize the ability of the new pyridinol analogues to 
preserve mitochondrial membrane potential in FRDA lymphocytes placed under 
oxidative stress. Treatment with DEM reduced the percentage of cells with intact 
mitochondrial membrane potential from 95% to 6%. Thus the reduction was even greater 
than the value of 22% achieved with FCCP, the classic uncoupler of oxidative 
phosphorylation, which dissipates mitochondrial membrane potential. Although most of 
the analogues have only been tested at two concentrations to date, very good protection 
was achieved with compounds 2.3, 2.4, 2.5, 2.6, 2.9 and 2.10. Compounds with an 
exocyclic amino group (2.19, 2.20, 2.22 and 2.23) also conferred protection but to a 
lesser extent than 2.9 and 2.10. As in the case of suppression of ROS, analogues 2.1, 
2.11, 2.12, 2.18, 2.24 and 2.25 functioned less well.  
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 Pyridinol analogues that inhibit the mitochondrial respiratory chain may function 
well as protective agents in the three assays described earlier, but are less likely to be able 
to confer cytoprotection to cells under oxidative stress, or to augment ATP production in 
cells with (partially) dysfunctional mitochondria (which is a hallmark of cells from 
individuals with mitochondrial disorders). While inhibition usually involves 
mitochondrial complex I, a number of compounds also inhibit complex III. Accordingly, 
an assay was designed which measures NADH oxidase activity, encompassing 
complexes I, II and III.
115-118,132
 As shown in Table 2.1, some of the compounds tested 
were substantially inhibitory to NADH oxidase, notably compounds 2.1, 2.3, 2.4, 2.13 
and 2.16. In contrast, much less inhibition was observed for other compounds in the 
series. 
 It is important to note that there are special characteristics of this assay that make 
interpretation somewhat more complicated. First, the assay gives a result that reflects 
events involving three individual mitochondrial complexes, and undoubtedly reflects both 
the avidity of individual compounds for individual complexes, as well as the dynamics of 
interaction with each of the complexes. Second, since the compounds being tested can be 
both substrates and inhibitors of each of the mitochondrial complexes, the aggregate 
“readout” can be misleading. Finally, a compound that simply fails to bind to any of the 
mitochondrial complexes, will show no inhibition of NADH oxidase, but has no chance 
of augmenting ATP production. Thus any (tentative) conclusions reached from this assay 
need to be confirmed by measuring the effects of the compounds on each of the 
complexes individually, and on the ability of the compound to support oxygen reduction 
in complex IV and ATP production in complex V. It may also be noted that the 
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concentrations of the compounds employed in Table 2.1 are purposefully higher than 
those used in the other assays (in order to provide mechanistic insights), but involve at 
least one concentration (10 µM) unlikely to be achieved physiologically. 
 Compounds were tested for their ability to augment ATP levels in CoQ10 deficient 
and FRDA lymphocyte cell lines (Tables 2.5 and 2.6). As is usual in this assay, the most 
favorable results were obtained at the lowest concentration (5 µM in this experiment). 
The least effective compounds were 2.6 and 2.17, which reduced the cellular ATP level 
to 3% and 2% of control, respectively at 25 µM concentration. These compounds were 
not strongly inhibitory to NADH oxidase activity (Table 2.1), and did not affect 
mitochondrial membrane potential negatively (Table 2.4), but may possibly interact with 
mitochondrial complexes II or V. There was not a single compound in the pyridinol 
series, which was able to augment ATP levels in CoQ10 deficient lymphocytes. However, 
compounds 2.30, 2.31 and 2.32 in the pyrimidinol series augmented ATP levels in FRDA 
lymphocytes (Table 2.6). Interestingly, they reduce ATP level by ~10% only even at the 
higher concentration (20 µM) whereas lead compound 2.2 reduced the ATP level by 
~20%. 
 The six different lymphocyte cell lines, from individuals with Leigh’s syndrome, 
FRDA, Leber’s syndrome, Alzheimer’s disease, Parkinson’s disease and early-onset 
morbid obesity were used in the assay to access the cytoprotection ability of the 
analogues (Figures 2.7 to 2.12). Each of the cell lines was derived from lymphocytes 
obtained from a patient with a specific mitochondrial disorder, or a disease having a 
significant component of mitochondrial dysfunction. The underlying biochemistry of 
mitochondrial dysfunction is likely to be quite similar in all of the diseases, the 
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implication of which is that it should in principle be possible to identify a single 
compound that can be developed for therapeutic intervention in many mitochondrial 
diseases. The above hypothesis has been tested by investigating few compounds in each 
of the six cell lines. An earlier study carried out with a limited number of compounds 
seemed to support this idea.
117
 Compounds having favorable properties as multifunctional 
radical quenchers were evaluated for cytoprotection in each of six cell lines. In 
comparison with the more limited study carried out previously, a greater spectrum of 
behavior was found. A number of compounds were found to be fairly effective in all six 
tested cell lines, while some worked well in few cell lines, but not in others. Interestingly, 
some cell lines (e.g. Parkinson’s disease lymphocytes) were more responsive to the 
majority of compounds tested than were other cell lines (e.g., Leber’s lymphocytes). If 
this proved to be true for multiple cell lines for specific diseases, it might suggest that the 
least responsive cells correspond to diseases less likely to be served well by therapeutic 
agents developed for other mitochondrial disorders. 
 
2.4. Experimental 
 
 
 Anhydrous grade solvents were purchased from Sigma-Aldrich Inc. (St. Louis, 
MO) and from Fisher Scientific. Most of the chemical reagents were purchased from 
Sigma-Aldrich and used without further purification. ImPrPh2•HCl, morpholine and 
iodine were purchased from TCI America. Azetidine hydrochloride, 3,4,7,8-tetramethyl-
1,10-phenanthroline and Cs2CO3 were purchased from Combi-Blocks. All glassware and 
needles were pre-dried in an oven at 120 °C prior to use. Tetrahydrofuran was distilled 
from sodium/benzophenone. All reactions were performed under a stream of argon. Flash 
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column chromatography was carried out using silica gel (Silicycle R10030B, 60 Å 
particle size, 230-400 mesh), applying a low pressure stream of nitrogen. Analytical thin 
layer chromatographic separations were carried out on silica gel (60 Å particle size, 250 
m thickness, F-254, Silicycle) coated glass plates. Spots were visualized with UV light, 
or developed by using iodine vapor, or by immersing the plates in 2% anisaldehyde in 
ethanol/sulfuric acid/acetic acid, followed by heating with a heat gun. 
The NMR spectra were recorded using 400 MHz and 500 MHz Varian Inova 
instruments.  Chemical shifts were reported in parts per million (ppm, ) relative to the 
residual 
1
H resonance of the solvent CDCl3 or CD3OD or DMSO-d6 at 7.26 ppm, 3.31 
ppm or 2.50 ppm, respectively. 
13
C NMR chemical shifts were reported relative to the 
central line of CDCl3 or CD3OD or DMSO-d6 at 77.16 ppm, 49.00 ppm or 39.52 ppm, 
respectively. Splitting patterns were designated as follows: s, singlet; br s, broad singlet; 
d, doublet; t, triplet; m, multiplet; q, quartet; dq, doublet of quartet and quint, quintet. 
High resolution mass spectra were obtained at the Arizona State University CLAS High 
Resolution Mass Spectrometry Laboratory. 
 
 
 
6-Amino-2,4,5-trimethylpyridin-3-ol (2.33).
117,119
 To a stirred solution of 20.0 g (97.3 
mmol) of pyridoxine hydrochloride in 80 mL of thionyl chloride was added 800 μL of 
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DMF. The reaction mixture was stirred at reflux for 2 h. The cooled reaction mixture was 
treated with 60 mL of Et2O. The suspension was stirred for 1 h and then filtered and the 
precipitate was washed with 60 mL of Et2O. The precipitate so obtained was dissolved in 
84 mL of glacial acetic acid and 19.0 g (29.1 mmol) of zinc dust was added in three 
portions. The reaction mixture was stirred at reflux for 2 h. The cooled reaction mixture 
was filtered and washed with glacial acetic acid. The filtrate was concentrated under 
diminished pressure and then neutralized with 6 M NaOH. The formed precipitate was 
filtered and washed with small amount of brine. The orange precipitate obtained was 
dissolved in 10 M HCl and solid NaCl was added to salt out 12.0 g of crude 2,4,5-
trimethylpyridin-3-ol. The obtained solid was dissolved in 400 mL of satd NaHCO3 and 
freshly prepared diazonium salt, made by slowly mixing 8.00 mL (87.8 mmol) of aniline 
in 80 mL of 6 M HCl at 0 
o
C with a solution of 6.00 g (88.0 mmol) NaNO2 in 30 mL of 
H2O, was added dropwise to the cooled reaction mixture. After 1 h, the red precipitate 
was filtered and dissolved in 160 mL of 1:1 methanol–formic acid. Zinc dust (28.2 g, 
44.0 mmol) was added to the reaction mixture in three portions. The reaction mixture was 
stirred at reflux for 2 h. The reaction mixture was cooled, filtered and washed with hot 
MeOH. The MeOH was concentrated and the white precipitate was filtered and washed 
with Et2O. The precipitate so obtained was dissolved in hot water, adjusted to pH 8.0 
with 6 M NaOH and allowed to cool. The white precipitate was filtered, dissolved in 
EtOH and again filtered through Celite. The filtrate was concentrated to afford 2.33 as a 
pale orange solid: yield  3.41 g (23%); mp 169-172 
o
C, lit
119
 mp 170-172 
o
C; silica gel 
TLC Rf 0.20 (9:1 CH2Cl2–MeOH); 
1
H NMR (DMSO-d6, 400 MHz) δ 1.88 (s, 3H), 2.00 
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(s, 3H), 2.12 (s, 3H), 4.86 (br s, 2H) and 7.40 (br s, 1H); 
13
C NMR (DMSO-d6, 100 MHz) 
δ 12.9, 13.4, 19.4, 112.7, 135.0, 140.2, 141.4 and 151.3.  
 
 
 
6-(N,N-Dimethylamino)-2,4,5-trimethylpyridin-3-ol (2.34).
117,119
 To a stirred solution 
containing 1.17g (7.69 mmol) of 2.33 in 30 mL of 1:1 acetonitrile–formalin was added 
2.76 g (43.9 mmol) of sodium cyanoborohydride followed by dropwise addition of 1.58 
mL (27.6 mmol) of glacial acetic acid at 0 
o
C. The reaction mixture was allowed to warm 
to room temperature and was then stirred for 16 h. The reaction mixture was poured into 
200 mL of satd NaHCO3 and extracted with 200 mL of EtOAc. The organic phase was 
washed with brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (20 × 3 cm). Elution with 
3:1 hexane–EtOAc afforded 2.34 as a colorless solid: yield 1.31 g (94%); mp 126-128 °C 
(lit
119 
mp 138-140 
o
C); silica gel TLC Rf  0.30 (2:1 hexane–EtOAc); 
1
H NMR (CD3OD, 
400 MHz) δ 2.15 (s, 3H), 2.17 (s, 3H), 2.33 (s, 3H), 2.65 (s, 6H) and 4.89 (br s, lH); 13C 
NMR (CD3OD, 100 MHz) δ 12.8, 14.6, 18.8, 43.3, 124.2, 137.0, 141.6, 146.9 and 156.4; 
mass spectrum (APCI), m/z 181.1336 (M+H)
+
 (C10H17N2O requires 181.1341). 
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3-(Benzyloxy)-6-N,N-dimethylamino-2,4,5-trimethylpyridine (2.35). To a stirred 
solution containing 1.30 g (7.21 mmol) of 2.34 in 40 mL of anh THF were added 1.29 
mL (10.8 mmol) of benzyl bromide followed by 519 mg (21.6 mmol) of sodium hydride 
(60% suspension in mineral oil). The reaction mixture was stirred at 23 
o
C for 3 h and 
then poured into 150 mL of water. The mixture was extracted with 300 mL of EtOAc, 
and the organic phase was washed with brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(20 × 3 cm). Elution with hexane followed by 2:1 hexane–EtOAc afforded 2.35 as a 
yellowish oil: yield 1.40 g (72%); silica gel TLC Rf  0.58 (2:1 hexane–EtOAc); 
1
H NMR 
(CDCl3, 400 MHz) δ 2.19 (s, 3H), 2.20 (s, 3H), 2.45 (s, 3H), 2.77 (s, 6H), 4.75 (s, 2H) 
and 7.34-7.51 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.2, 15.0, 19.5, 42.7, 74.9 121.9, 
128.0, 128.2, 128.7, 137.5, 140.5, 145.9, 147.7 and 158.3; mass spectrum (APCI), m/z 
271.1813 (M+H)
+
 (C17H23N2O requires 271.1810). 
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3-(Benzyloxy)-6-N,N-dimethylamino-2-decyl-4,5-dimethylpyridine (2.36) and 3-
(Benzyloxy)-6-N,N-dimethylamino-4-decyl-2,5-dimethylpyridine (2.41).
120
 To a 
stirred solution containing 350 mg (1.29 mmol) of 2.35 and 217 mg (1.93 mmol) of 
KOtBu in 18 mL of anh THF at –78 °C was added 1.03 mL (2.58 mmol) of a 2.5 M 
solution of n-BuLi in hexane. The reaction mixture was stirred at –78 °C for 30 min and 
then 295 μL (1.55 mmol) of 1-bromononane was added. The reaction was stirred at 0 oC 
for another 30 min, then quenched with satd aq ammonium chloride and extracted with 
150 mL of EtOAc. The combined organic phase was washed with brine, dried (MgSO4) 
and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (30 × 2 cm). Elution with hexane followed by 
96:4 hexane–Et2O afforded 2.36 and 2.41 as yellowish oils: yields 82.0 mg (16%) and 
240 mg (47%), respectively; silica gel TLC Rf  0.53 (4:1 hexane–Et2O) and Rf  0.43 (4:1 
hexane–Et2O); (2.36) 
1
H NMR (CDCl3, 400 MHz) δ 0.90 (t, 3H, J = 6.8 Hz), 1.25-1.35 
(m, 14H), 1.75 (m, 2H), 2.20 (s, 3H), 2.21 (s, 3H), 2.74-2.80 (m, 8H), 4.75 (s, 2H) and 
7.34-7.50 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.3, 14.3, 15.0, 22.8, 28.8, 29.5, 
29.78, 29.80, 29.84, 32.06, 32.08, 42.8, 75.4, 121.6, 127.9, 128.1, 128.7, 137.7, 140.3, 
147.4, 149.6 and 158.3; mass spectrum (APCI), m/z 397.3212 (M+H)
+
 (C26H41N2O 
requires 397.3219); (2.41) 
1
H NMR (CDCl3, 400 MHz) δ 0.86 (t, 3H, J = 7.2 Hz), 1.26-
1.46 (m, 14H), 1.56 (m, 2H), 2.27 (s, 3H), 2.51 (s, 3H), 2.66 (m, 2H), 2.81 (s, 6H), 4.82 
(s, 2H) and 7.35-7.54 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 14.4, 19.6, 22.8, 
27.7, 29.4, 29.5, 29.7, 30.3, 32.0, 42.7, 75.2, 121.3, 127.6, 128.0, 128.6, 137.7, 145.1, 
146.0, 147.6 and 158.7; mass spectrum (APCI), m/z 397.3226 (M+H)
+
 (C26H41N2O 
requires 397.3219). 
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3-(Benzyloxy)-6-N,N-dimethylamino-2-tridecyl-4,5-dimethylpyridine (2.37) and 3-
(Benzyloxy)-6-N,N-dimethylamino-4-tridecyl-2,5-dimethylpyridine (2.42).
120
 To a 
stirred solution containing 300 mg (1.11 mmol) of 2.35 and 187 mg (1.67 mmol) of 
KOtBu in 18 mL of anh THF at –78 °C was added 888 µL (2.22 mmol) of a 2.5 M 
solution of n-BuLi in hexane. The reaction mixture was stirred at –78 °C for 30 min and 
then 319 μL (1.33 mmol) of 1-bromododecane was added. The reaction was stirred at 0 
o
C for another 30 min, then quenched with satd aq ammonium chloride and extracted 
with 150 mL of EtOAc. The combined organic phase was washed with brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (30 × 2 cm). Elution with hexane followed by 
96:4 hexane–Et2O afforded 2.37 and 2.42 as yellowish oils: yields 73.0 mg (15%) and 
219 mg (45%), respectively; silica gel TLC Rf  0.59 (4:1 hexane–Et2O) and Rf  0.50 (4:1 
hexane–Et2O); (2.37) 
1
H NMR (CDCl3, 400 MHz) δ 0.89 (t, 3H, J = 7.2 Hz), 1.18-1.40 
(m, 20H), 1.75 (m, 2H), 2.19 (s, 3H), 2.20 (s, 3H), 2.72-2.81 (m, 8H), 4.74 (s, 2H) and 
7.33-7.51 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.3, 14.3, 15.0, 22.9, 28.8, 29.5, 29.8, 
29.82, 29.85, 29.86, 32.06, 32.08, 42.8, 75.5, 121.6, 127.9, 128.1, 128.7, 137.7, 140.4, 
147.4, 149.6 and 158.2; mass spectrum (APCI), m/z 439.3691 (M+H)
+
 (C29H47N2O 
requires 439.3688); (2.42) 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 6.8 Hz), 1.23-
1.34 (m, 20H), 1.49 (m, 2H), 2.21 (s, 3H), 2.45 (s, 3H), 2.59 (m, 2H), 2.76 (s, 6H), 4.76 
 77   
  
(s, 2H) and 7.34-7.51 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 14.3, 14.5, 19.6, 22.9, 
27.7, 29.5, 29.6, 29.8, 29.81, 29.9, 30.3, 32.1, 42.7, 75.3, 121.4, 127.7, 128.1, 128.7, 
137.8, 145.3, 146.1, 147.6 and 158.7; mass spectrum (APCI), m/z 439.3697 (M+H)
+
 
(C29H47N2O requires 439.3688). 
 
 
 
3-(Benzyloxy)-6-N,N-dimethylamino-2-pentadecyl-4,5-dimethylpyridine (2.38) and 
3-(Benzyloxy)-6-N,N-dimethylamino-4-pentadecyl-2,5-dimethylpyridine (2.43).
120 
To 
a stirred solution containing 355 mg (1.31 mmol) of 2.35 and 221 mg (1.97 mmol) of 
KOtBu in 20 mL of anh THF at –78 °C was added 1.05 mL (2.62 mmol) of a 2.5 M 
solution of n-BuLi in hexane. The reaction mixture was stirred at –78 °C for 30 min and 
then 468 μL (1.57 mmol) of 1-bromotetradecane was added. The reaction was stirred at 0 
o
C for another 30 min, then quenched with satd aq ammonium chloride and extracted 
with 150 mL of EtOAc. The combined organic phase was washed with brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (30 × 2 cm). Elution with hexane followed by 
96:4 hexane–Et2O afforded 2.38 and 2.43 as yellowish oils: yields 86.0 mg (14%) and 
263 mg (43%), respectively; silica gel TLC Rf  0.67 (4:1 hexane–Et2O) and Rf  0.55 (4:1 
hexane–Et2O); (2.38) 
1
H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 7.2 Hz), 1.23-1.32 
(m, 24H), 1.72 (m, 2H), 2.18 (s, 3H), 2.19 (s, 3H), 2.72-2.81 (m, 8H), 4.73 (s, 2H) and 
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7.31-7.51 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.3, 14.3, 15.0, 22.9, 28.8, 29.5, 29.8, 
29.9, 32.06, 32.1, 42.8, 75.5, 121.6, 127.9, 128.1, 128.7, 137.7, 140.4, 147.4, 149.7 and 
158.2; mass spectrum (APCI), m/z 467.4009 (M+H)
+
 (C31H51N2O requires 467.4001); 
(2.43) 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 7.2 Hz), 1.25-1.35 (m, 24H), 1.48 
(m, 2H), 2.20 (s, 3H), 2.43 (s, 3H), 2.59 (m, 2H), 2.74 (s, 6H), 4.75 (s, 2H) and 7.34-7.52 
(m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 14.3, 14.4, 19.6, 22.9, 27.7, 29.53, 29.54, 29.8, 
29.81, 29.83, 29.9, 30.3, 32.1, 42.7, 75.2, 121.3, 127.7, 128.1, 128.6, 137.8, 145.2, 146.1, 
147.6 and 158.7; mass spectrum (APCI), m/z 467.3998 (M+H)
+
 (C31H51N2O requires 
467.4001). 
 
 
 
3-(Benzyloxy)-6-N,N-dimethylamino-2-hexadecyl-4,5-dimethylpyridine (2.39) and 3-
(Benzyloxy)-6-N,N-dimethylamino-4-hexadecyl-2,5-dimethylpyridine (2.44).
120
 To a 
stirred solution containing 350 mg (1.29 mmol) of 2.35 and 217 mg (1.93 mmol) of 
KOtBu in 18 mL of anh THF at –78 °C was added 1.03 mL (2.58 mmol) of a 2.5 M 
solution of n-BuLi in hexane. The reaction mixture was stirred at –78 °C for 30 min and 
then 449 μL (1.55 mmol) of 1-bromopentadecane was added. The reaction mixture was 
stirred at 0 
o
C for another 30 min, then quenched with satd aq ammonium chloride and 
then extracted with 150 mL of EtOAc. The combined organic phase was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
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purified by chromatography on a silica gel column (30 × 2 cm). Elution with hexane 
followed by elution with 96:4 hexane–Et2O afforded 2.39 and 2.44 as yellowish oils: 
yields 93.0 mg (15%) and 279 mg (45%), respectively; silica gel TLC Rf  0.54 (4:1 
hexane–Et2O) and Rf  0.44 (4:1 hexane–Et2O); (2.39) 
1
H NMR (CDCl3, 400 MHz) δ 0.88 
(t, 3H, J = 6.8 Hz), 1.23-1.32 (m, 26H), 1.74 (m, 2H), 2.18 (s, 3H), 2.19 (s, 3H), 2.72-
2.77 (m, 8H), 4.73 (s, 2H) and 7.32-7.48 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.3, 
14.3, 15.0, 22.9, 28.8, 29.6, 29.82, 29.83, 29.84, 29.9, 32.08, 32.11, 42.8, 75.5, 121.5, 
127.9, 128.1, 128.7, 137.7, 140.3, 147.4, 149.6 and 158.2; mass spectrum (APCI), m/z 
481.4159 (M+H)
+
 (C32H53N2O requires 481.4158); (2.44) 
1
H NMR (CDCl3, 400 MHz) δ 
0.87 (t, 3H, J = 7.2 Hz), 1.21-1.38 (m, 26H), 1.49 (m, 2H), 2.21 (s, 3H), 2.44 (s, 3H), 
2.59 (m, 2H), 2.75 (s, 6H), 4.76 (s, 2H) and 7.30-7.48 (m, 5H); 
13
C NMR (CDCl3, 100 
MHz) δ 14.3, 14.5, 19.6, 22.9, 27.7, 29.6, 29.77, 29.83, 29.85, 29.89, 30.3, 32.1, 42.7, 
75.3, 121.3, 127.7, 128.1, 128.6, 137.8, 145.2, 146.1, 147.7 and 158.7; mass spectrum 
(APCI), m/z 481.4157 (M+H)
+
 (C32H53N2O requires 481.4158). 
 
 
 
3-(Benzyloxy)-6-N,N-dimethylamino-2-nonadecyl-4,5-dimethylpyridine (2.40) and 3-
(Benzyloxy)-6-N,N-dimethylamino-4-nonadecyl-2,5-dimethylpyridine (2.45).
120
 To a 
stirred solution containing 350 mg (1.29 mmol) of 2.35 and 217 mg (1.93 mmol) of 
KOtBu in 18 mL of anh THF at –78 °C was added 1.03 mL (2.58 mmol) of a 2.5 M 
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solution of n-BuLi in hexane. The reaction mixture was stirred at –78 °C for 30 min and 
then 517 mg (1.55 mmol) of 1-bromooctadecane was added. The reaction mixture was 
further stirred at 0 
o
C for another 30 min, quenched with satd aq ammonium chloride and 
then extracted with 150 mL of EtOAc. The combined organic phase was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (30 × 2 cm). Elution with hexane 
followed by elution with 96:4 hexane–Et2O afforded 2.40 and 2.45 as yellowish oils: 
yields 74.0 mg (11%) and 223 mg (33%), respectively; silica gel TLC Rf  0.55 (4:1 
hexane–Et2O) and Rf  0.46 (4:1 hexane–Et2O); (2.40) 
1
H NMR (CDCl3, 400 MHz) δ 0.89 
(t, 3H, J = 6.8 Hz), 1.24-1.34 (m, 32H), 1.75 (m, 2H), 2.19 (s, 3H), 2.20 (s, 3H), 2.73-
2.79 (m, 8H), 4.74 (s, 2H) and 7.32-7.49 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.3, 
14.3, 15.0, 22.9, 28.8, 29.5, 29.80, 29.82, 29.9, 32.07, 32.09, 42.8, 75.4, 121.5, 127.9, 
128.1, 128.7, 137.7, 140.3, 147.3, 149.6 and 158.2; mass spectrum (APCI), m/z 523.4633 
(M+H)
+
 (C35H59N2O requires 523.4627); (2.45) 
1
H NMR (CDCl3, 400 MHz) δ 0.94 (t, 
3H, J = 7.2 Hz), 1.29-1.45 (m, 32H), 1.55 (m, 2H), 2.27 (s, 3H), 2.51 (s, 3H), 2.66 (m, 
2H), 2.81 (s, 6H), 4.82 (s, 2H) and 7.34-7.52 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 
14.2, 14.4, 19.6, 22.8, 27.7, 29.5, 29.7, 29.79, 29.80, 29.85, 30.3, 32.1, 42.7, 75.2, 121.2, 
127.6, 128.0, 128.6, 137.7, 145.1, 146.0, 147.6 and 158.7; mass spectrum (APCI), m/z 
523.4623 (M+H)
+
 (C35H59N2O requires 523.4627). 
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6-N,N-Dimethylamino-2-decyl-4,5-dimethylpyridin-3-ol (2.3). To a solution 
containing 82.0 mg (0.21 mmol) of 2.36 in 5 mL of MeOH was added 5.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.3 as a colorless oil: yield 52.0 mg (82%); silica gel TLC Rf  0.52 (1:9 MeOH–
CHCl3); 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 6.8 Hz), 1.23-1.35 (m, 14H), 1.68 
(m, 2H), 2.12 (s, 3H), 2.17 (s, 3H), 2.61-2.76 (m, 8H) and 4.85 (br s, 1H); 
13
C NMR 
(CDCl3, 100 MHz) δ 12.5, 12.6, 14.3, 14.7, 22.9, 28.2, 29.5, 29.73, 29.77, 29.82, 32.0, 
32.1, 43.1, 122.2, 133.9, 142.4, 144.3 and 155.7; mass spectrum (APCI), m/z 307.2743 
(M+H)
+
 (C19H35N2O requires 307.2749). 
 
 
 
6-N,N-Dimethylamino-4-decyl-2,5-dimethylpyridin-3-ol (2.4). To a solution 
containing 220 mg (0.55 mmol) of 2.41 in 10 mL of MeOH was added 15.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
 82   
  
afforded 2.4 as a colorless oil: yield 153 mg (90%); silica gel TLC Rf  0.42 (1:9 MeOH–
CHCl3); 
1
H NMR (CDCl3, 400 MHz) δ 0.89 (t, 3H, J = 6.8 Hz), 1.24-1.43 (m, 14H), 1.48 
(m, 2H), 2.21 (s, 3H), 2.32 (s, 3H), 2.59 (m, 2H), 2.70 (s, 6H) and 5.32 (br s, 1H); 
13
C 
NMR (CDCl3, 100 MHz) δ 14.0, 14.2, 18.8, 22.8, 27.2, 28.6, 29.4, 29.6, 29.70, 29.72, 
30.1, 32.0, 42.9, 122.1, 139.25, 139.28, 144.6 and 156.1; mass spectrum (APCI), m/z 
307.2755 (M+H)
+
 (C19H35N2O requires 307.2749). 
 
 
 
6-N,N-Dimethylamino-2-tridecyl-4,5-dimethylpyridin-3-ol (2.5). To a solution 
containing 73.0 mg (0.16 mmol) of 2.37 in 5 mL of MeOH was added 5.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.5 as a colorless oil: yield 47.0 mg (86%); silica gel TLC Rf  0.23 (4:1 hexane–
Et2O); 
1
H NMR (CDCl3, 500 MHz) δ 0.88 (t, 3H, J = 7.0 Hz), 1.18-1.40 (m, 20H), 1.70 
(m, 2H), 2.15 (s, 3H), 2.19 (s, 3H), 2.61-2.79 (m, 8H) and 4.60 (br s, 1H); 
13
C NMR 
(CDCl3, 125 MHz) δ 12.6, 14.3, 14.7, 22.9, 28.2, 29.5, 29.7, 29.77, 29.82, 29.9, 32.1, 
43.1, 122.3, 134.0, 142.3, 144.4 and 155.5; mass spectrum (APCI), m/z 349.3225 (M+H)
+
 
(C22H41N2O requires 349.3219). 
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6-N,N-Dimethylamino-4-tridecyl-2,5-dimethylpyridin-3-ol (2.6). To a solution 
containing 201 mg (0.43 mmol) of 2.42 in 10 mL of MeOH was added 15.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.6 as a colorless oil: yield 134 mg (89%); silica gel TLC Rf  0.26 (4:1 hexane–
Et2O); 
1
H NMR (CDCl3, 500 MHz) δ 0.88 (t, 3H, J = 6.8 Hz), 1.23-1.34 (m, 20H), 1.47 
(m, 2H), 2.22 (s, 3H), 2.39 (s, 3H), 2.60 (m, 2H), 2.73 (s, 6H) and 4.20 (br s, 1H); 
13
C 
NMR (CDCl3, 125 MHz) δ 14.1, 14.3, 18.7, 22.9, 27.2, 28.7, 29.5, 29.7, 29.71, 29.8, 
29.81, 29.83, 30.2, 32.1, 43.1, 122.3, 138.5, 139.0, 144.7 and 153.6; mass spectrum 
(APCI), m/z 349.3214 (M+H)
+
 (C22H41N2O requires 349.3219). 
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6-N,N-Dimethylamino-2-pentadecyl-4,5-dimethylpyridin-3-ol (2.7). To a solution 
containing 80.0 mg (0.17 mmol) of 2.38 in 5 mL of MeOH was added 5.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.7 as a colorless oil: yield 56.0 mg (87%); silica gel TLC Rf  0.13 (4:1 hexane–
Et2O); 
1
H NMR (CDCl3, 500 MHz) δ 0.89 (t, 3H, J = 7.0 Hz), 1.22-1.34 (m, 24H), 1.70 
(m, 2H), 2.15 (s, 3H), 2.19 (s, 3H), 2.64-2.74 (m, 8H) and 4.32 (br s, 1H); 
13
C NMR 
(CDCl3, 125 MHz) δ 12.4, 14.1, 14.5, 22.7, 28.0, 29.4, 29.57, 29.61, 29.67, 29.7, 31.9, 
31.93, 42.9, 122.1, 133.6, 142.1, 144.1 and 155.5; mass spectrum (APCI), m/z 377.3527 
(M+H)
+
 (C24H45N2O requires 377.3532). 
 
 
 
6-N,N-Dimethylamino-4-pentadecyl-2,5-dimethylpyridin-3-ol (2.8). To a solution 
containing 251 mg (0.54 mmol) of 2.43 in 10 mL of MeOH was added 20.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
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afforded 2.8 as a colorless oil: yield 182 mg (90%); silica gel TLC Rf  0.22 (9:1 hexane–
Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 7.2 Hz), 1.23-1.33 (m, 24H), 1.48 
(m, 2H), 2.22 (s, 3H), 2.37 (s, 3H), 2.59 (m, 2H), 2.70 (s, 6H) and 4.15 (br s, 1H); 
13
C 
NMR (CDCl3, 100 MHz)  δ 14.1, 14.3, 18.9, 22.9, 27.2, 28.7, 29.5, 29.7, 29.8, 29.83, 
29.85, 30.2, 32.1, 43.1, 122.2, 138.6, 138.7, 144.5, and 156.2; mass spectrum (APCI), m/z 
377.3526 (M+H)
+
 (C24H45N2O requires 377.3532). 
 
 
 
6-N,N-Dimethylamino-2-hexadecyl-4,5-dimethylpyridin-3-ol (2.9). To a solution 
containing 90.0 mg (0.19 mmol) of 2.39 in 5 mL of MeOH was added 5.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.9 as a colorless solid: yield 62.0 mg (85%); mp 38-40 °C; silica gel TLC Rf 
0.28 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 6.8 Hz), 1.24-
1.35 (m, 26H), 1.70 (m, 2H), 2.15 (s, 3H), 2.20 (s, 3H), 2.67 (m, 2H), 2.72 (s, 6H) and 
4.56 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 12.6, 14.3, 14.7, 22.9, 28.2, 29.5, 29.7, 
29.77, 29.83, 29.9, 32.0, 32.1, 43.1, 122.3, 134.0, 142.3, 144.4 and 155.5; mass spectrum 
(APCI), m/z 391.3690 (M+H)
+
 (C25H47N2O requires 391.3688). 
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6-N,N-Dimethylamino-4-hexadecyl-2,5-dimethylpyridin-3-ol (2.10). To a solution 
containing 279 mg (0.58 mmol) of 2.44 in 10 mL of MeOH was added 15.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.10 as a colorless solid: yield 208 mg (92%); mp 36-38 °C; silica gel TLC Rf  
0.27 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 7.2 Hz), 1.23-
1.41 (m, 26H), 1.48 (m, 2H), 2.21 (s, 3H), 2.36 (s, 3H), 2.59 (m, 2H), 2.70 (s, 6H) and 
4.21 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.1, 14.3, 18.9, 22.9, 27.2, 28.7, 29.5, 
29.7, 29.8, 29.84, 29.86, 29.88, 30.2, 32.1, 43.1, 122.2, 138.6, 138.8, 144.5 and 156.2; 
mass spectrum (APCI), m/z 391.3681 (M+H)
+
 (C25H47N2O requires 391.3688). 
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6-N,N-Dimethylamino-2-nonadecyl-4,5-dimethylpyridin-3-ol (2.11). To a solution 
containing 62.0 mg (0.12 mmol) of 2.40 in 5 mL of MeOH was added 5.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.11 as a colorless solid: yield 41.0 mg (80%); mp 50-51 °C; silica gel TLC Rf  
0.48 (1:9 MeOH–CHCl3); 
1
H NMR (CDCl3, 400 MHz) δ 0.89 (t, 3H, J = 6.4 Hz), 1.24-
1.34 (m, 32H), 1.70 (m, 2H), 2.15 (s, 3H), 2.19 (s, 3H), 2.63-2.74 (m, 8H) and 4.77 (br s, 
1H); 
13
C NMR (CDCl3, 100 MHz) δ 12.6, 14.3, 14.7, 22.9, 28.2, 29.55, 29.60, 29.64, 
29.69, 29.71, 29.75, 29.79, 29.85, 29.9, 32.0, 32.1, 43.1, 122.2, 134.0, 142.5, 144.3 and 
155.7; mass spectrum (APCI), m/z 433.4165 (M+H)
+
 (C28H53N2O requires 433.4158). 
 
 
 
6-N,N-Dimethylamino-4-nonadecyl-2,5-dimethylpyridin-3-ol (2.12). To a solution 
containing 223 mg (0.43 mmol) of 2.45 in 10 mL of MeOH was added 15.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
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afforded 2.12 as a colorless solid: yield 175 mg (94%); mp 54-55 °C; silica gel TLC Rf  
0.43 (1:9 MeOH–CHCl3); 
1
H NMR (CDCl3, 400 MHz) δ 0.89 (t, 3H, J = 6.8 Hz), 1.24-
1.41 (m, 32H), 1.48 (m, 2H), 2.22 (s, 3H), 2.35 (s, 3H), 2.60 (m, 2H), 2.70 (s, 6H) and 
4.83 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.1, 14.2, 18.8, 22.8, 27.2, 28.7, 29.5, 
29.6, 29.75, 29.81, 29.9, 30.2, 32.1, 43.0, 122.1, 138.8, 144.5 and 156.1; mass spectrum 
(APCI), m/z 433.4148 (M+H)
+
 (C28H53N2O requires 433.4158). 
 
 
 
1-Bromo-11-cyclohexylundecane (2.46).
121
 To a solution containing 300 mg (1.29 
mmol) of 11-bromo-1-undecene and 880 μL (6.4 mmol) of vinyl cyclohexane in 6 mL of 
degassed CH2Cl2 was added 55.0 mg (0.064 mmol) of Grubbs’ 2nd generation catalyst. 
The reaction mixture was stirred at 40 °C for 48 h, and then concentrated under 
diminished pressure. The residue was dissolved in 20 mL of MeOH followed by addition 
of catalytic amount of Pd/C. Reaction mixture was bubbled with hydrogen for 30 min, 
and then the reaction mixture was kept under hydrogen atmosphere (1 bar) overnight. The 
reaction mixture was filtered through a Celite pad and the pad was washed with MeOH. 
The solution was concentrated under diminished pressure and the residue was purified by 
flash chromatography on a silica gel column (30 × 2 cm). Elution with 6:1 hexane–
EtOAc afforeded 2.46 as a colorless oil: yield 350 mg (86%); silica gel TLC Rf 0.74 (2:1 
hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.87 (m, 4H), 1.14-1.27 (m, 21H), 1.54-
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1.69 (m, 6H) and 3.39 (t, 2H, J = 6.8 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 22.9, 23.3, 
25.4, 26.6, 26.7, 27.0, 28.4, 29.0, 29.7, 33.1, 33.7, 34.9 and 38.2; mass spectrum (EI+), 
m/z 316.1768 (M)
+
 (C17H33Br requires 316.1766). 
 
 
 
3-(Benzyloxy)-2-(12-cyclohexyldodecyl)-6-N,N-dimethylamino-4,5-dimethylpyridine 
(2.47) and 3-(Benzyloxy)-4-(12-cyclohexyldodecyl)-6-N,N-dimethylamino-2,5-
dimethylpyridine (2.48).
120
 To a stirred solution containing 340 mg (1.26 mmol) of 2.35 
and 212 mg (1.89 mmol) of KOtBu in 18 mL of anh THF at –78 °C was added 1.01 mL 
(2.52 mmol) of a 2.5 M solution of n-BuLi in hexane. The reaction mixture was stirred at 
–78 °C for 30 min and then 480 mg (1.51 mmol) of 2.46 was added. The reaction mixture 
was further stirred at 0 
o
C for another 30 min, quenched with satd aq ammonium chloride 
and then extracted with 150 mL of EtOAc. The combined organic phase was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (30 × 2 cm). Elution with hexane 
followed by elution with 96:4 hexane–Et2O afforded 2.47 and 2.48 as yellowish oils: 
yields 90.0 mg (14%) and 269 mg (42%), respectively; silica gel TLC Rf  0.59 (4:1 
hexane–Et2O) and Rf  0.50 (4:1 hexane–Et2O); (2.47) 
1
H NMR (CDCl3, 400 MHz) δ 0.86 
(m, 2H), 1.14-1.35 (m, 26H), 1.69 (m, 5H), 2.19 (s, 6H), 2.76 (s, 8H), 4.73 (s, 2H) and 
 90   
  
7.33-7.51 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.3, 14.3, 15.0, 22.9, 28.8, 29.5, 29.6, 
29.7, 29.8, 29.82, 29.9, 32.07, 32.1, 42.8, 75.4, 121.5, 127.9, 128.1, 128.7, 137.7, 140.3, 
147.3, 149.6 and 158.2; mass spectrum (APCI), m/z 507.4303 (M+H)
+
 (C34H55N2O 
requires 507.4314); (2.48) 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 2H), 1.12-1.31 (m, 
24H), 1.49 (m, 2H), 1.67 (m, 5H), 2.21 (s, 3H), 2.45 (s, 3H), 2.61 (m, 2H), 2.76 (s, 6H), 
4.76 (s, 2H) and 7.32-7.51 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 14.5, 19.6, 26.6, 26.9, 
27.1, 27.7, 29.6, 29.8, 29.81, 29.83, 29.85, 29.9, 30.2, 30.3, 37.7, 37.9, 42.7, 75.3, 121.4, 
127.7, 128.1, 128.7, 137.8, 145.2, 146.1, 147.6 and 158.7; mass spectrum (APCI), m/z 
507.4305 (M+H)
+
 (C34H55N2O requires 507.4314). 
 
 
 
2-(12-Cyclohexyldodecyl)-6-N,N-dimethylamino-4,5-dimethylpyridin-3-ol (2.13). To 
a solution containing 82.0 mg (0.16 mmol) of 2.47 in 5 mL of MeOH was added 6.0 mg 
of 20% palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a 
H2 atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and 
the filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.13 as a colorless oil: yield 55.0 mg (82%); silica gel TLC Rf  0.50 (1:9 MeOH–
CHCl3); 
1
H NMR (CDCl3, 400 MHz) δ 0.85 (m, 2H), 1.14-1.36 (m, 26H), 1.69 (m, 5H), 
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2.17 (s, 6H) and 2.74 (s, 8H); 
13
C NMR (CDCl3, 100 MHz) δ 13.2, 14.3, 15.0, 22.8, 28.7, 
29.4, 29.5, 29.6, 29.7, 29.8, 29.9, 32.07, 32.1, 42.8, 128.1, 137.7, 140.3, 149.6 and 155.2; 
mass spectrum (APCI), m/z 417.3855 (M+H)
+
 (C27H49N2O requires 417.3845). 
 
 
 
4-(12-Cyclohexyldodecyl)-6-N,N-dimethylamino-2,5-dimethylpyridin-3-ol (2.14). To 
a solution containing 28.0 mg (0.05 mmol) of 2.48 in 5 mL of MeOH was added 5.0 mg 
of 20% palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a 
H2 atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and 
the filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.14 as a colorless oil: yield 18.0 mg (78%); silica gel TLC Rf  0.46 (1:9 MeOH–
CHCl3); 
1
H NMR (CDCl3, 500 MHz) δ 0.86 (m, 2H), 1.15-1.34 (m, 24H), 1.49 (m, 2H), 
1.67 (m, 5H), 2.22 (s, 3H), 2.38 (s, 3H), 2.60 (m, 2H), 2.71 (s, 6H) and 4.16 (br s, 1H); 
13
C NMR (CDCl3, 125 MHz) δ 14.1, 18.8, 26.6, 26.9, 27.1, 27.2, 28.7, 29.7, 29.75, 29.8, 
29.84, 29.87, 29.88, 30.18, 30.19, 33.6, 37.7, 37.8, 43.1, 122.2, 138.5, 138.6, 144.5 and 
156.0; mass spectrum (APCI), m/z 417.3841 (M+H)
+
 (C27H49N2O requires 417.3845). 
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10-Phenyldecyl-4-methylbenzenesulfonate (2.49). To a solution containing 300 mg 
(1.28 mmol) of 10-phenyl-1-decanol in 5 mL of anh CH2Cl2 was added 317 mg (1.67 
mmol) of p-toluenesulfonyl chloride, 16.0 mg (0.12 mmol) of DMAP, and 357 μL (2.56 
mmol) of triethylamine. The reaction mixture was stirred at room temperature for 16 h, 
and then quenched with 40 mL of H2O. The aqueous layer was washed with three 50-mL 
portions of CH2Cl2. The combined organic layer was washed with brine, dried (MgSO4) 
and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (20 × 3 cm). Elution with 3:1 hexane–EtOAc 
followed by 2:1 hexane–EtOAc afforded 2.49 as a yellowish oil: yield 423 mg (85%); 
silica gel TLC Rf  0.33 (3:1 hexane–EtOAc); 
1
H NMR (CDCl3, 500 MHz) δ 1.24-1.40 (m, 
12H), 1.66 (m, 4H), 2.45 (s, 3H), 2.65 (t, 2H, J = 7.5 Hz), 4.06 (t, 2H, J = 6.5 Hz), 7.16-
7.37 (m, 7H) and 7.83 (d, 2H, J = 8.0 Hz); 
13
C NMR (CDCl3, 125 MHz) δ 21.4, 25.2, 
28.7, 28.8, 29.1, 29.2, 29.3, 29.32, 31.4, 35.8, 70.5, 125.4, 127.7, 128.1, 128.2, 129.7, 
133.2, 142.6 and 144.5;  mass spectrum (APCI), m/z 389.2151 (M+H)
+
 (C23H33O3S 
requires 389.2150). 
 
 
 
3-(Benzyloxy)-6-N,N-dimethylamino-4-(11-phenylundecyl)-2,5-dimethylpyridine 
(2.50).
117
 To a stirred solution containing 98.0 mg (0.36 mmol) of 2.35 and 50.0 mg 3Ǻ 
molecular sieves in 3 mL of anh THF was added 54 μL (0.36 mmol) of N,N,N’,N’ -
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tetramethylethylenediamine (TMEDA), 152 μL (0.38 mmol) of a 2.5 M solution of n-
BuLi in hexane, followed by 155 mg (0.39 mmol) of 2.49 at 0 
o
C. After 15 min, 152 μL 
(0.38 mmol) of a 2.5 M solution of n-BuLi in hexane was added. The reaction was stirred 
at 0 
o
C for another 30 min, then quenched with satd aq ammonium chloride and then 
extracted with 150 mL of EtOAc. The combined organic phase was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (35 × 2 cm). Elution with 9:1 hexane–Et2O 
afforded 2.50 as a yellowish oil: yield 42.0 mg (24%); silica gel TLC Rf  0.52 (4:1 
hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 1.23-1.40 (m, 14H), 1.51 (m, 2H), 1.63 (m, 
2H), 2.24 (s, 3H), 2.47 (s, 3H), 2.62 (m, 4H), 2.78 (s, 6H), 4.78 (s, 2H) and 7.15-7.51 (m, 
10H); 
13
C NMR (CDCl3, 100 MHz) δ 14.5, 19.6, 27.7, 29.5, 29.51, 29.66, 29.7, 29.8, 
30.3, 31.7, 36.1, 42.7, 75.3, 121.4, 125.7, 127.7, 128.1, 128.3, 128.5, 128.7, 137.7, 143.1, 
145.3, 146.1, 147.6 and 158.6; mass spectrum (APCI), m/z 487.3690 (M+H)
+ 
(C33H47N2O 
requires 487.3688). 
 
 
 
6-N,N-Dimethylamino)-2,5-dimethyl-4-(11-phenylundecyl)pyridin-3-ol (2.15). To a 
solution containing 42.0 mg (0.08 mmol) of 2.50 in 5 mL of MeOH was added 6.0 mg of 
20% palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a 
H2 atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and 
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the filtrate was concentrated under diminished pressure. The residue obtained was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 1:9 MeOH–
CHCl3 afforded 2.15 as yellowish oil: yield 26.0 mg (76%); silica gel TLC Rf  0.23 (4:1 
hexane–Et2O); 
1
H NMR (CDCl3, 500 MHz) δ 1.25-1.45 (m, 14H), 1.51 (m, 2H), 1.64 (m, 
2H), 2.25 (s, 3H), 2.40 (s, 3H), 2.63 (m, 4H), 2.75 (s, 6H), 4.91 (br s, 1H) and 7.17-7.32 
(m, 5H); 
13
C NMR (CDCl3, 125 MHz) δ 14.1, 18.7, 27.2, 28.6, 29.4, 29.6, 29.61, 29.7, 
29.74, 30.1, 31.6, 36.1, 43.0, 122.2, 125.6, 128.3, 128.5, 138.7, 139.0, 143.0, 144.6 and 
155.8; mass spectrum (APCI), m/z 397.3224 (M+H)
+
 (C26H41N2O requires 397.3219). 
 
 
 
1-Bromo-11-phenylundecane (2.51).
121,139
 To a solution containing 300 mg (1.29 mmol) 
of 11-bromo-1-undecene and 736 μL (6.41 mmol) of styrene in 6 mL of degassed CH2Cl2 
was added 55.0 mg (0.06 mmol) of Grubbs’ 2nd generation catalyst. The reaction mixture 
was stirred at 40 °C for 48 h, and then concentrated under diminished pressure. The 
residue was dissolved in 20 mL of MeOH followed by addition of catalytic amount of 
Pd/C. Reaction mixture was bubbled with hydrogen for 30 min, and then the reaction 
mixture was kept under hydrogen atmosphere (1 bar) overnight. The reaction mixture 
was filtered through Celite and the Celite pad was washed with MeOH. The combined 
organic phase was concentrated under diminished pressure and the residue was purified 
by flash chromatography on a silica gel column (30 × 2 cm). Elution with 6:1 hexane–
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EtOAc gave 2.51 as a colorless oil: yield 340 mg (85%); silica gel TLC Rf 0.68 (2:1 
hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 1.37 (m, 14H), 1.71 (m, 2H), 1.89 (m, 
2H), 2.69 (m, 2H), 3.41 (m, 2H) and 7.21-7.33 (m, 5H).  
 
 
 
3-(Benzyloxy)-6-N,N-dimethylamino-2-(12-phenyldodecyl)-4,5-dimethylpyridine 
(2.52) and 3-(Benzyloxy)-6-N,N-dimethylamino-4-(12-phenyldodecyl)-2,5-
dimethylpyridine (2.53).
120
 To a stirred solution containing 360 mg (1.33 mmol) of 2.35 
and 224 mg (1.99 mmol) of KOtBu in 20 mL of anh THF at –78 °C was added 1.06 mL 
(2.66 mmol) of a 2.5 M solution of n-BuLi in hexane. The reaction mixture was stirred at 
–78 °C for 30 min and then 497 mg (1.59 mmol) of 2.51 was added. The reaction mixture 
was further stirred at 0 
o
C for another 30 min, quenched with satd aq ammonium chloride 
and then extracted with 150 mL of EtOAc. The combined organic phase was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (30 × 2 cm). Elution with hexane 
followed by elution with 96:4 hexane–Et2O afforded 2.52 and 2.53 as yellowish oils: 
yields 107 mg (16%) and 287 mg (43%), respectively; silica gel TLC Rf  0.35 (4:1 
hexane–Et2O) and 0.29 (4:1 hexane–Et2O), respectively; (2.52) 
1
H NMR (CDCl3, 500 
MHz) δ 1.18-1.38 (m, 16H), 1.60 (m, 2H), 1.72 (m, 2H), 2.18 (s, 3H), 2.21 (s, 3H), 2.58 
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(m, 2H), 2.76 (s, 8H), 4.72 (s, 2H) and 7.15-7.50 (m, 10H); 
13
C NMR (CDCl3, 125 MHz) 
δ 13.3, 14.3, 14.5, 15.0, 22.9, 27.7, 28.8, 29.5, 29.54, 29.7, 29.76, 29.8, 29.9, 30.3, 31.7, 
32.0, 36.2, 42.8, 75.5, 121.6, 125.7, 127.7, 127.9, 128.2, 128.3, 128.5, 128.7, 137.6, 143.1 
and 149.7; mass spectrum (APCI), m/z 501.3848 (M+H)
+
 (C34H49N2O requires 
501.3845); (2.53) 
1
H NMR (CDCl3, 500 MHz) δ 1.27-1.43 (m, 16H), 1.55 (m, 2H), 1.66 
(m, 2H), 2.27 (s, 3H), 2.51 (s, 3H), 2.65 (m, 4H), 2.82 (s, 6H), 4.82 (s, 2H) and 7.20-7.52 
(m, 10H); 
13
C NMR (CDCl3, 125 MHz) δ 14.5, 19.6, 27.7, 29.48, 29.49, 29.52, 29.53, 
29.6, 29.7, 29.71, 29.74, 29.77, 29.78, 30.3, 31.7, 36.1, 42.7, 75.3, 121.3, 125.7, 127.7, 
128.1, 128.3, 128.5, 128.6, 137.8, 143.0, 145.2, 146.1, 147.6 and 158.7; mass spectrum 
(APCI), m/z 501.3844 (M+H)
+
 (C34H49N2O requires 501.3845). 
 
 
 
6-(Dimethylamino)-4,5-dimethyl-2-(12-phenyldodecyl)pyridin-3-ol (2.16). To a 
solution containing 14.0 mg (0.02 mmol) of 2.52 in 2 mL of MeOH was added 4.0 mg of 
20% palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a 
H2 atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and 
the filtrate was concentrated under diminished pressure. The residue obtained was 
purified by column chromatography on a silica gel column (10 × 2 cm). Elution with 1:9 
MeOH–CHCl3 afforded 2.16 as a yellowish oil: yield 8.0 mg (70%); silica gel TLC Rf  
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0.50 (1:9 MeOH–CHCl3); 
1
H NMR (CDCl3, 500 MHz) δ 1.20-1.38 (m, 16H), 1.60 (m, 
2H), 1.70 (m, 2H), 2.18 (s, 3H), 2.21 (s, 3H), 2.59 (m, 2H), 2.77 (s, 8H), 4.28 (br s, 1H) 
and 7.15-7.28 (m, 5H); 
13
C NMR (CDCl3, 125 MHz) δ 14.0, 18.7, 27.2, 28.6, 29.4, 29.6, 
29.7, 29.73, 30.1, 31.6, 36.1, 43.0, 122.2, 125.6, 128.3, 128.4, 130.9, 138.9, 142.9, 144.6 
and 155.8; mass spectrum (APCI), m/z 411.3384 (M+H)
+
 (C27H43N2O requires 
411.3375). 
 
 
6-(Dimethylamino)-2,5-dimethyl-4-(12-phenyldodecyl)pyridin-3-ol (2.17). To a 
solution containing 62.0 mg (0.12 mmol) of 2.53 in 5 mL of MeOH was added 6.0 mg of 
20% palladium hydroxide on carbon. The reaction mixture was stirred at 23 
o
C under a 
H2 atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and 
the filtrate was concentrated under diminished pressure. The residue obtained was 
purified by chromatography on a silica gel column (10 × 2 cm). Elution with 1:9 MeOH–
CHCl3 afforded 2.17 as a yellowish oil: yield 40.0 mg (79%); silica gel TLC Rf  0.54 (1:9 
MeOH–CHCl3) respectively; 
1
H NMR (CD3OD, 500 MHz) δ 1.19-1.28 (m, 16H), 1.29 
(m, 2H), 1.38 (m, 2H), 1.49 (m, 2H), 2.10 (s, 3H), 2.26 (s, 3H), 2.46 (m, 2H), 2.57 (s, 
6H), 4.85 (br s, 1H) and 6.99-7.12 (m, 5H); 
13
C NMR (CD3OD, 125 MHz) δ 14.1, 18.7, 
28.0, 29.6, 30.3, 30.6, 30.67, 30.68, 30.7, 31.0, 32.7, 36.9, 43.3, 123.7, 126.5, 129.2, 
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129.3, 141.4, 142.1, 143.8, 146.7 and 156.3; mass spectrum (APCI), m/z 411.3370 
(M+H)
+
 (C27H43N2O requires 411.3375). 
 
 
 
 
(7R,11R,E)-1-Bromo-3,7,11,15-tetramethylhexadec-2-ene (2.54).
122
 To a flame dried 
two-necked round bottom flask, 500 mg (1.69 mmol) of natural phytol was taken and 
treated with 176 μL (1.85 mmol) of phosphorus tribromide at 0 °C. The reaction mixture 
was stirred for 2 h and then washed with satd NaHCO3. The organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (20 × 3 cm). Elution with hexane afforded 2.54 as 
a light yellowish oil: yield 390 mg (64%); silica gel TLC Rf  0.50 (hexane); 
1
H NMR 
(CDCl3, 500 MHz) δ 0.80-0.91 (m, 12H), 1.09-2.10 (m, 21H), 1.76 (s, 3H), 4.02 (d, 2H), 
5.53 (t, 1H, J = 6.5 Hz). 
 
 
 
3-(Benzyloxy)-6-N,N-dimethylamino-4-((8R,12R)-4,8,12,16-tetramethylheptadecyl)-
2,5-dimethylpyridine (2.55).
116
 To a stirred solution containing 98.0 mg (0.36 mmol) of 
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2.35 and 50.0 mg of 3Ǻ molecular sieves in 3 mL of anh THF was added 54 μL (0.36 
mmol) of N,N,N’,N’ -tetramethylethylenediamine (TMEDA), 145 μL (0.36 mmol) of a 
2.5 M solution of n-BuLi in hexane, followed by 143 mg (0.39 mmol) of 2.54 at 0 
o
C. 
After 15 min, 145 μL (0.36 mmol) of a 2.5 M solution of n-BuLi in hexane was added 
again. The reaction mixture was stirred at 0 
o
C for another 30 min, quenched with satd aq 
ammonium chloride and then extracted with 150 mL of EtOAc. The combined organic 
phase was washed with brine, dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (35 × 2 
cm). Elution with 9:1 hexane–Et2O afforded 2.55 as a yellowish oil: yield 40.0 mg 
(20%); silica gel TLC Rf  0.18 (9:1 hexane–Et2O); 
1
H NMR (CDCl3, 500 MHz) δ 0.80-
0.91 (m, 12H), 1.02-1.41 (m, 22H), 1.51 (m, 2H), 1.92 (m, 2H), 2.24 (s, 3H), 2.45 (s, 
3H), 2.65 (m, 2H), 2.76 (s, 6H), 4.78 (s, 2H), 5.18 (t, 1H, J = 7.2 Hz) and 7.21-7.52 (m, 
5H); 
13
C NMR (CDCl3, 125 MHz) δ 14.6, 16.0, 19.6, 19.8, 19.9, 22.8, 22.9, 23.5, 24.7, 
25.0, 25.5, 25.53, 28.0, 28.1, 32.9, 37.6, 39.5, 40.2, 42.7, 75.2, 123.3, 127.6, 127.7, 128.1, 
128.6, 136.5, 137.7, 147.7 and 158.7; mass spectrum (APCI), m/z 549.4797 (M+H)
+
 
(C37H61N2O requires 549.4784). 
 
 
6-N,N-Dimethylamino)-2,5-dimethyl-4-((8R,12R)-4,8,12,16-
tetramethylheptadecyl)pyridin-3-ol (2.18). To a solution containing 40.0 mg (0.07 
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mmol) of 2.55 in 5 mL of MeOH was added 8.0 mg of 20% palladium hydroxide on 
carbon. The reaction mixture was stirred at 23 
o
C under a H2 atmosphere (1 bar) for 
overnight. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under diminished pressure. The residue obtained was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 1:9 MeOH–CHCl3 
afforded 2.18 as a yellowish oil: yield 29.0 mg (85%); silica gel TLC Rf  0.33 (1:9 
MeOH–CHCl3) respectively; 
1
H NMR (CDCl3, 500 MHz) δ 0.80-0.93 (m, 15H), 1.01-
1.48 (m, 24H), 1.52 (m, 2H), 2.22 (s, 3H), 2.39 (s, 3H), 2.58 (m, 2H), 2.72 (s, 6H) and 
4.62 (br s, 1H); 
13
C NMR (CDCl3, 125 MHz) δ 14.1, 19.7, 19.79, 19.83, 19.85, 19.9, 
22.8, 22.9, 24.6, 24.9, 26.1, 27.5, 28.1, 32.9, 32.93, 37.4, 37.5, 37.53, 37.6, 29.5, 43.1, 
122.3, 138.6, 139.1, 144.7 and 155.7; mass spectrum (APCI), m/z 461.4472 (M+H)
+
 
(C30H57N2O requires 461.4471).
 
 
 
Morpholine–iodine complex (2.56).124,125 To a homogenized solution of 60 mL (0.68 
mol) of morpholine in 200 mL benzene was added 28.8 g (0.11 mol) of I2. The mixture 
was stirred in dark for 3 h. The orange precipitate obtained was filtered, washed with 
benzene and Et2O; and finally dried under vacuum in dark to afford 2.56 as an orange 
powder: yield 34.0 g (88%); 
1
H NMR (CDCl3, 400 MHz) 1.92-2.03 (br s, 1H), 3.21-
3.24 (m, 4H) and 3.94-3.96 (m, 4H). 
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6-Iodo-2,4,5-trimethylpyridin-3-ol (2.57).
119,123
 To a stirred solution of 20.0 g (97.3 
mmol) of pyridoxine hydrochloride in 80 mL of thionyl chloride was added 800 μL of 
DMF. The reaction mixture was stirred at reflux for 2 h. The cooled reaction mixture was 
treated with 60 mL of Et2O. The suspension was stirred for 1 h and then filtered and the 
precipitate was washed with 60 mL of Et2O. The precipitate so obtained was dissolved in 
84 mL of glacial acetic acid and 19.0 g (29.1 mmol) of zinc dust was added in three 
portions. The reaction mixture was stirred at reflux for 2 h. The cooled reaction mixture 
was filtered and washed with glacial acetic acid. The filtrate was concentrated under 
diminished pressure and then neutralized with 6 M NaOH. The formed precipitate was 
filtered and washed with small amount of brine. The orange precipitate obtained was 
dissolved in 10 M HCl and solid NaCl was added to salt out 12.0 g of crude 2,4,5-
trimethylpyridin-3-ol.  
To a mixture of 6.50 g (47.4 mmol) of crude 2,4,5-trimethylpyridin-3-ol and 19.6 
g (142 mmol) of K2CO3 in 100 mL of distilled water was added 32.3 g (94.8 mmol) of 
2.56 in eight portions over a period of 2 h. The reaction mixture was stirred for an 
additional 4 h in the dark and then washed with satd aq sodium thiosulfate. The crude 
product was extracted using CH2Cl2; the combined organic layer was washed with brine, 
dried (MgSO4), and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 6 cm). Elution with CH2Cl2 and then with 
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5:95 MeOH–CH2Cl2 afforded 2.57 as a colorless oil: yield 7.20 g (58%); silica gel TLC 
Rf  0.59 (1:9 MeOH–CH2Cl2); 
1
H NMR (CDCl3, 400 MHz)  s, 2.34, (s, 3H), 
2.40 (s, 3H) and 3.70 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz) 13.6, 18.9, 23.5, 113.8, 
132.8, 135.6, 144.1 and 149.1mass spectrum (EI+), m/z 262.9808 (M)+ (C8H10NOI 
requires 262.9807). 
 
 
 
3-(Benzyloxy)-6-iodo-2,4,5-trimethylpyridine (2.58). To a solution of 1.40 g (5.32 
mmol) of 2.57 in 50 mL dry DMF was added 2.94 g (21.3 mmol) of K2CO3 and 759 L 
(6.38 mmol) of BnBr under an argon atmosphere. The reaction mixture was stirred at 
room temperature for 3 h and then the DMF was concentrated under diminished pressure. 
The residue was dissolved in 100 mL CH2Cl2 and washed with saturated NaHCO3. The 
combined organic phase was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (15 × 3 cm). Elution 
with hexane followed by elution with 19:1 hexane–EtOAc and finally with EtOAc 
afforded 2.58 as a colorless solid: yield 1.17 g (62%); mp 39-40 °C; silica gel TLC Rf 
0.55 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 2.25 (s, 3H), 2.35 (s, 3H), 2.46 (s, 
3H), 4.76 (s, 2H) and 7.34-7.45 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 14.3, 19.4, 23.5, 
75.1, 118.9, 128.0, 128.5, 128.7, 136.1, 136.6, 140.0, 151.4 and 152.1; mass spectrum 
(EI+), m/z 353.0280 (M)
+
 (C15H16NOI requires 353.0277). 
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2-(Azetidin-1-yl)-5-(benzyloxy)-3,4,6-trimethylpyridine (2.59).
126
 In a sealed tube 
containing 24.0 mg (0.03 mmol) of Pd2(dba)3, 46.0 mg (0.11 mmol) of 1,3-bis(2,6-
diisopropylphenyl)imidazolium chloride, 827 mg (7.37 mmol) of KOtBu, and 654 mg 
(6.03 mmol) of azetidine hydrochloride was added 474 mg (1.34 mmol) of 2.58 in 7 mL 
of dry dioxane. The reaction mixture was stirred at 90 °C for 3 h. The cooled reaction 
mixture was filtered through Celite and the Celite pad was washed with CH2Cl2. The 
combined organic phase was washed with water and then with brine. The organic phase 
was dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by flash chromatography on a silica gel column (15 × 3 cm). Elution with hexane 
followed by elution with 95:5 hexane–Et2O afforded 2.59 as a colorless oil: yield 268 mg 
(71%); silica gel TLC Rf 0.45 (3:2 hexane–EtOAc);
 1
H NMR (CDCl3, 400 MHz) 
s, 2.18 (s, 3H), 2.27 (quint, 2H, J = 7.6 Hz), 2.42 (s, 3H), 4.04 (t, 4H, J = 7.2 
Hz), 4.72 (s, 2H) and 7.31-7.49 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) 12.8, 14.2, 17.0, 
19.4, 52.7, 75.0, 116.7, 128.0, 128.1, 128.7, 137.6, 140.0, 145.7, 146.0 and 156.9mass 
spectrum (EI+), m/z 282.1736 (M)
+
 (C18H22N2O requires 282.1732). 
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2-(Azetidin-1-yl)-5-(benzyloxy)-6-hexadecyl-3,4-dimethylpyridine (2.60) and 2-
(Azetidin-1-yl)-5-(benzyloxy)-4-hexadecyl-3,6-dimethylpyridine (2.61).
120
 To a stirred 
solution containing 109 mg (0.38 mmol) of 2.59 and 65.0 mg (0.57 mmol) of KOtBu in 6 
mL of anh THF at –78 °C was added 228 μL (0.57 mmol) of a 2.5 M solution of n-BuLi 
in hexane. The reaction mixture was stirred at –78 °C for 30 min and then 165 μL (0.57 
mmol) of 1-bromopentadecane was added dropwise. The reaction mixture was stirred at 0 
°C for an additional 30 min, quenched with satd aq ammonium chloride and then 
extracted with 100 mL of EtOAc. The combined organic phase was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a column of silica gel (30 × 2 cm). Elution with hexane followed by 
96:4 hexane–Et2O afforded 2.60 and 2.61 as yellowish oils: yields 43.0 mg (23%) and 
74.0 mg (40%), respectively; silica gel TLC Rf  0.50 (3:2 hexane–Et2O) and Rf  0.38 (3:2 
hexane–Et2O); (2.60) 
1
H NMR (CDCl3, 400 MHz) 0.90 (t, 3H, J = 7.2 Hz), 1.23-1.37 
(m, 26H), 1.76 (quint, 2H, J = 7.6 Hz), 2.06 (s, 3H), 2.19 (s, 3H), 2.27 (quint, 2H, J = 7.6 
Hz), 2.73 (t, 2H, J = 8.0 Hz), 4.05 (t, 4H, J = 7.6 Hz), 4.72 (s, 2H) and 7.32-7.50 (m, 5H); 
13
C NMR (CDCl3, 100 MHz)  12.9, 14.1, 14.3, 17.1, 22.8, 28.9, 29.5, 29.81, 29.87, 
29.9, 32.08, 32.1, 52.7, 75.5, 116.4, 127.9, 128.1, 128.6, 137.8, 139.8, 145.7, 149.5 and 
156.8; mass spectrum (APCI), m/z 493.4159 (M+H)
+
 (C33H53N2O requires 493.4158); 
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(2.61)1H NMR (CDCl3, 400 MHz) 0.89 (t, 3H, J = 7.2 Hz), 1.24-1.34 (m, 26H), 1.48 
(quint, 2H, J = 7.6 Hz), 2.07 (s, 3H), 2.27 (quint, 2H, J = 7.6 Hz), 2.44 (s, 3H), 2.61 (t, 
2H, J = 8.0 Hz), 4.05 (t, 4H, J = 7.2 Hz), 4.75 (s, 2H) and 7.33 -7.50 (m, 5H); 
13
C NMR 
(CDCl3, 100 MHz)  13.9, 14.3, 17.0, 19.5, 22.9, 27.1, 29.5, 29.6, 29.76, 29.82, 29.83, 
29.9, 30.3, 32.1, 52.7, 75.4, 116.2, 127.7, 128.0, 128.7, 137.9, 144.7, 145.85, 145.91 and 
157.1mass spectrum (APCI), m/z 493.4149 (M+H)+ (C33H53N2O requires 493.4158). 
 
 
 
6-(Azetidin-1-yl)-2-hexadecyl-4,5-dimethylpyridin-3-ol (2.19). To a solution 
containing 85.0 mg (0.17 mmol) of 2.60 in 5 mL of MeOH was added 5.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 °C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.19 as a yellowish oil: yield 59.0 mg (85%); silica gel TLC Rf  0.43 (1:9 
MeOH–CHCl3) 
1
H NMR (CDCl3, 400 MHz) 0.88 (t, 3H, J = 6.4 Hz), 1.19-1.38 (m, 
26H), 1.67 (quint, 2H, J = 6.4 Hz), 2.01 (s, 3H), 2.09 (s, 3H), 2.22 (quint, 2H, J = 6.8 
Hz), 2.61 (t, 2H, J = 7.2 Hz ), 3.96 (t, 4H, J = 6.8 Hz) and 5.31 (br s, 1H); 
13
C NMR 
(CDCl3, 100 MHz)  12.3, 14.1, 14.3, 17.1, 22.9, 28.4, 29.5, 29.8, 29.9, 32.1, 52.8, 116.9, 
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134.5, 142.8 and 154.5; mass spectrum (APCI), m/z 403.3700 (M+H)
+
 (C26H47N2O 
requires 403.3688). 
 
 
 
6-(Azetidin-1-yl)-4-hexadecyl-2,5-dimethylpyridin-3-ol (2.20). To a solution 
containing 149 mg (0.30 mmol) of 2.61 in 10 mL of MeOH was added 15.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 °C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 5:95 MeOH–CHCl3 
afforded 2.20 as a colorless solid: yield 114 mg (94%); mp 75-76 °C; silica gel TLC Rf  
0.34 (1:9 MeOH–CHCl3) 
1
H NMR (CDCl3, 400 MHz) 0.88 (t, 3H, J = 6.8 Hz), 1.23-
1.38 (m, 26H), 1.46 (quint, 2H, J = 7.6 Hz), 2.05 (s, 3H), 2.24 (quint, 2H, J = 7.2 Hz), 
2.36 (s, 3H), 2.58 (t, 2H, J = 7.2 Hz), 3.97 (t, 4H, J = 7.2 Hz) and 5.33 (br s, 1H); 
13
C 
NMR (CDCl3, 100 MHz)  13.7, 14.3, 17.0, 18.9, 22.8, 26.6, 29.0, 29.5, 29.7, 29.75, 
29.81, 29.85, 30.1, 32.1, 52.7, 116.8, 138.3, 138.5, 142.6 and 155.0;mass spectrum 
(APCI), m/z 403.3676 (M+H)
+
 (C26H47N2O requires 403.3688). 
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3-(Benzyloxy)-2,4,5-trimethyl-6-(piperidin-1-yl)pyridine (2.62).
126
 In a sealed tube 
containing 15.0 mg (0.02 mmol) of Pd2(dba)3, 28.0 mg (0.07 mmol) of 1,3-bis(2,6-
diisopropylphenyl)imidazolium chloride, 285 mg (2.54 mmol) of KOtBu and 161 µL 
(1.63 mmol) of piperidine was added 301 mg (0.82 mmol) of 2.58 in 8 mL of dry 
dioxane. The reaction mixture was stirred at 90 °C for 3 h. The cooled reaction mixture 
was filtered through Celite and the Celite pad was washed with CH2Cl2. The combined 
organic phase was washed with water and then with brine. The organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm). Elution with hexane followed by 
elution with 6:1 hexane–Et2O afforded 2.62 as a colorless solid: yield 201 mg (79%); mp: 
103-105 °C; silica gel TLC Rf 0.38 (6:1 hexane–EtOAc);
 1
H NMR (CDCl3, 400 MHz) 
1.62 (mmsss, 3.02 (t, 4H, J = 5.6 
Hz), 4.76 (s, 2H) and 7.34-7.53 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.1, 14.6, 19.4, 
24.7, 26.5, 51.8, 74.8, 122.7, 127.9, 128.1, 128.6, 137.5, 140.3, 146.1, 147.8 and 
158.5;mass spectrum (EI+), m/z 310.2051 (M)+ (C20H26N2O requires 310.2045). 
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3-(Benzyloxy)-4-hexadecyl-2,5-dimethyl-6-(piperidin-1-yl)pyridine(2.63).
120
 To a 
stirred solution containing 100 mg (0.32 mmol) of 2.62 and 72.0 mg (0.64 mmol) of 
KOtBu in 7 mL of anh THF at –78 °C was added 256 μL (0.64 mmol) of a 2.5 M solution 
of n-BuLi in hexane. The reaction mixture was stirred at –78 °C for 30 min and then 186 
μL (0.64 mmol) of 1-bromopentadecane was added dropwise. The reaction mixture was 
stirred at 0 °C for an additional 30 min, quenched with satd aq ammonium chloride and 
then extracted with 100 mL of EtOAc. The combined organic phase was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a column of silica gel (30 × 2 cm). Elution with hexane 
followed by 19:1 hexane–Et2O afforded 2.63 as a yellowish oil: yields 71.0 mg (43%); 
silica gel TLC Rf  0.39 (9:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.89 (t, 3H, J = 
7.2 Hz), 1.20-1.51 (m, 26H), 1.49 (m, 2H), 1.59 (m, 2H), 1.69 (m, 4H), 2.21 (s, 3H), 2.46 
(s, 3H), 2.60 (m, 2H), 3.01 (t, 4H, J = 5.2 Hz), 4.77 (s, 2H) and 7.33-7.49 (m, 5H); 
13
C 
NMR (CDCl3, 100 MHz) δ 14.1, 14.3, 19.5, 22.8, 24.7, 26.6, 27.8, 29.49, 29.52, 29.54, 
29.7, 29.8, 29.9, 30.3, 32.1, 51.9, 75.3, 122.3, 127.7, 128.1, 128.7, 137.7, 145.5, 146.3, 
147.8 and 158.8; mass spectrum (FAB), m/z 521.4487 (M+H)
+
 (C35H57N2O requires 
521.4471). 
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4-Hexadecyl-2,5-dimethyl-6-(piperidin-1-yl)pyridin-3-ol (2.21). To a solution 
containing 33.0 mg (0.06 mmol) of 2.63 in 3 mL of MeOH was added 5.0 mg of 20% 
palladium hydroxide on carbon. The reaction mixture was stirred at 23 °C under a H2 
atmosphere (1 bar) for 30 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 2 cm). Elution with 4:1 hexane–EtOAc 
afforded 2.21 as a colorless oil: yield 18.0 mg (66%); silica gel TLC Rf  0.36 (3:2 
hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 6.8 Hz), 1.21-1.34 (m, 
24H), 1.39 (m, 2H), 1.48 (m, 2H), 1.55 (m, 2H), 1.68 (m, 4H), 2.20 (s, 3H), 2.37 (s, 3H), 
2.59 (m, 2H), 2.92 (t, 4H, J = 5.2 Hz) and 4.20 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz)  
δ 13.8, 14.3, 18.8, 22.8, 24.7, 26.6, 27.2, 28.6, 29.5, 29.7, 29.73, 29.81, 29.83, 29.9, 30.2, 
32.1, 52.1, 122.8, 138.3, 138.8, 144.5 and 156.5; mass spectrum (FAB), m/z 431.4000 
(M+H)
+
 (C28H51N2O requires 431.4001). 
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4-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)morpholine (2.64).
126
 In a sealed tube 
containing 16.0 mg (0.02 mmol) of Pd2(dba)3, 29.0 mg (0.07 mmol) of 1,3-bis(2,6-
diisopropylphenyl)imidazolium chloride, 382 mg (3.40 mmol) of KOtBu and 221 µL 
(2.55 mmol) of morpholine was added 301 mg (0.85 mmol) of 2.58 in 8 mL of dry 
dioxane. The reaction mixture was stirred at 90 °C for 3 h. The cooled reaction mixture 
was filtered through Celite and the Celite pad was washed with CH2Cl2. The combined 
organic phase was washed with water and then with brine. The organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm). Elution with hexane followed by 
elution with 4:1 hexane–EtOAc afforded 2.64 as a colorless solid: yield 214 mg (81%); 
mp 88-89 °C; silica gel TLC Rf 0.37 (4:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) 
2.19 (s, 3H), 2.20 (s, 3H), 2.47 (s, 3H), 3.08 (m, 4H), 3.86 (t, 4H), 4.75 (s, 2H) and 
7.32-7.49 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.2, 14.5, 19.2, 50.9, 67.3, 74.8, 
122.5, 127.9, 128.2, 128.6, 137.2, 141.0, 146.4, 148.2 and 156.7;mass spectrum (EI+), 
m/z 312.1837 (M)
+
 (C19H24N2O2 requires 312.1838). 
 
 
 
4-(5-(Benzyloxy)-6-hexadecyl-3,4-dimethylpyridin-2-yl)morpholine (2.65) and 4-(5-
(Benzyloxy)-4-hexadecyl-3,6-dimethylpyridin-2-yl)morpholine (2.66).
120
 To a stirred 
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solution containing 100 mg (0.32 mmol) of 2.64 and 72.0 mg (0.64 mmol) of KOtBu in 7 
mL of anh THF at –78 °C was added 256 μL (0.64 mmol) of a 2.5 M solution of n-BuLi 
in hexane. The reaction mixture was stirred at –78 °C for 30 min and then 186 μL (0.64 
mmol) of 1-bromopentadecane was added dropwise. The reaction mixture was stirred at 0 
°C for an additional 30 min, quenched with satd aq ammonium chloride and then 
extracted with 100 mL of EtOAc. The combined organic phase was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a column of silica gel (30 × 2 cm). Elution with hexane followed by 
19:1 hexane–Et2O and then 9:1 hexane–Et2O afforded 2.65 and 2.66 as yellowish oils: 
yields 24.0 mg (14%) and 70.0 mg (42%), respectively; silica gel TLC Rf  0.30 (4:1 
hexane–Et2O) and Rf  0.18 (4:1 hexane–Et2O); (2.65) 
1
H NMR (CDCl3, 400 MHz) δ 0.86 
(t, 3H, J = 6.8 Hz), 1.19-1.37 (m, 24H), 1.71 (m, 2H), 1.84 (m, 2H), 2.17 (s, 3H), 2.19 (s, 
3H), 2.74 (t, 2H, J = 7.2 Hz), 3.07 (m, 4H), 3.85 (m, 4H), 4.73 (s, 2H) and 7.32-7.49 (m, 
5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.3, 14.3, 14.6, 22.9, 25.8, 28.8, 29.5, 29.8, 29.82, 
29.9, 32.0, 32.1, 51.0, 67.4, 68.1, 75.5, 122.1, 127.9, 128.2, 128.7, 137.5, 140.6, 148.0, 
150.3 and 156.9; mass spectrum (FAB), m/z 523.4274 (M+H)
+
 (C34H55N2O2 requires 
523.4264); (2.66) 
1
H NMR (CDCl3, 400 MHz) δ 0.89 (t, 3H, J = 6.8 Hz), 1.20-1.41 (m, 
26H), 1.50 (m, 2H), 2.23 (s, 3H), 2.46 (s, 3H), 2.61 (m, 2H), 3.07 (m, 4H), 3.85 (m, 4H), 
4.78 (s, 2H) and 7.32-7.51 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 14.0, 14.2, 19.5, 22.8, 
27.7, 29.5, 29.7, 29.76, 29.77, 29.8, 30.3, 32.0, 51.0, 67.4, 75.3, 121.9, 127.7, 128.1, 
128.7, 137.6, 145.5, 146.7, 148.2 and 157.3; mass spectrum (FAB), m/z 523.4260 
(M+H)
+
 (C34H55N2O2 requires 523.4264). 
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2-Hexadecyl-4,5-dimethyl-6-morpholinopyridin-3-ol (2.22). To a solution containing 
24.0 mg (0.04 mmol) of 2.65 in 2 mL of MeOH was added 5.0 mg of 20% palladium 
hydroxide on carbon. The reaction mixture was stirred at 23 °C under a H2 atmosphere (1 
bar) for 30 min. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 1:9 MeOH–CH2Cl2 afforded 2.22 as a 
colorless oil: yield 13.0 mg (67%); silica gel TLC Rf  0.34 (4:1 hexane–EtOAc); 
1
H NMR 
(CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 7.2 Hz), 1.22-1.36 (m, 26H), 1.69 (m, 2H), 2.15 (s, 
3H), 2.18 (s, 3H), 2.67 (t, 2H, J = 7.6 Hz), 3.02 (m, 4H), 3.84 (m, 4H) and 4.62 (br s, 
1H); 
13
C NMR (CDCl3, 100 MHz) δ 12.6, 14.3, 14.34, 22.9, 28.1, 29.5, 29.7, 29.8, 29.82, 
29.9, 32.0, 32.1, 51.2, 67.5, 122.5, 142.7, 144.7, 148.4 and 154.4; mass spectrum (FAB), 
m/z 433.3770 (M+H)
+
 (C27H49N2O2 requires 433.3794). 
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4-Hexadecyl-2,5-dimethyl-6-morpholinopyridin-3-ol (2.23). To a solution containing 
70.0 mg (0.13 mmol) of 2.66 in 3 mL of MeOH was added 15.0 mg of 20% palladium 
hydroxide on carbon. The reaction mixture was stirred at 23 °C under a H2 atmosphere (1 
bar) for 30 min. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (10 × 2 cm). Elution with 1:9 MeOH–CH2Cl2 afforded 2.23 as a 
colorless oil: yield 56.0 mg (97%); silica gel TLC Rf  0.30 (4:1 hexane–EtOAc); 
1
H NMR 
(CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 6.8 Hz), 1.20-1.42 (m, 26H), 1.48 (m, 2H), 2.21 (s, 
3H), 2.37 (s, 3H), 2.59 (m, 2H), 2.99 (m, 4H), 3.83 (t, 4H) and 4.60 (br s, 1H); 
13
C NMR 
(CDCl3, 100 MHz) δ 13.7, 14.2, 18.8, 22.8, 27.1, 28.6, 29.5, 29.6, 29.7, 29.77, 29.8, 
29.81, 30.1, 32.0, 51.2, 67.5, 122.4, 138.4, 139.1, 144.9 and 154.8; mass spectrum (EI+), 
m/z 432.3715 (M)
+
 (C27H48N2O2 requires 432.3716). 
 
 
 
Ethyl 2-(1,3-dioxoisoindolin-2-yl)propanoate (2.67).
127,128
 To a solution of 10.8 g (0.06 
mol) of potassium phthalimide in 70 mL dry DMF was added 9.8 mL (0.08 mol) of 2-
bromo propionate under an atmosphere of argon. The reaction mixture was stirred at 
room temperature for 2 h and then DMF was concentrated under diminished pressure. 
The residue obtained was dissolved in 300 mL CH2Cl2 and washed with water. The 
organic phase obtained was dried (MgSO4) and concentrated under diminished pressure 
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to afford 2.67 as a colorless solid: yield 14.0 g (98%); silica gel TLC Rf 0.48 (7:3 
hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) 1.22 (t, 3H,  J = 7.2 Hz), 1.68 (d, 3H, J = 
7.6 Hz), 4.20 (dq, 2H, J = 7.2 Hz), 4.95 (q, 1H, J = 7.2 Hz) and 7.72-7.83 (m, 4H).  
 
 
 
4-Hydroxy-3-methylisoquinolin-1(2H)-one (2.68).
127,128 
 In a sealed tube containing 
14.0 g (0.06 mol) of 2.67 in 50 mL dry MeOH was added 50 mL of freshly prepared 
NaOMe, prepared by the addition of 2.57 g (0.11 mol) of sodium in 50 mL MeOH. The 
reaction mixture was stirred at 100 °C for 2 h. The yellow solution obtained was cooled 
and then concentrated under diminished pressure. The residue obtained was dissolved in 
minimum amount of water and then 1 N HCl was added dropwise until precipitation 
started (~pH = 3). The precipitate obtained was filtered, washed with Et2O and dried in 
vacuum to afford 2.68 as a yellowish solid: yield 8.40 g (86%); silica gel TLC Rf 0.14 
(5:95 MeOH–CH2Cl2); 
1
H NMR (CD3OD, 400 MHz) s, 7.48 (t, 1H, J = 7.6 
Hz), 7.74 (t, 1H, J = 8 Hz), 7.94 (m, 1H) and 8.24 (m, 1H). 
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4-(Benzyloxy)-3-methylisoquinolin-1(2H)-one (2.69). To a solution of 8.40 g (0.05 
mol) of 2.68 in 100 mL dry DMF was added 32.4 g (0.24 mol) of K2CO3 and 5.7 mL 
(0.05 mol) of BnBr under an atmosphere of argon. The reaction mixture was stirred at 
room temperature for 16 h and then DMF was concentrated under diminished pressure. 
The residue was dissolved in 200 mL CH2Cl2 and washed with satd NaHCO3. The 
organic phase obtained was dried (MgSO4) and concentrated under diminished pressure. 
The crude was purified by chromatography on a silica gel column (15 × 6 cm). Elution 
with hexane followed by 4:1 hexane–EtOAc and finally with EtOAc afforded 2.69 as a 
slightly yellowish-orange oil: yield 9.20 g (72%); silica gel TLC Rf 0.31 (5:95 MeOH–
CH2Cl2); 
1
H NMR (CDCl3, 400 MHz) s, 4.98 (s, 2H), 7.32-7.59 (m, 6H), 
7.72 (t, 1H, J = 7.2 Hz), 7.81 (d, 1H, J = 8.0 Hz), 8.44 (d, 1H, J = 8.0 Hz) and 11.87 (s, 
1H); 
13
C NMR (CDCl3, 100 MHz) 14.0, 75.9, 120.9, 125.0, 126.1, 128.0, 128.3, 128.4, 
128.8, 129.9, 132.7, 135.0, 135.2, 137.1 and 163.3;mass spectrum (APCI), m/z 266.1187 
(M+H)
+
 (C17H16NO2 requires 266.1181).  
 
 
 
4-(Benzyloxy)-1-chloro-3-methylisoquinoline (2.70).
129
 In a sealed tube containing 2.01 
g (7.57 mmol) of 2.69 was added 706 μL of POCl3. The reaction mixture was stirred at 
90 °C for 1 h. Yellow solution obtained was cooled, diluted with 100 mL CH2Cl2 and 
then washed with cold water. The combined organic phase was dried (MgSO4) and 
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concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm). Elution with hexane followed by 9:1 
hexane–EtOAc afforded 2.70 as a colorless oil: yield 1.22 g (57%); silica gel TLC Rf 0.46 
(4:1 hexane–EtOAc); 1H NMR (CDCl3, 400 MHz)  2.60 (s, 3H), 4.98 (s, 2H), 7.32-7.52 
(m, 5H), 7.57 (t, 1H, J = 7.2 Hz), 7.68 (t, 1H, J = 7.6 Hz), 8.01 (d, 1H, J = 8.0 Hz) and 
8.22 (d, 1H, J = 8.4 Hz); 
13
C NMR (CDCl3, 100 MHz) 18.7, 76.2, 121.5, 126.5, 126.6, 
127.6, 128.0, 128.5, 128.7, 130.9, 133.3, 136.6, 143.2, 144.8 and 147.1;mass spectrum 
(APCI), m/z 284.0839 (M+H)
+
 (C17H15NOCl requires 284.0842). 

 
 
4-(Benzyloxy)-N,N,3-trimethylisoquinolin-1-amine (2.71).
126 
In a sealed tube 
containing 21.0 mg (0.02 mmol) of Pd2(dba)3, 39.0 mg (0.09 mmol) of 1,3-bis(2,6-
diisopropylphenyl)imidazolium chloride, 638 mg (5.68 mmol) of KOtBu and 368 mg 
(4.52 mmol) of dimethylamine hydrochloride was added 322 mg (1.13 mmol) of 2.70 in 
3.5 mL dry dioxane. The reaction mixture was stirred at 100 °C for 3 h. The reaction 
mixture was allowed to cool to room temperature, diluted with CH2Cl2, washed with 
water and then with brine. The combined organic phase was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm). Elution with CH2Cl2 followed by 
95:5 CH2Cl2–EtOAc afforded 2.71 as yellowish oil: yield 262 mg (79%); silica gel TLC 
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Rf  0.35 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) 2.57 (s, 3H), 3.08, (s, 6H), 
4.96 (s, 2H), 7.33-7.58 (m, 7H), 8.00 (d, 1H, J = 8.4 Hz) and 8.14 (d, 1H, J = 8.8 Hz); 
13
C 
NMR (CDCl3, 100 MHz) 19.1, 43.4, 75.7, 121.4, 124.9, 126.5, 128.1, 128.2, 128.7, 
129.5, 133.6, 137.6, 140.7, 142.6 and 157.8;mass spectrum (APCI), m/z 293.1655 
(M+H)
+
 (C19H21N2O requires 293.1654). 
 
 
 
4-(Benzyloxy)-3-hexadecyl-N,N-dimethylisoquinolin-1-amine (2.72).
120
 To a stirred 
solution containing 73.0 mg (0.25 mmol) of 2.71 and 78.0 mg (0.70 mmol) of KOtBu in 
3 mL of anh THF at –78 °C was added 172 μL (0.43 mmol) of a 2.5 M solution of n-
BuLi in hexane. The reaction mixture was stirred at –78 °C for 30 min and then 139 μL 
(0.48 mmol) of 1-bromopentadecane was added dropwise. The reaction mixture was 
stirred at 0 °C for an additional 30 min, quenched with satd aq ammonium chloride and 
then extracted with 100 mL of EtOAc. The combined organic phase was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a column of silica gel (30 × 2 cm). Elution with hexane 
followed by 19:1 hexane–Et2O and then 9:1 hexane–Et2O afforded 2.72 as a yellowish 
oil: yield 40.0 mg (32%); silica gel TLC Rf  0.55 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 
400 MHz) 0.89 (t, 3H, J = 7.2 Hz), 1.22-1.43 (m, 26H), 1.79 (m, 2H), 2.89 (m, 2H), 
3.07 (s, 6H), 4.96 (s, 2H), 7.31-7.59 (m, 7H), 8.00 (d, 1H, J = 8.4 Hz) and 8.14 (d, 1H, J 
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= 8.4 Hz); 
13
C NMR (CDCl3, 100 MHz) 14.3, 22.9, 28.9, 29.5, 29.8, 29.9, 31.8, 32.1, 
43.4, 76.3, 121.3, 121.6, 124.9, 126.4, 128.0, 128.2, 128.7, 129.3, 133.6, 137.8, 142.3, 
144.6 and 157.7;mass spectrum (APCI), m/z 503.4004 (M+H)+ (C34H51N2O requires 
503.4001). 
 
 
 
4-(Benzyloxy)-3-hexadecyl-N,N-dimethylisoquinolin-1-amine (2.73).
120 
To a stirred 
solution containing 40.0 mg (0.14 mmol) of 2.71 and 31.0 mg (0.27 mmol) of KOtBu in 
2 mL of anh THF at –78 °C was added 170 μL (0.27 mmol) of a 1.6 M solution of n-
BuLi in hexane. The reaction mixture was stirred at –78 °C for 30 min and then 39 μL 
(0.20 mmol) of 1-bromononane was added dropwise. The reaction mixture was stirred at 
0 °C for an additional 30 min, quenched with satd aq ammonium chloride and then 
extracted with 50 mL of EtOAc. The combined organic phase was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a column of silica gel (30 × 2 cm). Elution with hexane followed by 
19:1 hexane–Et2O followed by 9:1 hexane–Et2O afforded 2.73 as a yellowish oil: yield 
20.0 mg (35%); silica gel TLC Rf  0.53 (4:1 hexane–Et2O); 
1
H NMR  (CDCl3, 400 MHz) 
0.84 (t, 3H, J = 6.0 Hz), 1.21-1.41 (m, 14H), 1.75 (m, 2H), 2.86 (m, 2H), 3.05 (s, 6H), 
4.92 (s, 2H), 7.33-7.61 (m, 7H), 7.95 (d, 1H, J = 8.4 Hz) and 8.09 (d, 1H, J = 8.4 Hz); 
13
C 
NMR (CDCl3, 100 MHz) 14.3, 22.8, 29.0, 29.5, 29.8, 29.83, 32.1, 43.5, 76.3, 121.2, 
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121.7, 124.9, 124.95, 125.0, 126.37, 126.39, 128.0, 128.2, 128.7, 137.7, 142.3 and 
157.7;mass spectrum (APCI), m/z 419.3067 (M+H)+ (C28H39N2O requires 419.3062). 
 
 
 
1-(Dimethylamino)-3-hexadecylisoquinolin-4-ol (2.24). To a solution containing 40.0 
mg (0.08 mmol) of 2.72 in 7 mL of MeOH and 2 mL CHCl3 was added 6.0 mg of 10% 
palladium on carbon. The reaction mixture was stirred at 23 °C under H2 atmosphere (1 
bar) for 30 min. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under reduced pressure. The crude products were purified on Phenomenex 
C8 (2) reversed phase semi-preparative (LUNA 250 × 10 mm, 5 µm) HPLC column using 
a mobile phase consisting of aq 0.1% TFA and MeOH. A linear gradient of (99:1 0.1% 
aq TFA–MeOH  0:100 0.1% aq TFA–MeOH) was employed over a period of 25 min 
at a flow rate of 3.5 mL/min. The combined fractions were concentrated under 
diminished pressure. Diluted with CHCl3, dried (MgSO4) and  concentrated under 
reduced diminished to afforded 2.24 as a colorless oil: yield 4.0 mg (12%); silica gel TLC 
Rf  0.44 (1:19 MeOH–CH2Cl2) respectively;
 1
H NMR (CDCl3, 400 MHz) 0.88 (t, 3H, J 
= 7.2 Hz), 1.12-1.41 (m, 26H), 1.77 (m, 2H), 2.82 (m, 2H), 3.00 (s, 6H), 4.57 (br s, 1H), 
7.46 (t, 1H, J = 7.6 Hz), 7.61 (t, 1H, J = 7.2 Hz), 8.05 (d, 1H, J = 8.0 Hz) and 8.13 (d, 1H, 
J = 8.4 Hz); mass spectrum (APCI), m/z 413.3529 (M+H)
+
 (C27H45N2O requires 
413.3532). 
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3-Decyl-1-(dimethylamino)isoquinolin-4-ol (2.25). To a solution containing 20.0 mg 
(0.04 mmol) of 2.73 in 3 mL of MeOH and 1 mL CHCl3 was added 6.0 mg of 10% 
palladium on carbon. The reaction mixture was stirred at 23 °C under H2 atmosphere (1 
bar) for 30 min. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under reduced pressure. The crude products were purified on Phenomenex 
C8 (2) reversed phase semi-preparative (LUNA 250 × 10 mm, 5 µm) HPLC column using 
a mobile phase consisting of aq 0.1% TFA and MeOH. A linear gradient of (99:1 0.1% 
aq TFA–MeOH  0:100 0.1% aq TFA–MeOH) was employed over a period of 25 min 
at a flow rate of 3.5 mL/min. The combined fractions were concentrated under 
diminished pressure. Diluted with CHCl3, dried (MgSO4) and  concentrated under 
reduced pressure to afforded 2.25 as a colorless oil: yield 3.0 mg (23%); silica gel TLC Rf  
0.51 (1:9 MeOH–CH2Cl2) respectively;
 1
H NMR (CDCl3, 400 MHz)0.84 (t, 3H, J = 
6.8 Hz), 1.13-1.43 (m, 14H), 1.75 (m, 2H), 2.82 (m, 2H), 3.02 (s, 6H), 4.54 (br s, 1H), 
7.45 (t, 1H, J = 7.6 Hz), 7.59 (t, 1H, J = 7.2 Hz), 8.03 (d, 1H, J = 8.0 Hz) and 8.11 (d, 1H, 
J = 8.4 Hz); mass spectrum (APCI), m/z 329.2586 (M+H)
+
 (C21H33N2O requires 
329.2593). 
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2-Iodo-4-methoxy-6-methylpyrimidine (2.74).
130
 To a stirred solution containing 3.00 g 
(21.6 mmol) of 2-amino-4-methoxy-6-methylpyrimidine, 5.46 g (21.6 mmol) of iodine, 
4.31 g (22.6 mmol) of CuI and 2.5 mL (30.9 mmol) of CH2I2 in 120 mL of anh THF was 
added 10.5 mL (78.2 mmol) of isoamylnitrite. The reaction mixture was stirred at reflux 
for 3 h. The reaction mixture was allowed to warm to room temperature and then filtered 
through Celite and the Celite pad was washed with CH2Cl2. The combined organic phase 
was washed with water and then with brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica gel 
column (20 × 5 cm). Elution with hexane followed by 95:5 hexane–Et2O and then 80:20 
hexane–Et2O afforded 2.74 as a yellowish solid: yield 2.01 g (37%); mp 43-44 °C; silica 
gel TLC Rf  0.35 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 2.37 (s, 3H), 3.93 (s, 
3H) and 6.50 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 23.7, 54.6, 106.5, 127.4, 169.0 and 
169.1; mass spectrum (APCI), m/z 250.9675 (M+H)
+
 (C6H8N2OI requires 250.9682). 
 
 
 
2-(Azetidin-1-yl)-4-methoxy-6-methylpyrimidine (2.75).
131
 To a stirred solution 
containing 560 mg (5.98 mmol) of azetidine hydrochloride, 76.0 mg (0.39 mmol) of CuI, 
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and 3.90 g (11.9 mmol) of Cs2CO3 in 10 mL dry degassed DMF was added 1.00 g (3.99 
mmol) of 2.74 and 95.0 mg (0.39 mmol) of 3,4,7,8-tetramethyl-1,10-phenanthroline 
sequentially. The reaction mixture was stirred at 50 °C for 5 h. The mixture was allowed 
to warm to room temperature and then filtered through Celite and the Celite pad was 
washed with CH2Cl2. The combined organic phase was washed with water and then with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by flash chromatography on a silica gel column (20 × 3 cm). Elution with hexane 
followed by 95:5 hexane–EtOAc and then 85:15 hexane–EtOAc afforded 2.75 as a 
yellowish oil: yield 515 mg (72%); silica gel TLC Rf  0.26 (3:2 hexane–EtOAc); 
1
H NMR 
(CDCl3, 400 MHz) δ 2.25 (s, 3H), 2.30 (quint, 2H, J = 8.0 Hz), 3.84 (s, 3H), 4.11 (t, 4H, 
J = 7.6 Hz) and 5.83 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 16.3, 24.1, 50.2, 53.0, 95.0, 
163.2, 168.0 and 170.7; mass spectrum (APCI), m/z 180.1136 (M+H)
+
 (C9H14N3O 
requires 180.1137). 
 
 
 
2-(Azetidin-1-yl)-4-methoxy-6-hexadecylpyrimidine (2.76).
118
 To a stirred solution 
containing 261 mg (1.45 mmol) of 2.75 in 7 mL of anh THF at –78 °C was added 870 L 
(2.17 mmol) of a 2.5 M solution of n-BuLi in hexane. The reaction mixture was stirred at 
–78 °C for 15 min and then 300 μL (1.03 mmol) of 1-bromopentadecane was added. The 
reaction was stirred at 0 
o
C for another 30 min, then quenched with satd aq ammonium 
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chloride and extracted with 150 mL of EtOAc. The combined organic phase was washed 
with brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (20 × 3 cm). Elution with hexane 
followed by 95:5 hexane–Et2O afforded 2.76 as a yellowish solid: yield 142 mg (25%) 
and 87 mg (33%) starting material was recovered; mp 45-46 °C; silica gel TLC Rf  0.32 
(4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 7.2 Hz), 1.18-1.35 (m, 
26H), 1.62 (quint, 2H, J = 7.2 Hz), 2.29 (quint, 2H, J = 7.2 Hz), 2.48 (t, 2H, J = 7.6 Hz), 
3.82 (s, 3H), 4.10 (t, 4H, J = 7.6 Hz) and 5.83 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 
14.2, 16.3, 22.8, 28.7, 29.46, 29.5, 29.6, 29.7, 29.78, 29.8, 32.0, 37.9, 50.2, 52.9, 94.3, 
163.3, 170.7 and 172.2; mass spectrum (APCI), m/z 390.3481 (M+H)
+ 
(C24H44N3O 
requires 390.3484). 
 
 
 
2-(Azetidin-1-yl)-5-bromo-4-methoxy-6-hexadecylpyrimidine (2.77).
118
 To a stirred 
solution containing 106 mg (0.27 mmol) of 2.76 in 4 mL (1:1) CH2Cl2–acetonitrile was 
added 58.0 mg (0.33 mmol) of NBS under dark. The reaction mixture was stirred for 30 
min at room temperature under dark, then diluted with 50 mL CH2Cl2, washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 3 cm). Elution with hexane followed by 
95:5 hexane–Et2O afforded 2.77 as a colorless solid: yield 121 mg (96%); mp 82-83 °C; 
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silica gel TLC Rf  0.55 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 
7.2 Hz), 1.19-1.37 (m, 26H), 1.64 (quint, 2H, J = 7.2 Hz), 2.32 (quint, 2H, J = 7.2 Hz), 
2.69 (t, 2H, J = 7.6 Hz), 3.93 (s, 3H) and 4.10 (t, 4H, J = 7.6 Hz); 
13
C NMR (CDCl3, 100 
MHz) δ 14.3, 16.3, 22.8, 28.0, 29.5, 29.6, 29.7, 29.8, 29.9, 32.1, 37.0, 50.5, 54.3, 92.7, 
161.2, 165.7 and 169.6; mass spectrum (APCI), m/z 468.2589 (M+H)
+
 (C24H43N3OBr 
requires 468.2589). 
 
 
 
2-(Azetidin-1-yl)-4-methoxy-6-hexadecylpyrimidin-5-ol (2.26).
118
 To a stirred solution 
containing 93.0 mg (0.19 mmol) of 2.77 in 2 mL of anh THF at –5 °C was added 30 L 
(0.19 mmol) of TMEDA and 198 L (0.49 mmol) of a 2.5 M solution of n-BuLi in 
hexane. The reaction mixture was stirred at –5 °C for 15 min and then 66 μL (0.59 mmol) 
trimethoxyborane was added. The reaction was stirred for 30 min at room temperature 
followed by addition of 426 L (4.35 mmol) of H2O2 (35% v/v). The reaction mixture 
was stirred for additional 30 min and poured into 20 mL water, neutralized with dilute aq 
HCl and then extracted with 100 mL of EtOAc. The combined organic phase was washed 
with brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (15 × 3 cm). Elution with hexane 
followed by 90:10 hexane–EtOAc afforded 2.26 as a yellowish solid: yield 27.0 mg 
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(34%); mp 59-60 °C; silica gel TLC Rf  0.22 (4:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 
MHz) δ 0.88 (t, 3H, J = 7.2 Hz), 1.19-1.37 (m, 26H), 1.64 (quint, 2H, J = 7.2 Hz), 2.27 
(quint, 2H, J = 7.2 Hz), 2.61 (t, 2H, J = 8.0 Hz), 3.92 (s, 3H), 4.04 (t, 4H, J = 7.6 Hz) and 
4.61 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.3, 16.3, 22.8, 28.1, 29.5, 29.7, 29.72, 
29.8, 29.82, 29.9, 31.5, 32.1, 51.0, 53.6, 128.3, 155.2, 157.6 and 158.6; mass spectrum 
(APCI), m/z 406.3436 (M+H)
+
 (C24H44N3O2 requires 406.3434). 
 
 
 
2-(Azetidin-1-yl)-4,6-dimethylpyrimidine (2.78).
131
 To a stirred solution containing 655 
mg (6.99 mmol) of azetidine hydrochloride, 133 mg (6.99 mmol) of CuI, and 3.42 g (10.5 
mmol) of Cs2CO3 in 10 mL dry degassed DMF was added 500 mg (3.49 mmol) of 2-
chloropyrimidine and 165 mg (6.99 mmol) 3,4,7,8-tetramethyl-1,10-phenanthroline 
sequentially. The reaction mixture was stirred at 50 °C for 4 h. The mixture was allowed 
to warm to room temperature and then filtered through Celite and the Celite pad was 
washed with CH2Cl2. The combined organic phase was washed with water and then with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by flash chromatography on a silica gel column (15 × 3 cm). Elution with hexane 
followed by 4:1 hexane–EtOAc and then 1:1 hexane–EtOAc afforded 2.78 as yellowish 
solid: yield 372 mg (65%); mp 51-52 °C; silica gel TLC Rf  0.22 (3:2 hexane–EtOAc); 
1
H 
NMR (CDCl3, 400 MHz) δ 2.20 (s, 6H), 2.24 (t, 2H, J = 7.6 Hz), 4.05 (t, 4H, J = 7.2 Hz) 
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and 6.19 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 16.2, 23.9, 50.1, 109.1, 163.2 and 167.0; 
mass spectrum (FAB), m/z 164.1192 (M+H)
+
 (C9H14N3 requires 164.1188). 
 
 
 
2-(Azetidin-1-yl)-4-hexadecyl-6-methylpyrimidine (2.79).
118
 To a stirred solution 
containing 321 mg (1.96 mmol) of 2.78 in 10 mL of anh THF at –78 °C was added 1.02 
mL (2.56 mmol) of a 2.5 M solution of n-BuLi in hexane. The reaction mixture was 
stirred at –78 °C for 15 min and then 398 μL (1.37 mmol) of 1-bromopentadecane was 
added. The reaction was stirred at 0 
o
C for another 30 min, then quenched with satd aq 
ammonium chloride and extracted with 150 mL of EtOAc. The combined organic phase 
was washed with brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (20 × 3 cm). Elution with 
hexane followed by 96:4 hexane–EtOAc and then 90:10 hexane–EtOAc afforded 2.79 as 
a colorless solid: yield 307 mg (42%); mp 63-64 °C; silica gel TLC Rf  0.45 (3:2 hexane–
EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 0.86 (t, 3H, J = 6.8 Hz), 1.18-1.37 (m, 26H), 1.62 
(quint, 2H, J = 7.6 Hz), 2.27 (s, 3H), 2.29 (quint, 2H, J = 7.6 Hz), 2.49 (t, 2H, J = 7.2 
Hz), 4.11 (t, 4H, J = 7.2 Hz) and 6.24 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 16.4, 
22.8, 24.2, 28.8, 29.46, 29.5, 29.6, 29.64, 29.75, 29.8, 32.0, 37.9, 50.3, 108.6, 163.4, 
167.0 and 171.2; mass spectrum (FAB), m/z 374.3545 (M+H)
+
 (C24H44N3 requires 
374.3535). 
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2-(Azetidin-1-yl)-5-bromo-4-hexadecyl-6-methylpyrimidine (2.80).
118
 To a stirred 
solution containing 290 mg (0.77 mmol) of 2.79 in 5 mL CH2Cl2 was added 152 mg (0.85 
mmol) of NBS under dark. The reaction mixture was stirred for 30 min at room 
temperature under dark, then diluted with 20 mL CH2Cl2, washed with brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 3 cm). Elution with hexane followed by 
96:4 hexane–EtOAc afforded 2.80 as a colorless solid: yield 338 mg (97%); mp 74-75 
°C; silica gel TLC Rf  0.45 (4:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (t, 
3H, J = 7.2 Hz), 1.18-1.37 (m, 26H), 1.65 (quint, 2H, J = 7.6 Hz), 2.31 (quint, 2H, J = 7.6 
Hz ), 2.44 (s, 3H), 2.71 (t, 2H, J = 7.6 Hz) and 4.09 (t, 4H, J = 7.6 Hz); 
13
C NMR 
(CDCl3, 100 MHz) δ 14.2, 16.3, 22.8, 25.3, 27.8, 29.5, 29.6, 29.7, 29.8, 29.84, 32.1, 37.4, 
50.5, 108.6, 161.3, 165.7 and 168.8; mass spectrum (FAB), m/z 454.2611 (M+H)
+
 
(C24H43N3O
81
Br requires 454.2620). 
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2-(Azetidin-1-yl)-4-hexadecyl-6-methylpyrimidin-5-ol (2.27).
131
 To a stirred solution 
containing 57.0 mg (0.13 mmol) of 2.80 in 2 mL of anh THF at –5 °C was added 84 μL 
(0.75 mmol) of trimethoxyborane and 156 L (0.39 mmol) of a 2.5 M solution of n-BuLi 
in hexane. The reaction mixture was stirred at 23 °C for 30 min followed by addition of 
221 L (3.25 mmol) of H2O2 (50% v/v). The reaction mixture was stirred for additional 
30 min and poured into 20 mL water, neutralized with dilute aq HCl and then extracted 
with 100 mL of EtOAc. The combined organic phase was washed with brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 3 cm). Elution with 95:5 hexane–EtOAc 
followed by 80:20 hexane–EtOAc afforded 2.27 as a yellowish oil: yield 28.0 mg (55%); 
silica gel TLC Rf  0.27 (3:2 hexane–EtOAc); 
1
H NMR (CD3OD, 400 MHz) δ 0.90 (t, 3H, 
J = 6.8 Hz), 1.27-1.32 (m, 26H), 1.64 (m, 2H), 2.25-2.34 (m, 5H), 2.65 (m, 2H), 4.04 (t, 
4H, J = 7.6 Hz) and 4.28 (br s, 1H); 
13
C NMR (CD3OD, 100 MHz) δ 14.5, 17.0, 18.6, 
23.8, 29.1, 30.5, 30.6, 30.7, 30.8, 30.81, 30.83, 32.8, 33.1, 52.2, 140.7, 157.6, 159.9 and 
161.6; mass spectrum (FAB), m/z 390.3480 (M+H)
+
 (C24H44N3O requires 390.3484). 
 
 
 
 
2-Chloro-4-ethoxy-6-methylpyrimidine (2.81). To a stirred solution containing 2.01 g 
(12.3 mmol) of 2,4-dichloro-6-methylpyrimidine in 40 mL of anh THF was added 927 
mg (38.6 mmol) of NaH (60% suspension in oil) and 392 µL (12.9 mmol) of EtOH. The 
reaction mixture was stirred for 5 h at room temperature and then slowly poured into 200 
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mL of water. The crude was extracted with two 300-mL portions of EtOAc. The 
combined organic phase was washed with brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(15 × 6 cm). Elution with 19:1 hexane–EtOAc afforded 2.81 as a colorless solid: yield 
2.16 g (51%); mp 37-38 °C; silica gel TLC Rf  0.41 (4:1 hexane–EtOAc); 
1
H NMR 
(CDCl3, 400 MHz) δ 1.38 (t, 3H, J = 7.2 Hz), 2.42 (s, 3H), 4.42 (d, 2H, J = 7.2 Hz) and 
6.46 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.4, 23.8, 63.5, 105.7, 159.8, 169.8 and 
170.9; mass spectrum (APCI), m/z 173.0477 (M+H)
+
 (C7H10N2OCl requires 173.0482). 
 
 
 
 
 
2-(Azetidin-1-yl)-4-ethoxy-6-methylpyrimidine (2.82).
131
 To a round bottom flask 
containing 600 mg (3.48 mmol) of 2.81, 489 mg (5.22 mmol) of azetidine hydrochloride, 
131 mg (0.69 mmol) of CuI, 164 mg (0.69 mmol) of 3,4,7,8-tetramethyl-1,10-
phenanthroline and 2.83 g (8.70 mmol) of Cs2CO3 was added 15 mL dry degassed DMF. 
The reaction mixture was stirred at 50 °C for 3 h. The mixture was allowed to cool to 
room temperature and then filtered through Celite and the Celite pad was washed with 
CH2Cl2. The combined organic phase was washed with water and then with brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm). Elution with 19:1 hexane–EtOAc 
followed by 9:1 hexane–EtOAc afforded 2.82 as a colorless solid: yield 565 mg (84%); 
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mp 42-43 °C; silica gel TLC Rf  0.29 (3:2 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 
1.24 (t, 3H, J = 7.2 Hz), 2.16 (s, 3H), 2.20 (quint, 2H, J = 7.6 Hz), 4.01 (t, 4H, J = 7.6 
Hz), 4.20 (q, 2H, J = 7.2 Hz) and 5.73 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.4, 16.1, 
23.9, 49.9, 61.2, 95.0, 163.0, 167.7 and 170.1; mass spectrum (APCI), m/z 194.1289 
(M+H)
+
 (C10H16N3O requires 194.1293). 
 
 
 
 
2-(Azetidin-1-yl)-4-ethoxy-6-hexadecylpyrimidine (2.83).
118
 To a stirred solution 
containing 450 mg (2.32 mmol) of 2.82 in 20 mL of anh THF at –78 °C was added 1.02 
mL (2.56 mmol) of a 2.5 M solution of n-BuLi in hexane. The reaction mixture was 
stirred at –78 °C for 15 min and then 475 μL (1.63 mmol) of 1-bromopentadecane was 
added. The reaction was stirred at 0 
o
C for another 30 min, then quenched with satd aq 
ammonium chloride and extracted with 150 mL of EtOAc. The combined organic phase 
was washed with brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (15 × 3 cm). Elution with 
19:1 hexane–EtOAc afforded 2.83 as a colorless solid: yield 421 mg (45%); mp 40-41 
°C; silica gel TLC Rf  0.42 (4:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 0.84 (t, 
3H, J = 6.8 Hz), 1.18-1.33 (m, 29H), 1.60 (quint, 2H, J = 6.8 Hz), 2.24 (quint, 2H, J = 7.6 
Hz), 2.44 (t, 2H, J = 7.6 Hz), 4.05 (t, 4H, J = 7.6 Hz), 4.26 (q, 2H, J = 7.2 Hz) and 5.78 
(s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.1, 14.5, 16.2, 22.7, 28.6, 29.39, 29.42, 29.55, 
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29.61, 29.7, 29.8, 32.0, 37.8, 50.1, 61.3, 94.4, 163.2, 170.21 and 172.0; mass spectrum 
(FAB), m/z 404.3632 (M+H)
+
 (C25H46N3O requires 404.3641). 
 
 
 
 
2-(Azetidin-1-yl)-5-bromo-4-ethoxy-6-hexadecylpyrimidine (2.84).
118
 To a stirred 
solution containing 464 mg (1.15 mmol) of 2.83 in 10 mL CH2Cl2 was added 209 mg 
(1.17 mmol) of NBS under dark (round bottom flask was wrapped with aluminum foil). 
The reaction mixture was stirred for 30 min at room temperature under dark, then diluted 
with CH2Cl2, washed with brine, dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (15 × 3 
cm). Elution with hexane followed by 96:4 hexane–EtOAc afforded 2.84 as a colorless 
solid: yield 522 mg (94%); mp 69-70 °C; silica gel TLC Rf  0.56 (4:1 hexane–EtOAc); 
1
H 
NMR (CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 7.2 Hz), 1.18-1.40 (m, 29H), 1.64 (quint, 2H, 
J = 7.6 Hz), 2.29 (quint, 2H, J = 7.6 Hz), 2.69 (t, 2H, J = 7.6 Hz), 4.06 (t, 4H, J = 7.6 Hz) 
and 4.37 (q, 2H, J = 7.2 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 14.5, 16.2, 22.8, 27.9, 
29.5, 29.56, 29.58, 29.7, 29.78, 29.83, 32.1, 37.0, 50.3, 62.8, 92.9, 161.1, 165.2 and 
169.4; mass spectrum (FAB), m/z 482.2753 (M+H)
+
 (C25H45N3OBr requires 482.2746). 
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2-(Azetidin-1-yl)-4-ethoxy-6-hexadecylpyrimidin-5-ol (2.28).
118
 To a stirred solution 
containing 400 mg (0.83 mmol) of 2.84 in 10 mL of anh THF at –5 °C was added 663 μL 
(1.66 mmol) of a 2.5 M solution of n-BuLi in hexane and 278 L (2.49 mmol) of 
trimethoxyborane. The reaction mixture was stirred at 23 °C for 30 min followed by 
addition of 1.2 mL (18.3 mmol) of H2O2 (50% v/v). The reaction mixture was stirred for 
additional 30 min, poured into 20 mL NaHCO3 and then extracted with 100 mL of 
CH2Cl2. The combined organic phase was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (15 × 3 cm). Elution with 95:5 hexane–EtOAc afforded 2.28 as a 
colorless powder: yield 250 mg (72%); mp 79-80 °C; silica gel TLC Rf  0.33 (4:1 
hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 7.2 Hz), 1.19-1.39 (m, 
29H), 1.63 (quint, 2H, J = 7.6 Hz), 2.26 (quint, 2H, J = 7.2 Hz), 2.61 (t, 2H, J = 7.6 Hz), 
4.02 (t, 4H, J = 7.6 Hz), 4.37 (q, 2H, J = 7.2 Hz) and 4.89 (br s, 1H); 
13
C NMR (CDCl3, 
100 MHz) δ 14.3, 14.7, 16.3, 22.8, 28.1, 29.5, 29.71, 29.73, 29.77, 29.81, 29.85, 31.5, 
32.1, 50.9, 62.3, 128.3, 155.1, 157.6 and 158.3; mass spectrum (FAB), m/z 420.3578 
(M+H)
+
 (C25H46N3O2 requires 420.3590). 
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2-(Azetidin-1-yl)-4-methyl-6-(pentadecyloxy)pyrimidine (2.85).
131
 To a stirred 
solution containing 1.01 g (6.13 mmol) of 2,4-dichloro-6-methylpyrimidine in 20 mL of 
anh THF was added 620 mg (25.8 mmol) of NaH (60% suspension in oil) and 1.47 g 
(6.44 mmol) of 1-pentadecanol. The reaction mixture was stirred for 24 h at room 
temperature and then slowly poured into 100 mL of water. The crude was extracted with 
two 200-mL portions of EtOAc. The combined organic phase was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure to afford crude 790 mg of 2-
chloro-4-methyl-6-(pentadecyloxy)pyrimidine.  
To a round bottom flask containing 350 mg (0.99 mmol) of crude 2-chloro-4-
methyl-6-(pentadecyloxy)pyrimidine, 139 mg (1.49 mmol) of azetidine hydrochloride, 
19.0 mg (0.09 mmol) of CuI, 23.0 mg (0.09 mmol) of 3,4,7,8-tetramethyl-1,10-
phenanthroline and 806 mg (2.48 mmol) of Cs2CO3 was added 15 mL dry degassed 
DMF. The reaction mixture was stirred at 50 °C for 5 h. The mixture was allowed to cool 
to room temperature and then filtered through Celite and the Celite pad was washed with 
CH2Cl2. The combined organic phase was washed with water and then with brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm). Elution with 19:1 hexane–EtOAc 
followed by 9:1 hexane–EtOAc afforded 2.85 as a colorless solid: yield 282 mg (76%); 
mp 40-41 °C; silica gel TLC Rf  0.27 (4:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 
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0.86 (t, 3H, J = 6.8 Hz), 1.21-1.38 (m, 24H), 1.70 (quint, 2H, J = 7.2 Hz), 2.24 (s, 3H), 
2.29 (quint, 2H, J = 7.6 Hz), 4.09 (t, 4H, J = 7.6 Hz), 4.21 (t, 2H, J = 6.8 Hz) and 5.81 (s, 
1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.3, 16.4, 22.9, 24.2, 26.2, 29.1, 29.5, 29.7, 29.76, 
29.8, 29.9, 32.1, 50.3, 65.9, 95.3, 163.2, 168.0 and 170.6; mass spectrum (FAB), m/z 
376.3317 (M+H)
+
 (C23H42N3O requires 376.3328). 
 
 
 
2-(Azetidin-1-yl)-5-bromo-4-methyl-6-(pentadecyloxy)pyrimidine (2.86).
118
 To a 
stirred solution containing 145 mg (0.39 mmol) of 2.85 in 4 mL CH2Cl2 was added 72.0 
mg (0.41 mmol) of NBS under dark. The reaction mixture was stirred for 30 min at room 
temperature under dark, then diluted with CH2Cl2, washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (15 × 3 cm). Elution with hexane followed by 96:4 hexane–EtOAc 
afforded 2.86 as a colorless solid: yield 159 mg (90%); mp 71-72 °C; silica gel TLC Rf  
0.53 (4:1 hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 6.8 Hz), 1.21-
1.47 (m, 24H), 1.75 (quint, 2H, J = 7.6 Hz), 2.30 (quint, 2H, J = 7.2 Hz), 2.40 (s, 3H), 
4.07 (t, 4H, J = 7.6 Hz) and 4.30 (t, 2H, J = 6.8 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 
16.2, 22.8, 24.5, 26.1, 28.9, 29.45, 29.5, 29.7, 29.72, 29.8, 29.83, 32.1, 50.4, 67.1, 93.3, 
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161.0, 165.3 and 166.0; mass spectrum (FAB), m/z 454.2421 (M+H)
+
 (C23H41N3OBr 
requires 454.2433). 
 
 
2-(Azetidin-1-yl)-4-methyl-6-(pentadecyloxy)pyrimidin-5-ol (2.29).
118
 To a stirred 
solution containing 130 mg (0.28 mmol) of 2.86 in 3 mL of anh THF at –5 °C was added 
229 μL (0.57 mmol) of a 2.5 M solution of n-BuLi in hexane and 94 L (0.84 mmol) of 
trimethoxyborane. The reaction mixture was stirred at 23 °C for 30 min followed by 
addition of 419 µL (6.16 mmol) of H2O2 (50% v/v). The reaction mixture was stirred for 
additional 30 min, poured into 20 mL NaHCO3 and then extracted with 100 mL of 
CH2Cl2. The combined organic phase was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (15 × 3 cm). Elution with 95:5 hexane–EtOAc afforded 2.29 as a 
colorless powder: yield 66.0 mg (60%); mp 83-85 °C; silica gel TLC Rf  0.21 (3:2 
hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.86 (t, 3H, J = 6.8 Hz), 1.05-1.41 (m, 
24H), 1.70 (quint, 2H, J = 6.8 Hz), 2.15-2.32 (m, 5H), 4.01 (t, 4H, J = 7.2 Hz), 4.30 (t, 
2H, J = 6.8 Hz) and 5.11 (br s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.2, 16.3, 17.8, 
22.8, 26.1, 29.0, 29.5, 29.7, 29.74, 29.8, 29.83, 32.1, 50.9, 66.6, 128.6, 151.1, 157.3 and 
158.5; mass spectrum (FAB), m/z 392.3286 (M+H)
+
 (C23H42N3O2 requires 392.3277). 
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2-(Azetidin-1-yl)-4-cyclobutoxy-6-methylpyrimidine (2.87).
131
 To a stirred solution 
containing 1.01 g (6.13 mmol) of 2,4-dichloro-6-methylpyrimidine in 40 mL of anh THF 
was added 620 mg (25.8 mmol) of NaH (60% suspension in oil) and 504 µL (6.44 mmol) 
of 1-cyclobutanol. The reaction mixture was stirred for 24 h at room temperature and 
then slowly poured into 100 mL of water. The crude was extracted with two 200-mL 
portions of EtOAc. The combined organic phase was washed with brine, dried (MgSO4) 
and concentrated under diminished pressure to afford 810 mg crude 2-chloro-4-
cyclobutoxy-6-methylpyrimidine.  
To a round bottom flask containing 350 mg (1.76 mmol) of crude 2-chloro-4-
cyclobutoxy-6-methylpyrimidine, 247 mg (2.64 mmol) of azetidine hydrochloride, 34.0 
mg (0.18 mmol) of CuI, 41.0 mg (0.18 mmol) of 3,4,7,8-tetramethyl-1,10-phenanthroline 
and 1.43 g (4.40 mmol) of Cs2CO3 was added 15 mL dry degassed DMF. The reaction 
mixture was stirred at 50 °C for 5 h. The mixture was allowed to cool to room 
temperature and then filtered through Celite and the Celite pad was washed with CH2Cl2. 
The combined organic phase was washed with water and then with brine, dried (MgSO4) 
and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (20 × 3 cm). Elution with 19:1 hexane–EtOAc 
followd by 9:1 hexane–EtOAc afforded 2.87 as a colorless solid: yield 286 mg (74%); 
mp 60-61 °C; silica gel TLC Rf  0.22 (4:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 
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1.60 (m, 1H), 1.76 (m, 1H), 2.07 (m, 2H), 2.20 (s, 3H), 2.25 (quint, 2H, J = 7.6 Hz), 2.34 
(m, 2H), 4.05 (t, 4H, J = 7.6 Hz), 5.01 (m, 1H) and 5.74 (s, 1H); 
13
C NMR (CDCl3, 100 
MHz) δ 13.6, 16.2, 24.1, 30.7, 50.1, 70.0, 94.9, 163.1, 168.1 and 169.5; mass spectrum 
(APCI), m/z 220.1445 (M+H)
+
 (C12H18N3O requires 220.1450). 
 
 
 
2-(Azetidin-1-yl)-4-cyclobutoxy-6-hexadecylpyrimidine (2.88).
118
 To a stirred solution 
containing 180 mg (0.82 mmol) of 2.87 in 10 mL of anh THF at –78 °C was added 492 
µL (1.23 mmol) of a 2.5 M solution of n-BuLi in hexane. The reaction mixture was 
stirred at –78 °C for 20 min and then 214 μL (0.74 mmol) of 1-bromopentadecane was 
added. The reaction was stirred at 0 
o
C for 15 min and then at room temperature for 
another 30 min. The reaction mixture was quenched with satd aq ammonium chloride and 
extracted with 150 mL of EtOAc. The combined organic phase was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (20 × 3 cm). Elution with 19:1 hexane–Et2O 
afforded 2.88 as a colorless solid: yield 130 mg (37%); mp 39-40 °C; silica gel TLC Rf  
0.46 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (t, 3H, J = 7.2 Hz), 1.15-
1.36 (m, 26H), 1.62 (m, 3H), 1.79 (m, 1H), 2.13 (m, 2H), 2.28 (quint, 2H, J = 7.6 Hz), 
2.38 (m, 2H), 2.47 (t, 2H, J = 7.6 Hz), 4.08 (t, 4H, J = 7.6 Hz), 5.06 (m, 1H) and 5.77 (s, 
1H); 
13
C NMR (CDCl3, 100 MHz) δ 13.7, 14.2, 16.3, 22.8, 28.8, 29.46, 29.5, 29.6, 29.7, 
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29.8, 29.82, 30.8, 32.1, 37.9, 50.2, 70.1, 94.3, 163.3, 169.6 and 172.4; mass spectrum 
(FAB), m/z 430.3786 (M+H)
+
 (C27H48N3O requires 430.3797). 
 
 
 
2-(Azetidin-1-yl)-5-bromo-4-cyclobutoxy-6-hexadecylpyrimidine (2.89).
118
 To a 
stirred solution containing 130 mg (0.30 mmol) of 2.88 in 10 mL CH2Cl2 was added 57.0 
mg (0.32 mmol) of NBS under dark. The reaction mixture was stirred for 30 min at room 
temperature under dark, then diluted with CH2Cl2, washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (20 × 3 cm). Elution with hexane followed by 19:1 hexane–EtOAc 
afforded 2.89 as a colorless solid: yield 141 mg (92%); mp 71-73 °C; silica gel TLC Rf  
0.59 (6:1 hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 7.2 Hz), 1.19-
1.42 (m, 26H), 1.65 (m, 3H), 1.84 (m, 1H), 2.19 (m, 2H), 2.30 (quint, 2H, J = 7.6 Hz), 
2.41 (m, 2H), 2.69 (t, 2H, J = 7.6 Hz), 4.06 (t, 4H, J = 7.6 Hz) and 5.13 (m, 1H); 
13
C 
NMR (CDCl3, 100 MHz) δ 13.7, 14.3, 16.2, 22.8, 28.0, 29.5, 29.6, 29.7, 29.8, 29.81, 
29.9, 30.9, 32.1, 37.1, 50.4, 71.3, 92.7, 161.2, 164.7 and 169.5; mass spectrum (FAB), 
m/z 508.2897 (M+H)
+
 (C27H47N3OBr requires 508.2902). 
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2-(Azetidin-1-yl)-4-cyclobutoxy-6-hexadecylpyrimidin-5-ol (2.30).
118
 To a stirred 
solution containing 141 mg (0.27 mmol) of 2.89 in 5 mL of anh THF at –5 °C was added 
242 μL (0.60 mmol) of a 2.5 M solution of n-BuLi in hexane and 100 L (0.90 mmol) of 
trimethoxyborane. The reaction mixture was stirred at 23 °C for 30 min followed by 
addition of 449 µL (6.60 mmol) of H2O2 (50% v/v). The reaction mixture was stirred for 
additional 30 min, poured into 20 mL NaHCO3 and then extracted with 100 mL of 
CH2Cl2. The combined organic phase was washed with brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by chromatography on 
a silica gel column (15 × 3 cm). Elution with 95:5 hexane–EtOAc afforded 2.30 as a 
colorless powder: yield 72.0 mg (60%); mp 95-97 °C; silica gel TLC Rf  0.42 (4:1 
hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 7.2 Hz), 1.21-1.36 (m, 
26H), 1.63 (m, 3H), 1.83 (m, 1H), 2.12 (m, 2H), 2.26 (quint, 2H, J = 7.2 Hz), 2.41 (m, 
2H), 2.61 (t, 2H, J = 7.2 Hz), 4.01 (t, 4H, J = 7.2 Hz), 4.76 (br s, 1H) and 5.17 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 13.6, 14.3, 16.3, 22.8, 28.2, 29.5, 29.71, 29.73, 29.8, 
29.81, 29.9, 31.0, 31.5, 32.1, 50.9, 70.8, 128.1, 155.2, 157.6 and 157.7; mass spectrum 
(FAB), m/z 446.3742 (M+H)
+
 (C27H48N3O2 requires 446.3747) 
. 
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4-Chloro-6-methyl-(N,N-dimethylpyrimidin-2-amine-d6) (2.90). To a stirred solution 
containing 500 mg (3.48 mmol) of 2-amino-4-chloro-6-methylpyrimidine and 435 µL 
(6.96 mmol) of methyl iodide-(d3) in 10 mL of anh THF was added 417 mg (17.4 mmol) 
of NaH (60% suspension in oil) in two aliquots at 0 °C in the dark. The reaction mixture 
was slowly warmed to 23 °C, stirred for 5 h under dark and then slowly poured into 100 
mL of water. The crude was extracted with two 200-mL portions of EtOAc. The 
combined organic phase was washed with brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(15 × 3 cm). Elution with 9:1 hexane–EtOAc afforded 2.90 as a yellowish solid: yield 
533 mg (86%); mp 29-30 °C; silica gel TLC Rf  0.51 (4:1 hexane–EtOAc); 
1
H NMR 
(CDCl3, 500 MHz) δ 2.19 (s, 3H) and 6.23 (s, 1H); 
13
C NMR (CDCl3, 125 MHz) δ 23.9, 
36.0, 107.2, 160.5, 161.9 and 168.8; mass spectrum (APCI), m/z 178.1017 (M+H)
+
 
(C7H5N3
2
H6Cl requires 178.1018). 
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4-(Methoxy-d3) -6-(methyl-d1)-(N,N-dimethylpyrimidin-2-amine-d6) (2.91). To a 
stirred solution containing 530 mg (2.98 mmol) of 2.90 in 10 mL of anh THF was added 
430 mg (17.9 mmol) of NaH (60% suspension in oil) and 244 µL (5.96 mmol) of 
CD3OD. The reaction mixture was stirred at reflux for 20 h and then allowed to cool to 
room temperature. The mixture was slowly poured into 200 mL of water and extracted 
with two 300-mL portions of EtOAc. The combined organic phase was washed with 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (20 × 3 cm). Elution with hexane 
followed by 97:3 hexane–EtOAc afforded 2.91 as a colorless oil: yield 350 mg (66%); 
silica gel TLC Rf  0.25 (7:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 2.23 (m, 2H) 
and 5.77 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 24.2, 36.0, 52.0, 93.8, 162.4, 167.8 and 
170.3; mass spectrum (APCI), m/z 178.1762 (M+H)
+
 (C8H4N3O
2
H10 requires 178.1765). 
 
 
 
4-(Methoxy-d3)-6-(1-hexadecyl-d1)-(N,N-dimethylpyrimidin-2-amine-d6) (2.92).
118
 To 
a stirred solution containing 240 mg (1.36 mmol) of 2.91 in 15 mL of anh THF at –78 °C 
was added 817 µL (2.04 mmol) of a 2.5 M solution of n-BuLi in hexane. The reaction 
mixture was stirred at –78 °C for 20 min and then 355 μL (1.22 mmol) of 1-
bromopentadecane was added. The reaction was stirred at 0 
o
C for 15 min and then at 
room temperature for another 30 min. The reaction mixture was quenched with satd aq 
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ammonium chloride and extracted with 150 mL of EtOAc. The combined organic phase 
was washed with brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (30 × 3 cm). Elution with 
19:1 hexane–Et2O afforded 2.92 as a colorless solid: yield 250 mg (47%); mp 45-46 °C; 
silica gel TLC Rf  0.58 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 
6.8 Hz), 1.19-1.37 (m, 26H), 1.64 (m, 2H), 2.48 (q, 1H, J = 8.0 Hz) and 5.79 (s, 1H); 
13
C 
NMR (CDCl3, 100 MHz) δ 14.2, 22.8, 28.6, 29.4, 29.5, 29.52, 29.7, 29.73, 29.8, 29.9, 
32.1, 36.0, 37.6, 38.0, 52.0, 93.2, 162.5, 170.4 and 171.9; mass spectrum (FAB), m/z 
388.4117 (M+H)
+
 (C23H34N3
2
H10O requires 388.4112). 
 
 
 
3-Bromo-4-(methoxy-d3)-6-(1-hexadecyl-d1)-(N,N-dimethylpyrimidin-2-amine-d6) 
(2.93).
118
 To a stirred solution containing 320 mg (0.83 mmol) of 2.92 in 10 mL CH2Cl2 
was added 154 mg (0.87 mmol) of NBS under dark. The reaction mixture was stirred for 
30 min at room temperature under dark, then diluted with CH2Cl2, washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 3 cm). Elution with hexane followed by 
19:1 hexane–EtOAc afforded 2.93 as a colorless solid: yield 159 mg (90%); mp 63-64 
°C; silica gel TLC Rf  0.31 (19:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 0.88 (t, 
3H, J = 7.2 Hz), 1.19-1.40 (m, 26H), 1.66 (m, 2H) and 2.69 (q, 1H, J = 7.6 Hz); 
13
C 
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NMR (CDCl3, 100 MHz) δ 14.3, 22.8, 27.7, 29.5, 29.6, 29.63, 29.7, 29.8, 29.9, 32.1, 
36.5, 36.9, 53.3, 91.3, 160.3, 165.2 and 169.2; mass spectrum (APCI), m/z 468.3208 
(M+H)
+
 (C23H33N3O
2
H10
81
Br requires 468.3197). 
 
 
 
2-(N,N-dimethylamino-d6)-4-(1-hexadecyl-d1)-6-(methoxy-d3)-pyrimidin-5-ol 
(2.31).
118
 To a stirred solution containing 276 mg (0.59 mmol) of 2.93 in 10 mL of anh 
THF at –5 °C was added 473 μL (1.18 mmol) of a 2.5 M solution of n-BuLi in hexane 
and 197 L (1.77 mmol) of trimethoxyborane. The reaction mixture was stirred at 23 °C 
for 30 min followed by addition of 883 µL (12.9 mmol) of H2O2 (50% v/v). The reaction 
mixture was stirred for additional 30 min, poured into 20 mL NaHCO3 and then extracted 
with 100 mL of CH2Cl2. The combined organic phase was washed with brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (20 × 3 cm). Elution with 95:5 hexane–EtOAc 
afforded 2.31 as a colorless powder: yield 150 mg (63%); mp 75-76 °C; silica gel TLC Rf  
0.38 (4:1 hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 7.2 Hz), 1.19-
1.39 (m, 26H), 1.65 (m, 2H), 2.60 (m, 1H) and 4.50 (br s, 1H); 
13
C NMR (CDCl3, 100 
MHz) δ 14.3, 22.8, 27.9, 29.5, 29.6, 29.7, 29.72, 29.8, 29.82, 29.9, 32.1, 54.4, 127.1, 
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155.1, 156.1 and 158.2; mass spectrum (APCI), m/z 404.4067 (M+H)
+
 (C23H34N3O2
2
H10 
requires 404.4061). 
 
 
 
 
4-Cyclobutoxy-6-methyl-(N,N-dimethylpyrimidin-2-amine-d6) (2.94). To a stirred 
solution containing 500 mg (2.81 mmol) of 2.90 in 10 mL of anh THF was added 405 mg 
(16.9 mmol) of NaH (60% suspension in oil) and 343 µL (4.38 mmol) of 1-cyclobutanol. 
The reaction mixture was stirred at reflux for 48 h and then allowed to cool to room 
temperature. The mixture was slowly poured into 100 mL of water and extracted with 
two 150-mL portions of EtOAc. The combined organic phase was washed with brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (20 × 3 cm). Elution with 19:1 hexane–Et2O 
afforded 2.94 as a colorless oil: yield 391 mg (65%); silica gel TLC Rf  0.36 (4:1 hexane–
Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 1.62 (m, 1H), 1.78 (m, 1H), 2.10 (m, 2H), 2.21 (s, 
3H), 2.38 (m, 2H), 5.08 (quint, 1H, J = 7.2 Hz) and 5.71 (s, 1H); 
13
C NMR (CDCl3, 100 
MHz) δ 13.6, 24.2, 30.7, 36.0, 69.8, 93.9, 162.4, 167.9 and 169.2; mass spectrum (APCI), 
m/z 214.1832 (M+H)
+
 (C11H12N3O
2
H6 requires 214.1827). 
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4-Cyclobutoxy-6-hexadecyl-(N,N-dimethylpyrimidin-2-amine-d6) (2.95).
118
 To a 
stirred solution containing 391 mg (1.83 mmol) of 2.94 in 20 mL of anh THF at –78 °C 
was added 1.09 mL (2.74 mmol) of a 2.5 M solution of n-BuLi in hexane. The reaction 
mixture was stirred at –78 °C for 20 min and then 477 μL (1.64 mmol) of 1-
bromopentadecane was added. The reaction was stirred at 0 
o
C for 15 min and then at 
room temperature for another 30 min. The reaction mixture was quenched with satd aq 
ammonium chloride and extracted with 300 mL of EtOAc. The combined organic phase 
was washed with brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (20 × 3 cm). Elution with 
19:1 hexane–Et2O afforded 2.95 as a colorless solid: yield 434 mg (56%); mp 39-40 °C; 
silica gel TLC Rf  0.58 (4:1 hexane–Et2O); 
1
H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 
7.2 Hz), 1.15-1.39 (m, 26H), 1.65 (m, 3H), 1.81 (m, 1H), 2.14 (m, 2H), 2.41 (m, 2H), 
2.47 (m, 2H), 5.12 (quint, 1H, J = 7.2 Hz) and 5.74 (s, 1H); 
13
C NMR (CDCl3, 100 MHz) 
δ 13.7, 14.2, 22.8, 28.6, 29.48, 29.5, 29.6, 29.7, 29.8, 29.83, 30.8, 32.1, 36.0, 38.0, 69.8, 
93.3, 162.4, 169.2 and 172.0; mass spectrum (APCI), m/z 424.4182 (M+H)
+
 
(C26H42N3O
2
H6 requires 424.4174). 
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5-Bromo-4-cyclobutoxy-6-hexadecyl-(N,N-dimethylpyrimidin-2-amine-d6) (2.96).
118
 
To a stirred solution containing 286 mg (0.67 mmol) of 2.95 in 5 mL CH2Cl2 was added 
126 mg (0.71 mmol) of NBS under dark. The reaction mixture was stirred for 30 min at 
room temperature under dark, then diluted with 50 mL CH2Cl2, washed with brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 3 cm). Elution with hexane followed by 
98:2 hexane–EtOAc afforded 2.96 as a colorless solid: yield 306 mg (91%); mp 57-59 
°C; silica gel TLC Rf  0.66 (4:1 hexane–EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 0.89 (t, 
3H, J = 6.8 Hz), 1.21-1.41 (m, 26H), 1.68 (m, 3H), 1.84 (m, 1H), 2.22 (m, 2H), 2.45 (m, 
2H), 2.70 (m, 2H) and 5.16 (quint, 1H, J = 7.2 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 13.7, 
14.3, 22.9, 27.8, 29.5, 29.6, 29.64, 29.8, 29.9, 30.8, 32.1, 36.2, 37.0, 71.1, 91.4, 160.3, 
164.3 and 169.2; mass spectrum (APCI), m/z 502.3274 (M+H)
+
 (C26H41N3OBr
2
H6 
requires 502.3279). 
 
 
 
4-Cyclobutoxy-2-(N,N-dimethylamino-d6)-6-hexadecylpyrimidin-5-ol (2.32).
118
 To a 
stirred solution containing 270 mg (0.54 mmol) of 2.96 in 10 mL of anh THF at –5 °C 
was added 429 μL (1.07 mmol) of a 2.5 M solution of n-BuLi in hexane and 181 L 
(1.62 mmol) of trimethoxyborane. The reaction mixture was stirred at 23 °C for 30 min 
followed by addition of 808 µL (11.9 mmol) of H2O2 (50% v/v). The reaction mixture 
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was stirred for additional 30 min, poured into 20 mL NaHCO3 and then extracted with 
100 mL of CH2Cl2. The combined organic phase was washed with brine, dried (MgSO4) 
and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 3 cm). Elution with 97:3 hexane–EtOAc 
afforded 2.32 as a colorless powder: yield 160 mg (67%); mp 72-73 °C; silica gel TLC Rf  
0.53 (4:1 hexane–EtOAc); 1H NMR (CDCl3, 400 MHz) δ 0.88 (t, 3H, J = 6.8 Hz), 1.14-
1.44 (m, 26H), 1.68 (m, 3H), 1.83 (m, 1H), 2.14 (m, 2H), 2.43 (m, 2H), 2.61 (m, 2H), 
4.58 (br s, 1H) and 5.19 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 13.7, 14.3, 22.8, 27.9, 
29.5, 29.7, 29.72, 29.8, 29.82, 29.9, 31.0, 31.5, 32.1, 70.6, 127.0, 155.2, 156.2 and 157.2; 
mass spectrum (APCI), m/z 440.4119 (M+H)
+
 (C26H42N3O2
2
H6 requires 440.4123). 
 
Cell Lines and Culture Conditions 
 
Human mitochondrial disease cell lines, Friedreich’s ataxia lymphocytes 
(GM15850), and Leigh’s syndrome lymphocytes (GM13740) were obtained from Coriell 
Cell Repositories (Camden, NJ). Lymphocytes were cultured in RPMI-1640 medium 
(Gibco, Life Technologies, Grand Island, NY) with 15% fetal calf serum, 2 mM 
glutamine (HyClone, South Logan, UT) and 1% penicillin–streptomycin antibiotic 
supplement (Cellgro, Manassas, VA). Cells were passaged every other day to maintain 
them in log phase growth and kept at a nominal concentration of 5-10×10
5
 cell/mL. A 
CoQ10 deficient lymphocyte cell line (GM17932) was obtained from Coriell Cell 
Repositories.  A nutrient sensitized screening strategy to identify CoQ10 analogues that 
function within the mitochondrial respiratory chain was used by growing the CoQ10-
deficient lymphocyte in galactose containing media to force energy production 
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predominantly through oxidative phosphorylation rather than glycolysis.
117,118,135,136
 The 
lymphocytes were cultured in RPMI 1640 glucose free medium (Gibco, Grand Island, 
NY) supplemented with 25 mM galactose, 2 mM glutamine and 1% penicillin–
streptomycin, and 10% dialyzed fetal bovine serum (FBS) (<0.5 µg/mL) (Gemini Bio-
Product, West Sacramento, CA).  
 
NADH Oxidase Activity 
 
The effect of the exogenous CoQ10 analogues (Table 2.1) on the activities of 
complexes I, III and IV within the respiratory chain was evaluated using bovine heart 
mitochondria during the co-oxidation of their respective substrate (NADH) as described 
previously.
116,117 Briefly, a small scale preparation of bovine heart mitochondria was 
prepared as described by Smith.
140
 Bovine heart submitochondrial particles (SMPs) were 
prepared as described by Matsuno-Yagi and stored in a buffer containing 0.25 M sucrose 
and 10 mM Tris-HCl, pH 7.4, at –80 °C.141 SMPs were diluted to 0.5 mg/mL. 
Mitochondrial complexes I, III, and IV activity were assayed at 30 °C and monitored 
spectrophotometrically using a Beckman Coulter DU-530 (340 nm, ε = 6.22 mM-1cm-1). 
NADH oxidase activity was determined in 50 mM Hepes buffer containing 5 mM MgCl2, 
pH 7.5, in a total volume of 2.5 mL. The final mitochondrial protein concentration was 
30 µg/mL. The initial rates of NADH oxidation were calculated from the linear portion of 
the traces. Data are reported as the mean of three independent experiments each run in 
triplicate. 
 
 
 149   
  
Lipid Peroxidation Assay 
Lipid peroxidation was measured by a quantitative FACS assay using the 
oxidation-sensitive fatty acid probe C11-BODIPY
581/591
 (Molecular Probe) as 
described.
116-118
 The degree of probe oxidation was followed using flow cytometry. 
Briefly, FRDA lymphocytes (5 × 105 cell/mL) were plated (1 mL in 24-well plates), 
treated with the test compounds and incubated at 37 °C for 16 h in a humidified 
atmosphere containing 5% CO2 in air. The following day, cells were treated with 1 µM of 
C11-BODIPY
581/591
 probe in phenol red-free media and incubated at 37 °C in the dark for 
30 min. Oxidative stress was induced with 5 mM DEM in phenol red-free RPMI-1640 
media for 120 min. Cells were collected by centrifugation at 300 × g for 3 min and then 
washed with phosphate buffered saline (PBS). Cells were resuspended in phosphate 
buffered saline and were analyzed immediately by FACS (C6 Accuri, BD Biosciences, 
San Jose, CA), using a 488 nm excitation laser and the FL1-H channel 530 ± 15 nm 
emission filter. The generation of lipid peroxide was detected as a result of the oxidation 
of the polyunsaturated butadienyl portion of the dye, resulting in a shift of the 
fluorescence emission peak from red to green. In each analysis, 10,000 events were 
recorded after cell debris were electronically gated out. Data are reported as means ± 
S.E.M. (n = 3). Results were expressed as a percentage of lipid peroxidation scavenging 
activity. 
Reactive Oxygen Species (ROS) Assay 
 
Quantitative analysis of intracellular ROS levels in FRDA lymphocytes, 
challenged with 5 mM diethyl maleate (DEM) in presence or absence of the test 
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compounds, was obtained by FACS analysis using a dichlorodihydrofluorescein diacetate 
probe (DCFH-DA), as described previously.
112-117
 Briefly, 1 mL of FRDA lymphocytes 
(5 × 10
5
 cells) was plated in a 24-well plate, treated with the test compounds and 
incubated at 37 °C for 16 h in a humidified atmosphere containing 5% CO2 in air. Cells 
were treated with 5 mM diethyl maleate (DEM) for 80 min, collected by centrifugation at 
300 × g for 3 min and then washed with phosphate buffered saline (Life Technologies). 
Cells were resuspended in PBS containing 20 mM glucose and incubated at 37 °C in the 
dark for 25 min with 10 µM DCFH-DA. Cells were collected by centrifugation at 300 × g 
for 3 min and then washed with PBS. The samples were analyzed immediately by flow 
cytometry (C6 Accuri, BD Biosciences, San Jose, CA), using a 488 nm excitation laser 
and the FL1-H channel 530 ±15 nm emission filter. The generation of ROS, mainly 
peroxides, was detected as a result of the oxidation of DCFH. In each analysis, 10,000 
events were recorded after cell debris was electronically gated out. Results obtained were 
verified by running duplicates and repeating experiments in three independent runs. 
Results were expressed as a percentage of ROS scavenging activity. 
  
Preservation of Mitochondrial Membrane Potential (Δm) 
 
Mitochondrial membrane potential of FRDA lymphocytes was assessed using the 
fluorescence probe Mitotracker TMRM (tetramethylrhodamine methyl ester; Molecular 
Probes, Portland, OR) as described previously.
114-118
 TMRM is a lipophilic 
potentiometric dye which partitions between the mitochondria and cytosol in proportion 
to the negative membrane potential across the inner mitochondrial membrane, in 
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accordance with the Nernst equation.
135
 Therefore, the accumulation of dye in the 
mitochondria and the intensity of the signal is a direct function of mitochondrial 
potential. Mitochondrial depolarization then causes the redistribution of dye from 
mitochondria into the cytosol, causing a change in signal intensity. The detection of 
mitochondrial depolarization using TMRM was accomplished by flow cytometry as 
described before.
116-118
 Briefly, FRDA lymphocytes cells (5 × 105 cells) were pre-treated 
with or without the test compounds for 16 h. The cells were treated with 5 mM DEM for 
120 min, collected by centrifugation at 300 × g for 3 min and washed with phosphate 
buffered saline. The cells were resuspended in PBS containing 20 mM glucose and 
incubated at 37 °C in the dark for 15 min with 250 nM TMRM. Cells were collected by 
centrifugation at 300 × g for 3 min and washed with phosphate buffered saline. Cells 
were resuspended in phosphate buffered saline supplemented with 20 mM glucose and 
were analyzed immediately by FACS (FACS Caliber flow cytometer, Becton-Dickinson) 
using a 488 nm excitation laser and the FL2-H channel. For each analysis 10,000 events 
were recorded and the percentage of cells exhibiting a high level of TMRM uptake, 
which reflects normal mitochondrial membrane potential, was determined and analyzed 
using CellQuest software (BD Biosciences). The results obtained were verified in three 
independent experiments. FCCP (carbonyl cyanide p-trifluoromethoxyphenyl hydrazone), 
a mitochondrial uncoupler, was used to produce a negative control. The results were 
verified by repeating the experiments in duplicate. 
 
 
 152   
  
Cellular ATP Concentration Assay 
The intracellular ATP content was determined by a bioluminescence assay 
measuring the light output from the luciferin-luciferase reaction as described 
previously.
117,118
 Briefly, CoQ10 deficient lymphocytes (2 × 10
5 
cell/mL) were plated (1 
mL in 24-well plates) in glucose-free media supplemented with galactose and treated 
with the test compounds at final concentrations of 5, 10 and 25 µM, and then incubated at 
37 °C for 48 h in a humidified atmosphere containing 5% CO2 in air. Wells were mixed 
and cells in each well were transferred (100 µL) to 96-well microtiter black-walled cell 
culture plates (Costar, Corning, NY). The total intracellular ATP level was measured in a 
luminator (Clarity™ luminescence microplate reader) using an ATP Bioluminescence 
Assay Kit (ViaLight-Plus ATP monitoring reagent kit, Lonza, Walkersville, MD) 
following the manufacturer’s protocol. The total ATP level was expressed as a 
percentage of untreated control. Data are reported as the mean of at least three 
independent runs. 
 
Cytoprotection (Trypan Blue Exclusion Assay) 
 
          The cytoprotection conferred by the pyridinol derivatives was determined in six 
lymphocytes using the trypan blue exclusion method.
115-117
 This method is used to 
determine the number of viable cells present in cell suspension. It is based on the 
principle that live cells possess intact cell membranes that exclude trypan blue, whereas 
dead cells are not capable of excluding trypan blue. Briefly, lymphocytes were seeded at 
a density of 5 × 10
5
 cells per mL and treated with different concentrations of the test 
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compounds. Cells were incubated at 37 °C in a humidified atmosphere of 5% CO2 in air 
for 16 h. Oxidative stress was then induced by 5 mM diethyl maleate (DEM) treatment 
for 6 h. Cell viability was assessed microscopically by the use of a hemocytometer. The 
number of cells that absorbed the dye and those that excluded the dye were counted, from 
which the percentage of nonviable cell number over total cell number was calculated. 
Cytoprotection by the test compounds was assessed with respect to the untreated controls. 
Cells not treated with DEM had >90% cell viability whereas DEM treatment reduced cell 
viability to <20%. The cell viability was expressed relative to the vehicle control (DMSO 
only) group (n = 3).  
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CHAPTER 3 
PHARMACOKINETIC AND PHARMACOLOGICAL EVALUATION OF 
PYRIDINOL AND PYRIMIDINOL ANALOGUES 
 
3.1. Introduction 
 
The traditional method for drug discovery involves the preparation of test 
compounds followed by appropriate in vitro and in vivo biological evaluation. The 
resulting lead compounds are further evaluated for their metabolic and pharmacokinetic 
properties, and their toxic effects. Often, such projects are impacted due to the discovery 
of adverse effects of the lead compounds or their metabolites late in the discovery 
process.
142
 Currently, evaluation of drug metabolism, toxicity and pharmacokinetic 
characteristics are determined at an early stage. Information regarding the metabolic 
labilities of candidate drugs, the nature of their metabolites and their elimination route are 
important in choosing an optimized drug candidate for animal models, so as to avoid 
failures late in the drug discovery process.
143,144
 
There are several ways in which a potential drug can be administered; for 
convenience and compliance the oral route is usually preferred. A drug taken orally is 
absorbed through the gut wall and then passes through the liver. After surviving liver 
enzymes (first pass) the drug candidate proceeds to the target organs/receptors via 
circulation in the blood. The amount of drug in the blood/plasma circulation, and 
ultimately in the target organ(s), defines its oral bioavailability (Figure 3.1).
144
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Figure 3.1. Schematic of Route Followed by a Drug After Oral Dosage. Adapted From 
Ref. 144. 
 The xenobiotics (foreign compounds) in the liver after oral absorption are 
metabolized by oxidative enzymes which eventually affect their half life and oral 
bioavailability. These enzymes are classified into two categories, namely phase I and 
phase II (Figure 3.2).
145,146
 Phase I enzymes alter the molecule by adding a functional 
group or by exposing a functional group (e.g., reduction of ketones or aldehydes to the 
corresponding alcohols; reduction of azo or nitro compounds to the corresponding 
amines). Cytochrome P450 (CYP), xanthine oxidase (XO), aldehyde oxidase (AOX), 
monoamine oxidase (MAO), hydrolases and flavin-containing monooxygenase (FMO) 
are phase I enzymes.  Uridine 5’-diphospho-glucuronosyltransferase/UDP-
glucoronosyltransferase (UGT), glutathione S-transferase (GST), sulfotransferase 
(SULT), and N-acetyltransferase (NAT) represent examples of phase II enzymes. Phase 
II enzymes detoxify the xenobiotics by conjugation reactions, such as glutathione 
conjugation, sulfation and glucoronidation.
147
 Detoxification can be done solely by phase 
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I or phase II enzymes, or by a series of reactions involving functionalization by phase I 
enzymes, followed by conjugation by phase II enzymes.
148
  
 
Figure 3.2. Metabolites Generated by CYP, UGT and AOX.
148
 
A study in 2002 involving of the top 200 prescribed drugs revealed that 73% of 
the drugs were eliminated by hepatic clearance, 25% were eliminated through the kidneys 
and the remaining 2% by biliary clearance (Figure 3.3).
149
 Cytochrome P450 enzymes 
were responsible for the drugs eliminated in the liver, reflecting the importance of 
cytochrome P450 in drug metabolism.
148 
Cytochrome P450 enzymes, which include 57 
different species, are present mostly in human liver, but they are also expressed in the 
kidney, intestines, adrenal glands and other tissues.
150,151
 UGT and cytochrome P450 
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enzymes are located in the endoplasmic reticulum (ER) as they are membrane bound 
proteins and are isolated as a liver microsomal fraction. Soluble enzymes such as AOX, 
XO and SULT are found in the cytosol, which is referred to as the S9 fraction.
152
 
 
Figure 3.3. Organs Involved in Drug Metabolism (a) Major Drug Metabolizing Organ (b) 
Minor Drug Metabolizing Organs. 
 
The catalytic cycle of cytochrome P450-mediated metabolism was first proposed 
in 1968 and over the years much refinement of the mechanism has been realized. 
Cytochrome P450-mediated biotransformations are mostly oxidative in nature. The 
enzymes involved are thereby referred to as mixed-function oxidases or 
monooxygenases.
153,154
 The biotransformation of xenobiotics (RH) to oxidized 
metabolites (ROH) is represented by the following equation:
155,156
 
 
Cytochrome P450 induced metabolism mainly includes heteroatom oxygenation 
(N-oxygenation), C-hydroxylation (aromatic/aliphatic), epoxide formation, S-oxidation, 
O-dealkylation, heteroatom release (N-dealkylation) and 1,2-migration reactions. The 
first step of the catalytic cycle involves binding of oxidized iron (Fe
3+
) and substrate. In 
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the next step, one electron is transferred from NADPH-dependent cytochrome P450 
reductase (flavoprotein or iron-sulfur protein) to the cytochrome P450–substrate complex 
which reduces the ferric ion cofactor (Fe
3+
) to the ferrous (Fe
2+
) form. The reduced 
cytochrome P450–substrate complex binds to molecular oxygen; it is believed that the 
complex so formed undergoes one electron reduction either by cytochrome P450 
reductase–NADPH and/or cytochrome b5 reductase–NADPH to generate a peroxide 
dianion–P450 (Fe3+)–substrate complex. At stage 5, a water molecule is released from the 
intermediate to give the activated oxygen–P450–substrate complex. The activated oxygen 
in the complex is transferred to substrate as it is highly electron deficient and a potent 
oxidizing agent. The oxidized substrate (ROH) is liberated from the enzyme complex and 
regenerates the oxidized form which is the resting state of cytochrome P450 (Figure 
3.4).
157,159
 
 
Figure 3.4. General Catalytic Cycle for a Cytochrome P450-mediated Oxidative 
Biotransformation. Adapted From Ref. 158 and 159.  
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Hence drug discovery and lead identification can be reinforced by assessing the 
metabolic fate of orally administered drugs using simple microsomal incubation 
experiments. Accordingly, in vitro microsomal studies were designed and carried out 
using bovine liver microsomes to screen available pyridinol and pyrimidinol analogues of 
our multifunctional radical quenchers (MRQs) for their metabolic stability. The exocyclic 
heteroatom present in these analogues can undergo the following transformations:
160,161
 
 
Scheme 3.1. (a) Oxygenation of Heteroatom N by two Subsequent 1e
-
 Transfer/Oxygen 
Rebound. (b) 1-Electron Transfer, Proton Abstraction and Oxygen Rebound Steps 
Occurring During N-dealkylation.   
 
 
 
Scheme 3.2. Cytochrome P450-mediated Oxidation of Carbon-Oxygen Bond.
159,162 
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3.2. Results and Discussion 
 
Potential drug candidates are expected to exhibit pharmacokinetic parameters 
consistent with reasonable bioavailability. The metabolic fate of many orally 
administered drugs is often a function of clearance in the liver.
85,86
 Accordingly, in vitro 
microsomal incubations were performed on available pyridinol, pyrimidinol and quinone 
analogues of our MRQs to assess their percentage recovery after incubation with bovine 
liver microsomes. The structures of the pyridinol analogues evaluated are shown in 
Figure 3.5.  
 
 
Figure 3.5. Structures of the Pyridinol Analogues Evaluated for Metabolic Stability in 
Bovine Liver Microsomes. 
 
Reversed phase HPLC analysis afforded the results summarized in Figures 3.6, 
3.8 and 3.10. Compound 2.1, having a side chain the same as that found in idebenone, 
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was substantially degraded following 30 minutes of microsomal incubation (~60% 
degradation), consistent with an earlier metabolic study of idebenone, in which oxidation 
of the side chain was found.
163
 The omission of the side chain OH group from compound 
2.1 (affording 2.3) resulted in a substantial improvement in metabolic stability (~25% 
degradation). Increasing the side chain length (from 10 to 16 carbon atoms) afforded 
compounds (2.9 and 2.10) having about the same microsomal stability (~20-25% 
degradation).   
 
Figure 3.6. Microsomal Stability of Compounds Expressed as Percent of Compound 
Recovered After Reaction With Activated Microsomes for 30 Minutes. Microsomal 
Stability Values Represent Means ± SD. The Microsomal Incubation Assay for 
Compounds 2.11 and 2.12 was Performed by Dr. Yana Chen.  
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Isomeric compounds 2.11 and 2.12 having 19 carbon atom side chains, were less 
stable in this assay with 50-65% recovery. The exocyclic N,N-dimethylamino groups in 
compounds 2.9 and 2.10 are susceptible to oxidative demethylation by liver microsomes. 
This is consistent with the observed 70-80% recovery of compounds 2.3, 2.4, 2.9 and 
2.10 after a 30-minute incubation. The effects of alteration of the N,N-dimethylated 
amino group, providing compounds 2.19 and 2.20, was also studied under the same 
conditions. The azetidine analogues (2.19 and 2.20) were recovered in good yields 
(~95%) after a 30-minute microsomal incubation. Compounds 2.19 and 2.20 appear to 
possess sufficient metabolic stability to enable their study in vivo using animal disease 
models.  
In order to diversify the study, compounds with different heterocyclic cores were 
included for evaluation in bovine liver microsomes. The structures of the pyridinol, 
pyrimidinol and quinone analogues included in the study are shown in Figure 3.7. The 
primary aim of the study was to identify sites in chosen compounds prone to oxidative 
damage from CYP450 and then design metabolically more stable compounds on the basis 
of the results obtained in the microsomal incubation assays that can further be evaluated 
in animal disease models. 
Pyridinol analogues 2.8 and 2.23 showed good recovery. The lead compound, 2.2, 
showed only 60% recovery, presumably due to the presence of two susceptible oxidative 
sites (–OMe and –NMe2). The structurally modified analogues (2.26 and 2.28) similar to 
lead compound 2.2 in pyrimidinol series were recovered in good yields (80% and 77%, 
respectively) after a 30-minute microsomal incubation. Compound 3.1, which had a 
modified chain with one oxygen atom in the middle of the chain, did not show any 
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improvement over compound 2.2 and was recovered only in 61% yield, again due to the 
presence of two sites susceptible to oxidative transformation. Improved recovery (82%) 
was observed for compound 3.2, with one less labile site (replacement of –OMe with –
Me) as compared to 2.2.  
 
Figure 3.7. Structures of the Compounds Evaluated for Oxidative Metabolism in Bovine 
Liver Microsomes. Compounds 2.2, 3.1, 3.2, 3.3 and 3.4 Were not Prepared as Part of 
This Thesis, but Were Included in the Assay. Compounds 2.2 and 3.2 Were Synthesized 
by Dr. Pablo M. Arce, Compound 3.1 was Synthesized by Cameron Cripe, Whereas 
Compounds 3.3 and 3.4 Were Synthesized by Dr. Manikandadas M. Madathil. 
 
Compound 2.27, having an exocyclic azetidine substituent in place of the N,N-
dimethyl amino group (compound 2.2), underwent only 13% degradation after a 30-min 
microsomal incubation. Compound 2.29 was designed to have a long chain and alkoxy 
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ether linkage that could be introduced in just one step, thereby avoiding the synthetic step 
involving n-BuLi which generally proceeds in low yield. As expected, 2.29 showed better 
recovery (80%) as compared to 2.2 but this modification drastically affected the efficacy 
of the compound in biochemical and biological assays (data not shown). Recovery for 
quinone analogues 3.3 and 3.4 following microsomal treatment were low (57% and 75%, 
respectively), which might have been anticipated based on to the presence of the –OMe 
group (Figure 3.8). 
 
 
Figure 3.8. Microsomal Stability of Compounds Expressed as Percent of Compound 
Recovered After Treatment With Activated Microsomes. The Microsomal Incubation 
Assay for Compounds 2.28 and 2.29 was Performed by Dr. Yana Chen.  
 
In further evaluation of pyrimidinol analogues in bovine liver microsomes, 
pyrimidine (2.2) was included as a negative control, as it was unstable metabolically 
presumably due to oxidation of –OMe and –NMe2 functionalities. Pyridinol 2.20 was 
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again included as a positive control, since it was the most stable compound and had 
shown the highest recovery (95%) with another batch of bovine liver microsomes. After 
the preliminary screening of a number of compounds and identification of plausible sites 
of oxidation by CYP450, new analogues were designed, synthesized and evaluated 
biochemically. New pyrimidinol analogues included deuterated pyrimidinol 2.31 and 
pyrimidinols with a cyclic ether (2.30 and 2.32). These compounds were evaluated for 
their metabolic labilities to treatment with bovine liver microsomes (Figure 3.9).  
 
 
Figure 3.9. Structures of the Analogues Evaluated for Oxidative Lability in Bovine Liver 
Microsomes, Employing a New Microsome Preparation.  
 
Compound 2.2, having a methoxy group, was substantially degraded within 30 
minutes of microsomal incubation (~48% degradation), reflecting a slightly lesser 
recovery than the earlier metabolic study of compound 2.2 (Figure 3.8). The azetidine 
analogue (2.20) was also recovered in only 77% yield, as compared to 95% yield under 
the same experimental conditions, but with a different batch of bovine liver microsomes. 
The deuterated analogue 2.31 showed substantial improvement in stability as compared 
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to its counterpart, compound 2.2. The recovery of compound 2.31 after 30 minutes of 
microsomal incubation was comparable to the recovery observed for compound 2.20 
(75% and 77%, respectively). The stability and hence the recovery of the pyrimidinol was 
further improved with the introduction of a cyclic ether (compounds 2.30 and 2.32) 
instead a linear ether linkage to the heterocyclic core. Compounds 2.30 and 2.32 were 
degraded only to the extent of ~10% after a 30-minute microsomal incubation (Figure 
3.10). In compound 2.31 all the C-H bonds were replaced with C-D bonds for –OMe and 
–NMe2 and that resulted in a metabolically more stable compound as compared to 2.2. It 
can be explained on the basis of kinetic isotopic effect (~kD/kH) due to which C-D bonds 
are more stable than C-H bonds.
164
 Replacement of –OMe group with cyclic ether as in 
2.30 and 2.32 increased the steric bulk which could be the reason for the better recovery 
(90% and 93%, respectively) observed for these two compounds. 
 
 
Figure 3.10. Microsomal Stability of Compounds Expressed as Percent of Compound 
Recovered After Reaction With Activated Microsomes. Microsomal Incubation Assay for 
Compounds 2.30 and 2.32 was Performed by Dr. Yana Chen.  
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 Chromatogram obtained from the reversed phase HPLC for assessing the 
percentage recovery are shown in Figures 3.11 to 3.17. HPLC profile of the compound 
2.2 with elution at 15.4 min. is shown in Figure 3.11. Internal standard, fluorene, was 
eluted at 9.6 min. (Figure 3.12). HPLC profiles for compound 2.2 after 30 minutes of 
deactivated and activated microsomal incubation are shown in Figures 3.13 and 3.14 
respectively. Figure 3.15 shows the HPLC profile of compound 2.31 with elution at 15.2 
minutes. Compound 2.31 HPLC profiles after 30 minutes of deactivated and activated 
microsomal incubation are shown in Figures 3.16 and 3.17, respectively. 
 
 
Figure 3.11. HPLC Profile for Compound 2.2 (λmax 297 nm).  
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Figure 3.12. HPLC Profile for Internal Standard Fluorene (λmax 262 nm).  
 
 
Figure 3.13. HPLC Profile for Compound 2.2 After a 30-minute Incubation in 
Deactivated Bovine Liver Microsomes.  
 
 
2.2 
fluorene 
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Figure 3.14. HPLC Profile for Compound 2.2 After a 30-minute Incubation in Activated 
Bovine Liver Microsomes.  
 
 
 
Figure 3.15. HPLC Profile for Compound 2.31 (λmax 300 nm). 
 
2.2 
fluorene 
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Figure 3.16. HPLC Profile for Compound 2.31 After a 30-minute Incubation in 
Deactivated Bovine Liver Microsomes.  
 
 
Figure 3.17. HPLC Profile for Compound 2.31 After a 30-minute Incubation in 
Activated Bovine Liver Microsomes.  
 
 
2.31 
2.31 
fluorene 
fluorene 
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3.3. Experimental 
 
3.3.1. Microsomal Enzyme Preparation 
Bovine liver microsomes were prepared from liver of a freshly slaughtered animal 
as previously reported, with some modifications.
165
 Briefly, liver tissues were diced into 
small pieces and then washed with isotonic sucrose buffer (0.25 M sucrose, 10 mM Tris-
HCl, 0.5 mM EDTA, pH 7.8).  The diced tissue was passed through a precooled meat 
grinder and mixed with three-fold ice cold sucrose buffer supplemented with a mixture of 
protease inhibitors. The suspension was homogenized in a Waring blender for 25 sec at 
high speed. At this stage, the pH of the suspension was adjusted to 7.4 with 1 M Tris 
base. The homogenate was centrifuged for 20 min at 1200 × g to remove cell debris. The 
supernatant suspension was homogenized in a tight fitting Teflon-glass Potter-Elvejhem 
homogenizer and then centrifuged twice at 10,000 × g for 20 min, collecting the 
supernatant each time to remove mitochondria. The floating fat layer was carefully 
removed by filtering the supernatant through layers of cheesecloth. The supernatant was 
centrifuged at 150,000 × g for 30 min (Beckman-Coulter ultracentrifuge, XL-100K -01, 
SW 55 Ti rotor). The pellet (microsomal fraction) was suspended in 0.25 M sucrose 
buffer containing 10 mM Tris-HCl, pH 7.4, with 20% (v/v) glycerol, and centrifuged 
once more at 150,000 × g. The pellet was resuspended in sucrose buffer with 20% (v/v) 
glycerol. The protein concentration after resuspension was approximately 20 mg/mL, as 
determined by BCA protein assay (Pierce Chemical) using bovine serum albumin as a 
standard. Aliquots of microsomal suspensions were stored at –80 °C (Figure 3.18).  
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Figure 3.18. Schematic Diagram of Microsomal Preparation From Bovine Liver. 
Adapted From Ref. 166. 
 
3.3.2. Microsomal Stability Assay 
          In vitro metabolic stability was determined in bovine liver microsomes at a protein 
concentration of 1 mg/mL in 50 mM phosphate buffer, pH 7.4, containing 5 mM MgCl2 
in a final incubation volume of 0.5 mL. Each test compound was added to a final 
concentration of 25 µM. This mixture was pre-warmed to 37 °C prior to starting the 
reaction by the addition of β-NADPH to 1 mM final concentration. After incubation for 
30 min at 37 °C, the reaction was quenched by the addition of 1 mL of propanol, 
vortexed for 2 min and centrifuged at 15,000 × g for 20 min to pellet the precipitated 
protein. The resulting supernatant was removed by pipetting and then concentrated under 
diminished pressure. A parallel incubation of the test compound with deactivated 
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microsomes lacking β-NADPH and quenched immediately with propanol served as a 
control and was run for each test agent to detect microsome-independent degradation. 
The sample was reconstituted in 130 µL MeOH and centrifuged again at 15,000 × g for 3 
min. The supernatant was removed and 4 µM fluorene was added as an internal standard 
prior to HPLC analysis. HPLC analyses were performed on a reversed phase Zorbax SB-
Phenyl reversed phase analytical (150 × 4.6 mm, 5 µm) HPLC column using a mobile 
phase consisting of MeOH/H2O. A linear gradient of (50:50 MeOH/H2O 100:0 
MeOH/H2O) was employed over a period of 14 min at a flow rate of 1 mL/min. 
Metabolic stability was expressed as percent of control remaining. The experiments were 
carried out in duplicate to verify the results for some of the compounds. 
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